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ABSTRACT 
This  thesis  addresses  two  important  topics  in  HIV-1  medicine;  (i)  the  clinical 
relevance of pre-treatment G→A hypermutation and the contribution of host and 
viral genetics to its development and; (ii) the influence of genetic variation in host 
enzymes  responsible  for  antiretroviral  drug  metabolism  on  response  to  therapy. 
These themes are outlined below.  
HIV-1 Hypermutation 
At present, limited data exists regarding the relative roles of host encoded cytidine 
deaminases  APOBEC3G  and  APOBEC3F  in  promoting  G→A  hypermutation  of 
HIV-1  proviral  DNA  in  vivo,  nor  the  clinical  relevance  of  hypermutation  or  the 
influence of genetic diversity of the APOBEC3G locus and of the viral encoded vif 
protein that counteracts the action of APOBEC3G. The analyses contained within 
this  thesis  demonstrate  that  within  the  WA  HIV  cohort,  clinically  relevant 
hypermutation  is  restricted  to  a  minority  of  individuals  and  is  mediated 
predominantly by APOBEC3G. In this study, the presence of HIV-1 hypermutation 
had a substantially greater effect on plasma viremia than other known host antiviral 
factors such as CCR5∆32 or specific HLA-B alleles. Furthermore, the considerable 
genetic  diversity  of  the  vif  gene  is  likely  to  make  a  greater  contribution  to  the 
development of hypermutation than the limited genetic diversity of the APOBEC3G 
gene  in  Caucasians.  These  data  indicate  that  G→A  hypermutation  is  a  clinically 
relevant phenomenon and may provide a fresh perspective to the area of HIV/AIDS 
therapies.    ii 
Genetic Determinant of HIV-1 Treatment Response  
Thymidine  kinase  2  (TK2)  and  thymidylate  kinase  (dTMPK)  are  rate  limiting 
enzymes for the metabolism of the antiretrovirals d4T and AZT, respectively, and 
are thus central to the antiviral efficacy and toxicity of these agents. However, the 
genetic diversity of TK2 and dTMPK and their influence on toxicities associated 
with their use is largely unknown. The results discussed in this thesis indicate that in 
contrast  to  the  highly  conserved  TK2  locus,  the  dTMPK  locus  of  Caucasian 
individuals,  including  regulatory  regions  potentially  influencing  transcription  and 
translation, is considerably polymorphic and organised into five common haplotypes.  
The  results  regarding  the  contribution  of  dTMPK  genetic  variation  to  toxicities 
associated with AZT therapy are encouraging. A common dTMPK haplotype had 
significant, albeit modest, effect on haematological parameters  (haemoglobin and 
mean  corpuscular  volume)  in  HIV-infected  patients,  although  no  AZT-specific 
treatment effect was observed in this relatively haematologically stable cohort. In 
addition, another common dTMPK haplotype provided significant protection against 
AZT-induced adipocyte mtDNA depletion in a pilot study of AZT- and d4T-treated 
individuals.  The  dTMPK  haplotypes  characterised  in  this  thesis  should  facilitate 
further studies regarding dTMPK genetic variation in HIV-1 infection and response 
to treatment, which are warranted from the clinical results presented herein.   iii 
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CHAPTER ONE 
 
 
1  POPULATION LEVEL ANALYSIS OF HYPERMUTATION AND 
ITS RELATIONSHIP WITH APOBEC3G AND VIF GENETIC 
VARIATION   2 
1.1  GENERAL INTRODUCTION AND REVIEW OF THE LITERATURE 
Apolipoprotein  B  mRNA-editing  enzyme,  catalytic  polypeptide-like  3G 
(APOBEC3G)  and  the  closely  related  APOBEC3F  are  recently  identified 
anthropoid-specific proteins that restrict human immunodeficiency virus-1 (HIV-1) 
replication by  deaminating  cytosine  residues in  intermediary single-stranded HIV 
DNA. This host antiviral strategy thereby introduces DNA editing errors into the 
retroviral  genome  sequence,  resulting  in  the  fixation  of  an  inordinate  number  of 
proviral  HIV  DNA  guanine  to  adenine  (G→A)  substitutions  referred  to  as 
hypermutation. Previous studies have defined polynucleotide motifs within single-
stranded DNA that are preferentially targeted by APOBEC3G (resulting in proviral 
DNA GG→AG substitutions) and APOBEC3F (GA→AA). These studies have also 
identified  HIV-1  viral  infectivity  protein  (vif)  as  the  principal  viral  factor  that 
counteracts  APOBEC3-mediated  DNA  editing  by  promoting  the  degradation  of 
APOBEC3-vif complexes via the proteasomal pathway. Recent in vitro data also 
indicate that APOBEC3G and APOBEC3F are partially resistant to vif, suggesting a 
more  fundamental  role  for  these  APOBEC3  proteins  in  directing  HIV-1  genetic 
variation.  
However, at present little is known of the disease-modulating effects of APOBEC3G 
and/or  APOBEC3F  in  HIV-infected  patients,  and  it  is  uncertain  if  APOBEC3-
mediated HIV DNA editing in vivo requires permissive conditions such as defective 
vif activity and/or APOBEC3 genetic variation. This chapter of the thesis, accepted 
for publication in Journal of Virology (Pace et al, 2006), aims to address these issues 
at the population level and begins with an extensive review of the relevant literature.   3 
1.1.1   HYPERMUTATION 
 
1.1.1.1   DESCRIPTION OF HIV-1 HYPERMUTATION 
Hypermutation,  defined  as  extensive,  monotonous  guanine  to  adenine  (G→A) 
substitutions,  was  first  described  by  Vartanian  and  colleagues
1  and  Li  and 
colleagues
2.  In  1991,  Vartanian  et  al,
1  described  seven  clones  of  HIV-1  proviral 
DNA  in  which  over  90%  of  all  mutations  were  G→A  and  Li  et  al,
2  reported 
quasispecies  with  8.2%  nucleotide  differences  comprised  of  almost  exclusively 
G→A substitutions from uncultured brain tissue from a patient with AIDS dementia 
complex.  In  both  studies,  63-90%  of  the  G→A  substitutions  affected  guanidine 
residues within GA dinucleotides. In contrast, Fitzgibbon and colleagues
3 described 
a second type of G→A hypermutation from longitudinal PBMC proviral DNA from 
an AIDS patient that preferentially affected one or more 5’ guanidines in runs of 
guanidines. Adenine to inosine (A-I) hypermutation which has been described in 
measles  and  vesicular  stomatitis  genomes  has  not  been  observed  from  HIV-1 
genomes. 
1.1.1.2  CAUSE OF HIV-1 HYPERMUTATION 
Initial  describers  of  G→A  hypermutation  attributed  the  phenomena  to  base 
mispriming, temporary dislocation of the primer and template and the low fidelity of 
HIV-1  reverse  transcriptase  (RT)  and/or  altered  intracellular  nucleotide  pool 
balances
4-7.   4 
Work from Martinez and colleagues
6 demonstrated that G→A hypermutation could 
be  achieved  in  vitro  using  HIV-1  RT  and  biased  deoxynucleotide  triphosphate 
(dNTP)  concentrations,  in  particular,  low  ratio  of  deoxycytidine  triphosphate 
(dCTP): deoxythymidine triphosphate (dTTP), in a dose-dependent manner. HIV-1 
RT  is  particularly  sensitive  to  such  biased  deoxynucleotide  pools,  generating 
significantly more G→A changes than RT of avian myeloblastosis virus or Moloney 
murine leukemia virus in a suboptimal dCTP environment
5. However, suboptimal 
dCTP concentrations are unlikely to produce G→A hypermutation specifically in the 
GA and GG contexts. Vartanian et al
7 agreed that suboptimal dCTP concentrations 
would account for type 2 G→A hypermutation (one or more 5’ guanidines in runs of 
guanidines)  due  to  the  progressive  depletion  of  dCTP  in  the  microenvironment 
caused by runs of guanidines, but suggested that dislocation mutagenesis consequent 
to dCTP depletion was the mechanism for hypermutation in the GA context.  
The theory that hypermutation was caused by biased deoxynucleotide pools appeared 
less likely following the discovery that hypermutation occurred only in cells and cell 
lines  that  were  non-permissive  for  HIV-1  infection,  despite  having  similar 
deoxynucleotide pools to permissive cells
8. Non-permissive cells are cells in which 
the viral-encoded viral infectivity factor (vif) is indispensable for HIV-1 infection 
(PBMCs,  HUT78,  H9,  CEM)  as  opposed  to  permissive  cells  in  which  vif  is 
dispensable for HIV-1 infectivity (Figure 1.1).  
Using  cell-fusion  experiments,  Simon  and  colleagues
9  and  Madani  &  Kabat
10 
discovered that the non-permissive phenotype was dominant, suggesting that non-
permissive cells produce an antiviral factor that is suppressed by vif, and through   5 
cDNA  subtraction  studies,  Sheehy  and  colleagues
11  discovered  that  APOBEC3G 
was abundantly expressed in non-permissive cells but only minimally expressed, or 
absent, in a variety of lymphoid and non-lymphoid permissive cells. Subsequently, 
APOBEC3G
12-14 , APOBEC3F
15-17 and APOBEC3B
18 were found to induce G→A 
hypermutation  in  HIV-1  proviral  DNA  in  vitro.  Based  on  the  specific  sequence 
contexts that APOBEC3 proteins exhibit in regard to cytidine deamination sites and 
their tissue distribution (section 1.1.2.5), APOBEC3G
19,20 and APOBEC3F
15 appear 
to mediate HIV-1 hypermutation in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Replication of HIV-1 in non-permissive and permissive T cells. CEM and CEM-SS 
cells  were  challenged  with  normalized  stocks  of  wild-type  or  ∆vif  X4-tropic  viruses,  and  virus 
replication  was  monitored  as  the  supernatant  accumulation  of  p24gag.  Taken  from  reference  11 
(Reprinted by permission from Macmillan Publishers, Ltd) [Nature, 2002;418:646-50]. 
 
 
 
1.1.1.3  MECHANISM OF APOBEC3-MEDIATED HYPERMUTATION 
As illustrated in Figure 1.2, the HIV-1 RNA genome is reverse transcribed in the 
cytoplasm by the viral-encoded reverse transcriptase producing the first (negative) 
DNA strand. Following RNase H-dependent dissociation of the RNA-DNA hybrid, 
APOBEC3 proteins deaminate the cytidine molecules on the negative strand cDNA,   6 
due  to  their  single-strand  DNA  specificity
21,  yielding  uracil  molecules.  During 
replication of the negative strand cDNA, the uracil molecules are identified by the 
DNA polymerase as thymidine molecules and therefore result in the incorporation of 
adenine  molecules  in  place  of  the  guanidine  molecules  in  the  proviral  DNA 
precursor,  or  G→A  hypermutation.  Alternatively,  uridine  containing  cDNAs  are 
targeted  by  cellular  uracil  DNA  glycosylase,  which  excises  the  contaminating 
uridine  molecule,  leaving  an  abasic  site  which  is  endonucleolytically  cleaved  by 
apyrimidinic  endonucleases  yielding  severed  proviral  DNA  precursors  that  are 
incapable of being integrated into the cellular genomic DNA
14.  
 
 
 
 
 
 
Figure  1.2  Schematic  representation  of  the  mechanism  of  APOBEC3G  mediated  G→ → → →A 
hypermutation.  Viral  RNA  is  reverse  transcribed  by  reverse  transcriptase  to  generate  the  first 
(negative) strand DNA, which upon RNase H-mediated degradation of the genomic RNA, becomes 
single-stranded and targeted by APOBEC3G.  The deamination of cytosine by APOBEC3G yields 
uridine molecules, which are either identified as thymidine molecules by DNA polymerase and result 
in the incorporation of adenine molecules, and once integrated, become fixated as G→A substitutions 
in proviral DNA. Alternatively, uracil-containing DNA is targeted by uracil DNA glycosylase, which 
excises  the  contaminating  uracil,  leaving  an  abasic  site  which  is  endonucleolytically  cleaved  by 
apyrimidinic  endonucleases  yielding  severed  proviral  DNA  precursors.  Taken  from  reference  14 
(reprinted by permission from Elsevier Science) [Cell, 2003;113:803-9]. 
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1.1.2  APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC(-
LIKE) POLYPEPTIDES 
 
1.1.2.1  INTRODUCTION TO THE AID/APOBEC SUPERFAMILY  
The  AID/APOBEC  proteins  are  a  superfamily  of  DNA  and  RNA  cytidine 
deaminases. The superfamily can be segregated into activation-induced deaminase 
(AID), apolipoprotein-B RNA editing enzyme, catalytic polypeptide 1 (APOBEC1), 
APOBEC2  and  APOBEC3  subgroups  based  on  the  sequences  surrounding  the 
conserved zinc-binding motifs characteristic of all cytidine deaminases
22. 
The founding member, APOBEC1, an RNA deaminase is expressed exclusively in 
the  small  intestine
23.  APOBEC1  is  the  catalytic  component  of  a  complex  that 
deaminates cytidine6666 of the apolipoprotein B mRNA polynucleotide, creating a 
premature stop codon that results in the tissue-specific production of a truncated 
form of apoB-100, termed apoB-48
24. 
AID  is  a  single  stranded  DNA  deaminase  expressed  exclusively  in  activated  B 
lymphocytes
25 and functions in adaptive humoral immune response by potentiating 
antibody gene diversification through somatic hypermutation and gene conversion of 
the immunoglobulin V gene
26 and switch recombination of the IgC gene
27,28. 
APOBEC2 is expressed exclusively in heart and skeletal muscle but its function is to 
date  unknown
29.  Mice  deficient  in  APOBEC2  through  gene  targeting  reveal 
APOBEC2 is unessential for mouse development, survival or fertility
30.   8 
APOBEC3 family members are single stranded DNA cytidine deaminases, some of 
which  provide  innate  antiviral  restriction  of  retroviral  (APOBEC3G)
13,31, 
hepadnaviral  (hepatitis  B)  (APOBEC3B,  -3C,  -3F  and  -3G)  and  endogenous 
retroelement replication intermediaries
21,32 by cytidine deamination and non-cytidine 
deamination  mechanisms.  Some  APOBEC3  family  members  are  abundantly 
expressed in a variety of tumour cell lines suggesting they may also have a role in 
neoplastic transformation
33. 
Recently, a new subfamily of the AID/APOBEC superfamily, termed APOBEC4, 
has been identified from iterative databases  with readily identifiable orthologs in 
mammals, chicken, and frog, but not fishes. In mammals, APOBEC4 is expressed 
primarily in testis which suggests the possibility that it is an editing enzyme for 
mRNAs involved in spermatogenesis
34.  
1.1.2.2  STRUCTURE OF AID/APOBEC PROTEINS 
By analogy to APOBEC1, the functional domains of APOBEC3G can be separated 
into an N-terminal domain, a first active site, a first linker region, a pseudoactive 
site, a second active site, a second linker region, and a C-terminal domain
33 (Figure 
1.3). All APOBEC proteins contain one or two copies of a His/Cys-X-Glu-X23-28-
Pro-Cys-X2-Cys signature motif that is characteristic of all cytidine deaminases and 
represents the active site
35. This motif contains zinc-binding ligands and a glutamate 
involved in proton shuffling.    9 
 
Figure  1.3  Domain  organisation  of  AID/APOBEC  proteins.  The  proteins  were  aligned  on  the 
active site residues of APOBEC1 and the predicted active site residues at the N terminus of the 
APOBEC3  proteins.  Taken  from  reference  33  (reprinted  by  permission  from  Elsevier  Science) 
[Genomics, 2002;79:285-296]. 
The secondary structure of any APOBEC protein is yet to be determined; however 
computer-assisted  secondary  structure  prediction  programs  predict  the  secondary 
structure  of  the  catalytic  core  is  well  conserved  between  nucleotide  and 
polynucleotide cytidine deaminases
35. Crystallographic studies of nucleotide cytidine 
deaminases from Escherichia coli
36, Bacillus subtilus
37, Saccharomyces cerevisiae
38 
and humans
39 reveal a core β1β2α1β3α2β4β5 arrangement. Two α-helices, that contain 
the His, Cys and Glu residues that are required for zinc- coordination, proton transfer 
and catalysis are supported by the five β-sheets in a parallel position
40 (Figure 1.4A). 
The most striking difference between the predicted secondary structures of APOBEC 
proteins and the established structures of nucleotide cytidine deaminases is that all 
APOBEC proteins have an intervening α-helix (α3) between β3 and β4, which is 
lacking in nucleotide cytidine deaminases (Figure 1.4B). Interestingly, the α3-helix 
contains a critical amino acid residue required for species-specific interactions with   10 
HIV-1 and SIV vif proteins. Therefore, APOBEC proteins are predicted to conform 
to  a  β1β2α1β3α2β4α3β5  arrangement  rather  than  the  β1β2α1β3α2β4β5  arrangement 
characteristic of nucleotide cytidine deaminases
40. 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Structure of the cytidine deaminase catalytic domain. (A) A mixed β-sheet is formed 
by the consensus β1β2α1β3α2β4β5 motif, which supports the proper positioning of the α-helices that 
contain the catalytic and zinc-coordinating residues. (B) Between β4 and β5, all APOBEC proteins 
contain a predicted α-helical structure α3, which in APOBEC3G, is adjacent to residue 128 and is 
associated  with  the  species-specific  interaction  with  vif.  Taken  from  reference  35  (reprinted  by 
permission from Elsevier Science) [Virology, 2005;334:147-53]. 
 
 
 
1.1.2.3  EVOLUTION OF THE AID/APOBEC SUPERFAMILY 
Phylogenetic  analysis  of  AID/APOBEC  sequences  suggest  that  APOBEC1  and 
APOBEC3 are most likely to have arisen by duplication of the AID locus. Consistent 
with  gene  duplication,  the  AID,  APOBEC3  and  APOBEC1  genes  have  similar 
location of intron/exon boundaries
22. Analysis of the amino acid sequences of the 
APOBEC active sites, linker and repeated linker sequences suggest that APOBEC1 
is  more  closely  related  to  AID,  and  then  to  APOBEC2,  in  both  the  active  site 
(consisting  of  three  zinc  ligands,  critical  residues  for  substrate  binding,  and  a 
glutamate involved in proton shuffling during catalysis) and linker sequences, but all   11 
three are more distant from APOBEC3 than from each other
33. AID and APOBEC2 
homologues can be traced back to cartilaginous fish and bony fish, respectively, with 
neither  protein  identifiable  among  nonchordates,  nor  the  invertebrate  chordate, 
Ciona intestinalis
22. APOBEC1 and APOBEC3 orthologs are restricted to mammals. 
However, unlike the single APOBEC3 gene in mouse and rat, there are 8 APOBEC3 
genes in primates and humans, designated APOBEC3A to APOBEC3H, arranged in 
tandem  and  each  orientated  with  a  centromeric  5’  end  on  chromosome  22q12-
q13.2
33. Synteny between the human, chicken and pufferfish genomes is evident in 
the  region  flanking  the  APOBEC3  locus  and  thus,  while  the  APOBEC3  genes 
themselves are missing, the genes flanking the APOBEC3 locus are conserved in 
chicken  and  pufferfish,  supporting  the  later  origin  of  the  APOBEC3  locus.  All 
APOBEC3 orthologs are present in the chimpanzee genome and therefore it appears 
that the expansion of this locus occurred at the beginning of the primate evolution
22. 
1.1.2.4  EXPANSION OF THE APOBEC3 LOCUS 
In  contrast  to  mice  and  other  non-primate  mammals,  which  have  only  a  single 
APOBEC3  gene,  the  APOBEC3  locus  of  primates  and  humans  has  undergone 
expansion and tandem duplication, resulting in the acquisition of seven APOBEC3 
genes (APOBEC3A-3D and APOBEC3F-H) and one pseudogene (APOBEC3E). 
The APOBEC3B and APOBEC3G genes each comprise eight exons, APOBEC3F 
comprises  seven  exons,  APOBEC3A  comprises  five  exons,  APOBEC3C  and 
APOBEC3E  each  comprise  four  exons  and  APOBEC3D  comprises  three  exons 
(Figure 1.5). APOBEC3B, APOBEC3G and APOBEC3F share identical intron/exon   12 
boundaries,  except  APOBEC3F  terminates  after  exon  7.  In  APOBEC3B, 
APOBEC3G and APOBEC3F, exons 2, 3 and 4 are duplicated in exons 5, 6 and 7, 
with  introns  1-4  in  the same  position  as  introns  5-7.  Between  exons  4  and  5  of 
APOBEC3B and APOBEC3F, a duplicated exon one-like sequence containing the 
initiating methionine and the other five amino acids of exon 1, is skipped rather than 
spliced due to a thymidine to guanidine substitution within a 3’-splice donor site at 
position 2 of the intron. No such exon skipping is present in APOBEC3G
33. The 
sequence corresponding to the third intron of the APOBEC3 genes is not spliced out 
of the APOBEC3D mRNA sequence and has a continuous open reading frame with 
the equivalent exons three and four to the other APOBEC3 genes. This however, is 
not due to defective 3’ splice donor and acceptor sites
33.  
 
 
 
 
 
 
 
Figure 1.5 APOBEC3 locus on chromosome 22. The exons are numbered and boxed and assembled 
into cDNA where they are known to be expressed. The numbers corresponding to The Sanger Centre 
chromosome 22 sequence (bK150C2) are shown. Asterisks (*) indicate APOBEC3A exon one-like 
sequence  present  in  APOBEC3B  and  3F  but  skipped.  Taken  from  reference  33  (reprinted  by 
permission from Elsevier Science) [Genomics, 2002;79:285-296].   13 
The  zinc-coordinating  domains  of  APOBEC3  proteins  provide  evidence  of  their 
evolution. The zinc-coordinating domains can be grouped into two major clades, 
labelled  Z1  and  Z2.  The  Z1  domains,  common  to  other  AID/APOBEC  family 
members,  retain  the  SWS  motif  upstream  of  the  PC-C  motif  unlike  Z2  domains 
which contain a threonine residue in place of the first serine residue; Z1 domains are 
further  divisible  into  Z1a  and  Z1b.  As  represented  in  Figure  1.6,  the  double 
domained rodent APOBEC3 is a Z1-Z2 composite, while all human APOBEC3’s are 
either single or double Z1 domained, except for APOBEC3H which consists of a 
single Z2 domain. It is therefore likely that the APOBEC3 locus evolved from a 
common ancestor that harboured both Z1 and Z2 domains either in the single- or 
double-domained APOBEC3 proteins
22. 
 
 
 
 
 
Figure  1.6  Hypothetical  scheme  of  the  origin  and  divergence  of  the  APOBEC3  family  in 
mammals. Two ancestral domains, Z1 domains (circles) and Z2 domains (squares) either constituted 
a double-domained APOBEC3 or two single domained APOBEC3s. The Z1 domains in primates is 
then considered to have diversified into Z1a (open circles) and Z1b (closed circles) subtypes. Taken 
from  reference  22  (reprinted  by  permission  from  Oxford  University  Press,  Ltd)  [Mol  Biol  Evol, 
2005;22:367-77]. 
APOBEC3B,  APOBEC3G  and  APOBEC3F  are  unique  among  the  APOBEC 
proteins by containing a duplicated active site, insert and linker peptide and part of   14 
the  pseudoactive  site.  It  has  been  proposed  therefore,  together  with  phylogenetic 
analyses,  that  duplication  of  either  APOBEC3A,  APOBEC3C,  APOBEC3D  or 
APOBEC3E  led  to  the  origin  of  either  APOBEC3B  or  APOBEC3G,  and 
subsequently duplication of APOBEC3B or APOBEC3G formed APOBEC3F
33. The 
similarity in intron 4 of APOBEC3B  and APOBEC3F is evidence of the former 
while  the  similarity  in  the  promoter  sequence  of  APOBEC3D,  APOBEC3F  and 
APOBEC3G is evidence of the latter
33. 
Analysis of the APOBEC3 genes from ten primate species representing 33 million 
years  of  evolution  indicates  that  APOBEC3G  (Figure  1.7),  APOBEC3B, 
APOBEC3D and APOBEC3C and amino acids 117-250 of APOBEC3F, has been 
subject  to  positive  selection  throughout  the  history  of  primate  evolution,  evident 
from  the  excess  of  non-synonymous  substitutions  relative  to  synonymous 
substitutions (ω)
41.  Interestingly, despite the lack of evidence that APOBEC3E is a 
functional  gene,  it  exhibited  the  highest  ω  value  seen  among  any  human-chimp 
comparison leading the authors to argue that it is an active participant in some form 
of  genetic  conflict
41.    APOBEC3A  was  the  only  APOBEC3  gene  that  exhibited 
evidence of purifying selection (referring to an excess of synonymous substitutions 
relative to non-synonymous substitutions due to non-synonymous substitutions being 
more likely to be deleterious and therefore typically culled out by selection).  
Primate lentiviruses are no older than 1 million years and therefore have not been in 
the  primate  population  long  enough  to  account  for  the  positive  selection  of  the 
mentioned  APOBEC3  proteins.  The  authors  conclude  that  the  ancient,  constant 
pressure of positive selection on APOBEC3 proteins, in particular APOBEC3G, in   15 
primates suggest that at least some of its evolution may be due to genetic conflict in 
the  germline,  where  APOBEC3G  is  abundantly  expressed  and  where  genome 
restricted mobile genetic elements need to transpose to ensure survival, rather than in 
the  lymphocytes.  They  argue  that  over  time,  the  steady  retrotransposition  of 
endogenous retroviruses that have recently been shown to be targets of APOBEC3 
proteins
42-44 are likely to be more detrimental to a species than scattered, episodic 
interactions with viruses.  
 
 
 
 
 
 
 
 
 
Figure  1.7  Phylogeny  of  APOBEC3G  in  Primates.  APOBEC3G  has  been  under  positive 
selection for at least 33 million years. Numbers represent ω (non-synonymous: synonymous ratio; 
actual numbers in parentheses). HIV/SIV-infected species are indicated by asterisks (*). Taken from 
reference 41 (No permission required to reprint). 
Alternatively, I identified a putative mitochondrial localisation signal in the amino 
acid sequence of APOBEC3G, APOBEC3F and APOBEC3H and it was suggested 
that  mitochondrial  localised  APOBEC3  proteins  may  have  contributed  to  the 
establishment  or  maintenance  of  the  asymmetrical  nucleotide  distribution 
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characteristic  of  mammalian  mitochondrial  DNA  (G-rich  H-strand  and  C-rich  L-
strand) (David Nolan, pers comm). Utilising confocal microscopy and western blot 
analyses, endogenous and recombinant APOBEC3G and -3F proteins were indeed 
found to localise to mitochondria and analyses of the dinucleotide composition and 
codon usage of the human mitochondrial DNA Cambridge reference sequence seem 
to support the hypothesis (Figure 1.8, Prada et al, in preparation). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 APOBEC3G colocalises with mitochondria. (A) Endogenous (PBMC) and recombinant 
(3G-HEKT  cells)  APOBEC3G  proteins  were  found  to  colocalise  with  mitochondria  by  confocal 
microscopy  and  (B)  recombinant  APOBEC3G  by  western  blot  analyses;  red  staining  represents 
mitochondria;  green  staining  represents  APOBEC3G  protein;  yellow  staining  represents  co-
localisation (Prada et al, in preparation). 
 
 
 
1.1.2.5  EXPRESSION OF APOBEC3 PROTEINS  
All members of the AID/APOBEC superfamily exhibit tissue-specific expression. 
As mentioned in 1.1.1.4, AID is specifically expressed in activated B lymphocytes
23, 
APOBEC1 in intestinal epithelial cells
25, APOBEC2 in skeletal and heart muscle
29 
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and APOBEC4 primarily in testis
34. Similarly, APOBEC3 proteins are expressed in a 
tissue-specific manner. APOBEC3G, APOBEC3F and APOBEC3C are expressed in 
spleen, peripheral blood lymphocytes, ovary and testes (Figure 1.9). APOBEC3B, 
APOBEC3C,  and  to  a  lesser  extent,  APOBEC3A,  are  abundantly  expressed  in  a 
variety  of  tumour  cells  including  colorectal  adenocarcinoma  cells,  promyelocytic 
leukemia cells and lung carcinoma cells
33.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 Northern blot analysis of APOBEC3 genes. Multiple tissue and multiple tumour cell line 
northern blots were analysed for sites of expression of APOBEC3B, 3G, and 3C. Site of expression of 
actin control is also shown. Taken from reference 33 (reprinted by permission from Elsevier Science) 
[Genomics, 2002;79:285-96]. 
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1.1.2.6  TRANSCRIPTIONAL REGULATION OF APOBEC3G 
Unlike many other antiviral factors, such as adenosine deaminases, ribonuclease L 
and Mx GTPase, transcription of APOBEC3G mRNA is unaffected by type 1 or type 
2 interferons or tumour necrosis factor-α (TNFα)
45 or by HIV-1 infection per se
46,47. 
Data from Rose and colleagues
45 presented in Figure 1.10 suggest that transcription 
of APOBEC3G mRNA is regulated by the cell cycle via a protein kinase cascade 
involving  protein  kinase  C-α  and  -β1,  mitogen-activate  protein  kinase  1  and  2 
(MEK)  and  extracellular  signal-regulated  protein  kinase  (ERK)  1  and  2.  This  is 
consistent  with  data  from  Stopak  and  colleagues
46  that  indicate  an  increase  in 
APOBEC3G in resting T lymphocytes following activation with interleukin-2 and 
phytohemagglutinin. In addition, the 5’-untranslated region of APOBEC3G contains 
potential  binding  sites  for  transcription  factors  Ets-1,  c-Myc  and  Elk-1,  each  of 
which are activated by the mitogen-activated protein kinase pathway
45,48. 
1.1.2.7  POST-TRANSCRIPTIONAL REGULATION OF APOBEC3G 
Similar  to  the  transcriptional  regulation  of  APOBEC3G,  the  post-transcriptional 
regulation of APOBEC3G is also achieved by the cell cycle via the assembling of 
APOBEC3G into an inactive high molecular mass (HMM) complex. Work by Chiu 
and colleagues
31 indicates that in unstimulated peripheral blood CD4+ T cells and 
monocytes,  where  HIV-1  replication  is  typically  blocked,  APOBEC3G  resides 
almost  exclusively  as  a  low  molecular  mass  (LMM)  of  approximately  46-kDa. 
However, mitogen activation of CD4
+ T cells and differentiation of monocytes to 
macrophages induces the recruitment of the endogenous 46-kDa LMM APOBEC3G  19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 APOBEC3G mRNA levels are regulated by PKC and MEK1/2. A, H9 cells were 
treated with the general PKC inhibitors, PKC inhibitor 20-28 (100 nM) or Calphostin C (50 nM), or 
with the PKC-specific inhibitors, Go6976 (200 nM) and Ro-32-0432 (100 nM), for 1 h prior to the 
addition of PMA (100 nM). B, H9 cells were treated with the specific MEK inhibitors U0126 (20 µM) 
or PD98059 (50 µM) or mock-treated with Me2SO alone for 1 h prior to the addition of PMA (100 
nM) or 4 α-PMA (100 nM), an inactive phorbol ester. The Me2SO concentrations were equal in all of 
the cultures. RNA was isolated from cells at the indicated times and was analysed by quantitative 
real-time PCR for APOBEC3G mRNA levels. C, Northern blot analysis of H9 cells treated with 
U0126 (20 µM) or mock-treated for 1 h prior to the addition of PMA (100 nM) using a [
32P]-labelled 
DNA  probe  specific  for  APOBEC3G.  The  Northern  blot  was  subsequently  probed  with  a  [
32P]-
labelled  DNA  probe  for  the  S2  ribosomal  RNA  loading  control.  Taken  from  reference  45  (No 
permission required to reprint).   20 
protein into a HMM ribonucleoprotein complex, of approximately 700-kDa in mass, 
and correlated with a sharp increase in permissiveness for HIV infection (Figure 
1.11). Specifically, they noted that progression into the G1b, but not the S phase of 
the cell cycle was necessary for HMM APOBEC3G complex formation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 Inducibility of HMM APOBEC3G complex formation in primary CD4
+ T cells with 
different stimuli, and correlation of the HMM complex with permissivity for HIV infection. (A) 
APOBEC3G  complexes  were  identified  by  FPLC,  SDS–PAGE  and  immunoblotting  with  anti-
APOBEC3G  antibody.  Single-round  infection  experiments  were  performed  with  the  VSV-G-
pseudotyped  NL4-3  HSA  virus.  Ranges  of  HIV  infectivity  were  determined  by  normalizing  the 
percentage of HSA-positive cells obtained with each treatment to the response in cells stimulated with 
PHA and IL-2 (assigned a value of 100%). HIV infectivity: >70% (high, +++); 30–70% (moderate, 
++); 5–30% (low, +); <5% (none, -). Scoring was based on the infectivity data obtained from cells 
isolated from four healthy donors. PMA, phorbol 12-myristate 13-acetate. Taken from reference 31 
(reprinted by permission from Macmillan Publishers, Ltd) [Nature, 2005;435:108-14]. 
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1.1.2.8  APOBEC3G-VIF INTERACTION 
Lentiviral vif proteins generally exhibit high species-specificity such that it has been 
hypothesised  that  vif  may  be  a  key  regulator  of  the  primate  species  tropism  of 
primate immunodeficiency viruses
9,49. The chimpanzee variant of SIV, which gave 
rise  to  HIV-1,  and  sooty  mangabey  SIV,  which  gave  rise  to  HIV-2,  encode  vif 
proteins that are able to block human APOBEC3G, thus allowing their crossover into 
human populations as zoonotic infections. In contrast, the vif protein encoded by 
African green monkey (agm) SIV is active against the agm APOBEC3G protein but 
does not inhibit human APOBEC3G and thus replicates poorly in primary human 
cells
9,49. 
Despite the high degree of homology between human and agm APOBEC3G (77%), 
several  laboratories  have  demonstrated  that  the  species-specific  interaction  of 
APOBEC3G and vif is highly dependent on a single APOBEC3G amino acid
50-53. 
These  in  vitro  studies  demonstrated  that  mutation  of  the  aspartic  acid  residue  at 
position 128 of human APOBEC3G to that observed in agm (lysine) renders the 
mutant human APOBEC3G resistant to HIV-1 vif and sensitive to SIVagm vif and 
conversely, agm APOBEC3G that contained the reciprocal K128D mutation became 
resistant to SIVagm vif and sensitive to HIV-1 vif (Figure 1.12A). Furthermore, the 
exchange at position 128 switched the specificity with which APOBEC3G bound 
SIVagm or HIV-1 vif (Figure 1.12B). This species-specificity suggests APOBEC3G 
and vif interact directly rather than through an RNA or protein intermediary
51.    22 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12 The APOBEC3G D128K mutation selectively allows APOBEC3G to bind HIV-1 vif 
or SIVagm vif. (A) 293T cells were cotransfected with the pNL-Luc-HXB_Vif proviral indicator 
construct  together  with  the  HIV-1  Vif  expression  plasmid  pgVif  or  the  SIVagm  Vif  expression 
pSIVagmVif, or a control plasmid, and finally with plasmids expressing wild-type or mutant forms of 
h3G or agm3G. At 44 h after transfection, the supernatant media were harvested and used to infect 
CD4
+, CXCR4
+ 293T cells. A further 28 h later, the infected cells were lysed and the level of virus-
encoded Luc activity was quantified. Data are expressed relative to the level of Luc activity induced 
by  virus  derived  from  a  culture  transfected  with  pNL-Luc-HXB_Vif  in  the  absence  of  any 
APOBEC3G  or  Vif  expression  plasmid,  which  was  arbitrarily  set  at  100.  The  average  of  three 
independent  experiments  with  SD  is  indicated.  (B)  Transfected  293T  cells  with  the  HIV-1  Vif 
expression plasmid pgVif and a plasmid encoding the indicated HA-tagged APOBEC3G protein. At 
48 h after transfection, the cells were lysed and subjected to immunoprecipitation by using a mouse 
anti-HA mAb. Proteins present in the total lysate (T) or immunoprecipitate (IP) were then separated 
by gel electrophoresis, transferred to a nitrocellulose filter, and analysed by Western blot analysis by 
using rabbit polyclonal antisera specific for the HA tag (Upper) or the HIV-1 Vif protein (Lower). The 
negative (Neg) control lane was transfected with the control pcDNA3 plasmid. This experiment used 
2% of the total lysate and 10% of the immunoprecipitate in each lane. Taken from reference 53 (No 
permission required to reprint). 
However, it has been reported that a fragment of APOBEC3G consisting of residues 
54-124 is able to specifically interact with HIV-1 in transfected cells 
22. Thus, it is 
likely that position 128 does not directly participate in vif-APOBEC3G binding, but 
A
B
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rather facilitates complex formation
53. Consistent with such a conclusion, Xu and 
colleagues
54 also observed inhibited HIV-1 replication in the presence of the D128K 
APOBEC3G mutant and wild type vif however, in contrast to previous studies, the 
APOBEC3G D128K mutant was able to form complexes with HIV-1 vif (Figure 
1.13A) but steady-state levels of the D128K APOBEC3G mutant were not depleted 
and failed to be degraded (Figure 1.13B). This was not due to a disruption of a 
structural element that serves as a recognition signal for proteasomal degradation 
because  the  D128K  mutant  was  efficiently  degraded  when  complexed  with 
SIVmac239 vif or HIV-2 vif. Taken together, these results suggest that the HIV-1 vif-
APOBEC3G  interaction  induces  a  conformational  change  in  APOBEC3G  that 
exposes the asp-128 residue which synergistically binds vif, promoting APOBEC3G 
inhibition
50 and initiates vif-APOBEC3G complex degradation
54. 
   
 
 
 
 
 
Figure 1.13 HIV-1 Vif is able to interact and form complexes with APOBEC3G D128K mutant 
(A) but fails to reduce steady-state levels of the mutant APOBEC3G protein (B). (A) Wild-type 
and  Apo12  (contains  D128K  mutation)  APOBEC3G  interact  with  HIV-1  Vif  as  determined  by 
coimmunoprecipitation.  An  anti-myc  antibody  attached  to  magnetic  beads  was  used  to 
immunoprecipitate the wild-type APOBEC3G and the Apo12 mutant proteins from cell lysates. The 
cellular proteins that were coimmunoprecipitated were analysed for the presence of Vif by using an 
anti-Vif antibody. (B) Western blot analysis of the steady-state levels of wild-type APOBEC3G and 
D128K  mutant  of  APOBEC3G  in  the  absence  of  any  Vif  or  presence  of  HIV-1,  SIVmac239 
(SIVmac), and HIV-2 Vif proteins. The APOBEC3G proteins were detected by using an anti-myc tag 
antibody,  and  the  tubulin  proteins  were  detected  with  an  anti-tubulin  antibody  to  normalize  the 
amounts of cell lysates analysed. Taken from reference 54 (No permission required to reprint). 
A B A A B B  24 
1.1.2.9  VIRION ENCAPSIDATION OF APOBEC3G 
Both  the  N-  and  C-terminals  of  APOBEC3G  are  required  for  encapsidation  of 
APOBEC3G into nascent virions.  APOBEC3G mutants lacking the 67 N-terminal 
or  39  C-terminal  amino  acids  fail  to  incorporate  into  virions
55.  Navarro  and 
colleagues
56 discovered that virion encapsidation was primarily mediated via the zinc 
coordinating and RNA binding residues of the N-terminal cytidine deaminase (CD1) 
domain. Mutation of the zinc coordinating Cys residues, Cys97 and Cys100, and the 
two highly conserved aromatic residues within the CD1 that mediate RNA binding 
(Phe70 and Tyr91), but not the corresponding amino acids of the C-terminal cytidine 
deaminase  (CD2)  domain  (Cys288,  Cys291,  Phe262  and  Phe282),  prevented 
encapsidation (Figure 1.14). The stable expression of the zinc coordinating mutants 
was reduced 2- to 4-fold compared to other mutants suggesting they also play a 
structural role
56. The requirement of the APOBEC3G CD1 domain for APOBEC3G 
encapsidation is conserved in HIV-1, human T cell leukemia virus type 1 (HTLV-1) 
and murine leukemia virus (MuLV)
56. The first linker region of APOBEC3G may 
also  play  a  role  in  virion  encapsidation  as  significant  reductions  in  APOBEC3G 
encapsidation has been observed with mutants lacking amino acids 104-156
57.  
Virion encapsidation of APOBEC3G is highly dependent on the gag nucleocapsid 
(NC)  domain
57-62.  Indeed,  APOBEC3G  is  able  to  interact  specifically  with  gag 
proteins produced by every retrovirus and endogenous retroelement examined so far 
and also with the HBV core antigen (for review see Cullen
63). Specifically, the N-
terminal  11  amino  acids  of  the  p7  region  of  NC  are  required  for  APOBEC3G 
encapsidation
57.  It  is  unclear  if  APOBEC3G  binds  directly  to  NC;  as  such   25 
interactions only occur in the presence of RNA
59. However, the RNA is unlikely to 
bridge  the  APOBEC3G-gag  interaction  as  APOBEC3G-gag  complexes  can  be 
immunoprecipitated from cell lysates following RNase treatment
61. The requirement 
of gag for virion encapsidation of APOBEC3G is highlighted by MuLV, a simple 
retrovirus that is largely unaffected by expression of the catalytically active cognate 
murine APOBEC3, despite the fact it does not encode a vif protein (or any auxiliary 
protein), because its gag protein is unable to bind murine APOBEC3 and therefore 
does not encapsidate APOBEC3
64. 
 
 
 
 
 
 
Figure 1.14 Mutations of the zinc coordinating (Cys97 andCys100, 1CCAA) and RNA binding 
(Phe70 and Tyr91, 1FYAA) residues of CD1 but not of the CD2 (2CCAA & 2FFAA) domain 
reduces HIV-1 encapsidation of APOBEC3G. Virions were generated with ∆vif NL4-3 (∆vif) and 
the mutated APOBEC3G-HA expression vector indicated above each lane. Taken from reference 56 
(reprinted by permission from Elsevier Science) [Virology, 2005;333:374-86]. 
Thus, it appears that APOBEC3G exploits the key role of gag to recruit the viral 
RNA genome into virion particles to infiltrate virus particles. Therefore, by utilising 
a relatively non-specific mechanism of encapsidation, retroviruses are unlikely to 
develop specific escape mutations that prevent APOBEC3G encapsidation and may   26 
explain  why  lentiviruses  have  evolved  a  gene  whose  sole  function  is  to  remove 
APOBEC3G from the cell
59. 
1.1.2.10  ANTIVIRAL DOMAINS OF APOBEC3G  
The duplicated active sites of APOBEC3G mediate distinct antiviral mechanisms. 
Newman and colleagues
65 discovered using APOBEC3G mutants that single point 
mutations  in  the  CD2  domain  (H257R,  E259Q,  C288S  and  C291S)  significantly 
decreased  DNA-mutating  activity  compared  to  both  wild  type  APOBEC3G  and 
APOBEC3G  mutants  harbouring  corresponding  CD2  domain  mutations  (H65R, 
E67Q, C97S, and C100S) (Figure 1.15A). The antiviral activity of these CD1 and 
CD2 domain mutants however was similar to that of wild type APOBEC3G and 
significant reductions in antiviral activity were only observed in the APOBEC3G 
mutants that harboured point mutations in both the CD1 and CD2 domains (Figure 
1.15B).  In  contrast,  Navarro  and  colleagues
56  demonstrated  that  mutation  of  the 
catalytic residue of the CD2 domain (Glu259) but not that of the analogous residue 
of the CD1 domain (Glu67), is sufficient to significantly diminish antiviral activity 
of APOBEC3G. Although consistent with the results of Newman and colleagues
65, 
the  CD2  mutant  had  selectively  lost  cytidine  deaminase  activity.  Thus,  the  CD2 
domain of APOBEC3G is necessary for the DNA deaminase activity of APOBEC3G 
and the CD1 domain exerts a DNA deaminase-independent antiviral function.  
Consistent with the premise that the duplicated active sites of APOBEC3G function 
independently,  two  separate  domains  of  AID  are  independently  responsible  for 
somatic hypermutation  and class switch recombination. Furthermore, catalytically   27 
inactive  APOBEC3G  mutants  are  as  effective  at  inhibiting  hepatitis  B  DNA 
synthesis as wild type APOBEC3G and despite incorporation of APOBEC3G into 
HBV virions, C to U mutations were not detected
66. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15 The Cytidine Deaminase Activity of APOBEC3G Is Not Required for an Antiviral 
Effect.  (A)  The  ability  of  wild-type  or  mutated  APOBEC3G  proteins  to  mutate  E.  coli  DNA. 
APOBEC3G-expressing  vectors  were  transformed  into  bacteria,  and  the  resulting  induction  of 
rifampicin resistance was quantitated by counting rifR colonies (relative to viable cell counts). The 
mutation rates for the mutant APOBEC3G proteins are plotted as a percentage of that seen with wild-
type  protein  (set  at  100%).  Error  bars  represent  the  standard  deviation.  The  lower  panel  shows 
immunoblots confirming comparable expression of the mutant APOBEC3G proteins in bacteria. (B) 
Antiviral function of APOBEC3G mutant proteins. Vif-deficient HIV-1 was produced in 293T cells 
transiently  transfected  with  APOBEC3G  expression  vectors.  Virus-containing  supernatants  were 
harvested at 24 hr and quantitated with a p24Gag ELISA. Normalized inocula were used to infect the 
C8166-CCR5/HIV-LTR CAT indicator cell line and the antiviral activity of each mutant protein is 
presented as a percentage of that seen for wild-type APOBEC3G. Error bars represent the standard 
deviation.  The  lower  panel  is  an  immunoblot  confirming  expression  of  the  mutant  APOBEC3G 
proteins in producer cell lysates. Taken from reference 65 (reprinted by permission from Elsevier 
Science) [Curr Biol, 2005;15:166-70].   28 
The  trinucleotide  target  specificity  exhibited  by  APOBEC3G  (CCC)  and 
APOBEC3F (TTC) is governed by the CD2 domain. A chimeric APOBEC3F protein 
in which the CD2 domain was replaced by either the CD2 domain of APOBEC3G or 
the  single  cytidine  deaminase  domain  of  APOBEC3C  exhibited  the  sequence 
specificity  of  the  CD2  domain
67.  Interestingly  however,  chimeric  APOBEC3F 
proteins in which the N- or C-terminal halves of the APOBEC3F CD2 domain were 
substituted  by  corresponding  portions  from  APOBEC3C  exhibited  a  dinucleotide 
specificity (C/TCC) quite distinct from that of either APOBEC3F or APOBEC3C 
(TC/TC), yet similar to that of APOBEC3G.   29 
1.1.3  VIRAL INFECTIVITY FACTOR (VIF) 
 
1.1.3.1  HIV ACCESSORY/REGULATORY GENES 
Although  the  life  cycle  of  lentiviruses  such  as  HIV-1  is  the  same  as  for  other 
retroviruses, lentiviral genomes are unique among retroviruses in that they encode 
six regulatory/accessory proteins involved in regulation of viral gene expression and 
infectivity  (Figure  1.16)  (Tat,  Rev,  Vpu,  Nef,  Vpr,  and  Vif).  These  proteins  are 
essential  for  viral  pathogenesis  in  vivo  but  are  often  not  required  for  viral 
replication/infectivity in vitro (for reviews, see Emerman & Malim
68,69and Anderson 
& Hope
69).  
 
 
 
 
 
 
 
 
 
Figure 1.16 Schematic representation of the HIV-1 genome. Blue – structural proteins; Yellow - 
accessory proteins; Pink - regulatory proteins; Grey – transcriptional start sites. 
Briefly, transactivating transcription factor (Tat) regulates high level transcription of 
the  proviral  DNA  mostly  at  the  level  of  transcriptional  elongation  rather  than 
initiation
70,71. Regulator of viral protein synthesis (Rev) binds to a cis-acting RNA 
target (Rev response element) present in all unspliced viral transcripts and targets 
them  for  nuclear  export.  Viral  protein  U  (Vpu)  and  negative  factor  (Nef) 
cooperatively  down  regulate  surface  expression  of  the  primary  HIV-1  receptor, 
CD4
+; Vpu binds to CD4 in the endoplasmic reticulum and promotes its proteolysis   30 
by recruitment into the ubiquitin-proteasome pathway while Nef removes CD4
+ from 
the  cell  surface  by  accelerating  endocytosis  through  clathrin-coated  pits.  Viral 
protein R (Vpr) helps to maximise virus production by preventing infected cells from 
proliferating, arresting the cells in the G2 phase of the cell cycle, the phase in which 
the  viral  long  terminal  repeat  (LTR)  is  more  active
72.  The  role  of  the  virion 
infectivity factor (vif) had been the least understood of the HIV-1 proteins, until 
Sheehy and colleagues
11 isolated APOBEC3G, the cellular target of vif.  
1.1.3.2  ROLE TO VIF   
Vif is a highly basic, 23 kDa protein
73 that functions to prevent the encapsidation of 
APOBEC3G into virions for degradation via the proteasomal pathway
46,74-80. Early 
researchers had noted that ∆vif HIV-1 virions had reduced infectivity (approximately 
1000-fold) despite the production of similar amount of viral particles as wild-type 
(wt) HIV-1 virions
81,82. This was not due to impaired cellular entry or block in the 
early replication stages
83 but rather the impaired kinetics and extent of provirus DNA 
production
84-87. 
The requirement of  vif  for efficient HIV-1  replication was found to be cell type 
dependent, required for HIV-1 replication in the CD4
+ T-cell lines CEM and H9 as 
well as in peripheral blood T lymphocytes, but dispensable for replication in the 
SupT1, C8166, and Jurkat T-cell lines (Figure  1.17). This suggested that vif can 
compensate for cellular factors required for production of infectious virus particles 
that are present in some cell lines such as SupT1, C8166, and Jurkat but are absent in 
others such as CEM and H9 as well as peripheral blood T lymphocytes
82,88. Indeed,   31 
work by Simon and colleagues
9 and Madani & Kabat
10 utilising heterokaryons of 
permissive  and  non-permissive  cells,  demonstrated  that  HIV-1  virions  produced 
from the heterokaryons are fully infectious, strongly supporting the conjecture that 
the  natural  targets  of  HIV-1  contain  a  potent  endogenous  inhibitor  of  HIV-1 
replication that is overcome by vif.  
 
 
 
 
Figure 1.17 Replication of vif-positive and vif-negative HXB2viruses in CD4
+ human  T-cell 
lines.  Reverse transcriptase activity in the  supernatants  of T-cell cultures transfected  with  10µg of 
pHXB2 (open circles) or pHXB2∆vif (solid circles) plasmid DNA. Taken from reference 82 (reprinted 
by permission from American Society for Microbiology) [J Virol, 1992;66:6489-95]. 
Through cDNA subtraction assays utilising cDNA from a non-permissive cell line 
(CEM)  and  a  permissive  subclonal  cell  line  (CEM-SS),  Sheehy  and  colleagues
11 
demonstrated that CEM15, a novel cellular protein, was abundantly expressed in 
non-permissive cells and absent or minimally expressed in permissive cells, and its 
ectopic expression in permissive cells renders them non-permissive. Analysis of the 
amino  acid  sequence  of  CEM15  revealed  significant  sequence  homology  to 
mammalian APOBEC1 and was subsequently termed APOBEC3G.    32 
1.1.3.3  VIF-MEDIATED DEGRADATION OF APOBEC3G 
Vif  functions  at  several  levels  to  prevent  virion  encapsidation  of  cellular 
APOBEC3G, preventing APOBEC3G-mediated cytidine deamination of the progeny 
virions within the target cell. Vif binds APOBEC3G and sequesters APOBEC3G, 
excluding it from virion encapsidation, promotes degradation of the vif-APOBEC3G 
complex via the proteasomal pathway
49,74-76 and impairs the stability and translation 
of  APOBEC3G  mRNA
46.  Thus,  vif  functions  to  remove  APOBEC3G  from  both 
nascent virions and virus producing cells.  
The vif proteins of HIV-1, HIV-2 and SIVagm contain a highly conserved region with 
homology  to  the  SOCS-box  motif  of  cellular  proteins  that  bind  to  Elongin  B/C 
heterodimers.  Indeed,  coimmunoprecipitation  and  mass  spectrometry  revealed  vif 
binds Elongin B (EloB), Elongin C (EloC) and Cullin 5 (Cul5), core subunits of an 
E3 ubiquitin ligase complex that promote the polyubiquitination of proteins, a post-
translational  modification  that  controls  the  activity,  localisation  and  proteasomal 
degradation  of  many  cellular  proteins  (Figure  1.18A).  Several  studies  have 
demonstrated that coexpression of vif and APOBEC3G in 293T cells result in the 
polyubiquitination and decreased expression of both APOBEC3G and vif
74,78,79,89. 
The  half-life  of  APOBEC3G  in  the  presence  of  vif  (1-2  minutes)  indicates  that 
APOBEC3G is the most rapidly degraded protein studied to date
75. In addition, Cul5 
mutants and proteasomal inhibitors blocked the ability of vif to induce APOBEC3G 
degradation (Figure 1.18B). Therefore, vif is similar to F-box proteins, in that it is 
autoubiquitinated within its own E3 ligase complex. Thus a reciprocal relationship 
exists wherein vif and APOBEC3G influence steady state levels of each other.    33 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.18  HIV-1  vif  interacts  with  cellular  proteins  Cul5,  ElonginB  and  ElonginC  (A)  to 
promote  the  polyubiquitination  and  subsequent  proteasomal-mediated  degradation  of  vif-
APOBEC3G  complexes  (B).  (A)  Coimmunoprecipitation  of  cellular  proteins  with  Vif-HA.  Cell 
lysates from HXB2-or HXB2VifHA infected H9 cells were immunoprecipitated with HA antibody, 
followed by SDS–polyacrylamide gel electrophoresis (PAGE) and silver staining. The identification 
of Cul5, Elongin B, and Elongin C was achieved by mass spectroscopic analysis; these proteins were 
not detected in the control HXB2 samples; kDa – kilodaltons. Taken from reference 77 (reprinted by 
permission from American Society for the Advancement of Science) [Science, 2003;302:1056-60]. 
(B)  293T  cells  were  transfected  with  pNLA1.Vif-FLAG  (10µg),  pAPOBEC3G:HA  (5µg),  and 
pRbG4-His6-myc-Ub (5µg) vectors and treated with chloroquine (lysosomal inhibitor) or MG132/β-
lactone (proteasomal inhibitors) for 6 h before lysis. APOBEC3G and Vif were detected by Western 
blotting with anti-HA and anti-Vif antibodies, respectively. Taken from reference 79 (No permission 
required to reprint). 
 
As mentioned, vif proteins contain a highly conserved SOCS-box motif required for 
binding  to  EloBC  heterodimers  and  the  subsequent  proteasomal  degradation  of 
APOBEC3G. This motif consists of approximately 25-40 amino acids and contains 
an  N-terminal  BC-box  sequence  and  a  C-terminal  PPLP  motif.  The  BC-box 
sequence of HIV-1 vif (145SLQYLAL151) is the most conserved sequence among 
lentivirus vif proteins and differs from the BC-box of other viral and cellular proteins 
by containing an alanine at position 6 instead of cysteine. In addition to binding 
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EloBC  heterodimers,  dependent  on  leucine  at  position  7,  the  BC-box  motif  also 
binds Cul5. Precipitation of Cul5 with vif was completely abolished when wild type 
vif was replaced by vif mutant ∆SLQYLAL. Specifically, it was found that it is the 
alanine for cysteine substitution at position 6 of the BC-box motif that distinguishes 
lentiviral vif from other viral and cellular BC-box motifs, in addition to the leucine at 
position 2, which allows vif to bind to Cul5
79. However, it was also found that the 
precipitation  of  vif  with  Cul5  was  significantly  impaired  for  the  vif  mutant 
C114/133S, in which cysteines 114 and 133 are substituted for serine. The cysteine 
molecules lack significant homology to other cullin-binding proteins and therefore 
are unlikely to be directly involved in binding; rather they may be important for 
protein  conformation  or  other  as  yet  unknown  functions
79.  Such  conclusions  are 
consistent with conflicting results from Kobayashi and colleagues
90. They found that 
vif  C114S  and  C133S  mutants  were  able  to  bind  Cul5  and  were  able  to  form 
APOBEC3G-vif-EloBC-Cul5 complexes, however such complexes had lost their E3 
ligase activity towards APOBEC3G (Figure 1.19). 
The role of the C-terminal  161PPLP164 domain is unclear. Reports from Yang and 
colleagues
91,92  indicate  that  the  proline/leucine-rich  domain  is  required  for  vif 
function by allowing vif multimerisation. Vif, like most HIV-1 proteins, possesses a 
strong tendency to self-association and is a requirement for their functionality (for 
review,  see  Frankel  &  Young
93).  Yang  and  colleagues
92  demonstrated  using 
synthesised overlapping 15-mers covering the entire vif sequence that vif-derived 
peptides containing the  161PPLP164 domain inhibited the vif-vif interaction and that 
deletion of the domain significantly impaired the capability of vif proteins to interact 
with each other.   35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.19 Vif C114S and C133S mutants are able to bind Cul5 (A) but fail to ubiquitinate 
APOBEC3G (B) despite similar levels of vif, EloBC and Cul5 expression (C). (A) Hi Five cells 
were  co-infected  with  recombinant  baculoviruses  expressing  His-vif  (WT  or  mutants),  myc-Cul5, 
EloB, EloC, and Rbx1. The lysates  were immunoprecipitated with anti-vif mAb and analysed by 
immunoblotting with anti-c-myc mAb (top panel) and anti-vif serum (middle panel). Cell lysates were 
also analysed by immunoblotting with anti-c-myc mAb (bottom panel). Vif WT as well as C114S and 
C133S  mutants  could  bind  to  Cul5  through  EloB  and  EloC  (lanes  1–3,  respectively),  but  the 
SLQ144/146AAA mutant did not (lane 4). (B) An in vitro ubiquitin (Ub) conjugation assay was 
performed  with  a  vif-BC-Cul5  complex  (WT,  C114S,  or  C133S).  GST-ubiquitin-conjugated 
APOBEC3G was specifically detected as a ladder (arrows) only in a WT vif-BC-Cul5 complex (lane 
3) but not in C114S and C133S vif-BC-Cul5 complex (lanes 4 and 5, respectively). (C) Hi Five cells 
were co-infected with recombinant baculoviruses expressing His-Vif (WT, C114S, or C133S), Cul5, 
EloB,  EloC,  and  Rbx1,  and  His-Vif  protein  was  purified  with  NTA  beads.  Purified  His-Vif  and 
associated proteins were visualized by immunoblotting with the appropriate antibodies. Taken from 
reference 90 (No permission required to reprint). 
 
 
1.1.3.4  VIF ENCAPSIDATION  
Vif is a cytosolic protein that, in the absence of APOBEC3G, associates with the 
plasma membrane via an interaction with gag
94,95 that allows co-encapsidation of 
both  vif  and  gag  into  virions
96,97.  Vif  specifically  associates  with  the  Pr55  gag 
precursor, with no interaction with the mature capsid protein. Deletion of the gag 
residues H421-T470, which corresponded to the C-terminal region of nucleocapsid 
(NC), including the second zinc finger, the intermediate spacer peptide sp2 and the 
N-terminal  half  of  the  p6  domain,  significantly  decreased  vif  encapsidation 
efficiency,  and  complete  deletion  of  NC  abolishes  vif  encapsidation.  In  vif,  four 
discrete gag-binding sites were identified, within residues T68-L81 (site I) and W89-
P100 (site II) in the central domain, and within residues P162-R173 (III) and P177-  36 
M189 (IV) at the C terminus. Substitutions in site I and deletion of site IV were 
detrimental to vif encapsidation, whereas substitution of basic residues for alanine in 
sites III and IV had a positive effect
96. 
1.1.3.5  REGULATION OF VIF    
Phosphorylation of vif plays an important role in regulating HIV-1 replication and 
infectivity. Indeed, several HIV-1 proteins, including p24Gag, p17Gag, Vpu, Rev 
and Nef have been shown to be regulated, at least in part, by phosphorylation
98-102. In 
vitro  phosphorylation  studies  utilising  32P-labelled  vif  and  protease  digestion 
followed  by  HPLC  resolution  and  radioactive  sequencing  revealed  vif 
phosphorylation  is  restricted  to  the  C-terminus  amino  acids,  Ser144,  Thr155  and 
Thr188103,104. Despite Thr155 and Thr188 being contained within the R/KXXS*/T* 
and  R/KXXXS*/T*  recognition  motifs  used  by  serine/threonine  protein  kinases, 
such as cGMP-dependent kinase and protein kinase C, inhibitors of such kinases 
failed to inhibit vif phosphorylation, questioning the role of these phosphorylation 
sites.  Indeed,  Thr188  is highly  conserved  amongst  HIV-1  isolates  but  not  among 
other lentiviruses while Thr155 is not highly conserved. In contrast, substitution of 
Ser144 for Ala144, which is contained within the highly conserved BC-box motif 
145SLQYLAL151 and is critical for vif function, resulted in loss of vif function and 
over 90% inhibition of HIV-1 replication (Figure 1.20)
103. The kinase responsible for 
phosphorylation of Ser144 was not identified.  
Subsequent  studies  from  the  same  group
104,105  identified  two  additional 
phosphorylation  sites,  Thr96  and  Ser165,  that  were  phosphorylated  by  p44/42   37 
mitogen-activated protein kinase (MAPK, also known as extracellular protein kinase 
1 (ERK1) and ERK2) despite them not being located in the PX(S/T)P or (S/T)P 
consensus motifs for MAPK substrates. MAPK play critical roles in regulation of 
cell proliferation and differentiation in response to mitogens and a wide variety of 
growth factors and cytokines (reviewed by Marshall
106,107 and Seger & Krebs
107). 
Thus, phosphorylation of vif by MAPK may contribute to the activation of HIV-1 
replication by mitogens and other extracellular stimuli. 
 
 
 
 
 
 
 
 
 
Figure  1.20  Phosphorylation  of  HIV-1  proteins  by  MAPK.  In  vitro  kinase  assays  were 
performed  using  recombinant  p42  MAPK.  MAPK  immunocomplexes  were  isolated  from  cell 
lysates  by  using  anti-ERK1  and  anti-ERK2.  MAPK  was  incubated  with  2  mg  of  each  indicated 
recombinant HIV-1 protein for in vitro kinase assays performed in the presence of [g-32P]ATP. The 
results of phosphorylated amino acid analysis are shown on the right. The positions of phosphorylated 
Ser, Thr, and Tyr (pSer, pThr, and pTyr) markers are indicated. Phosphorylated amino acids detected 
in the recombinant HIV-1 proteins comigrated with pSer and pThr but not with pTyr. Taken from 
reference 104 (No permission required to reprint). 
 
 
1.1.3.6  VIF-APOBEC3 BINDING  
As  mentioned  in  section  1.1.3.3,  in  addition  to  facilitating  the  formation  of  vif-
APOBEC3G-Cul5-EloBC  E3  ligase  complexes  that  promote  the  degradation  of 
APOBEC3G through the ubiquitination and proteasomal pathway, vif also prevents 
encapsidation of APOBEC3G by simply forming vif-APOBEC3G complexes that 
are sufficient to inhibit deaminase activity.   38 
Ectopic  coexpression  of  APOBEC3G  and  vif  in  E.coli  allowed  Santa-Marta  and 
colleagues
50  to  investigate  the  role  of  proteasomal  degradation  in  inhibiting 
APOBEC3G  activity  as  E.coli  lack  ubiquitin-proteasomal  machinery.  Using  this 
approach, it was found that expression of vif was sufficient to inhibit APOBEC3G 
deaminase  activity.  In  addition,  substitution  of  the  vif  C114  residue,  which  is 
required for E3 ligase activity
90, failed to restore APOBEC3G deaminase activity, 
clearly  demonstrating  that  vif-APOBEC3G  binding  is  sufficient  for  inhibition  of 
APOBEC3G  deaminase  activity.  This  is  consistent  with  confocal  observations 
presented in Figure 1.21, demonstrating that APOBEC3G can be stably expressed in 
the presence of excess vif and that viruses produced from cells stably coexpressing 
APOBEC3G and vif are fully infectious
108. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.21  Stable  coexpression  of  APOBEC3G  and  vif.  Cells  were  stained  with  a  rabbit 
polyclonal antibody to APOBEC3G (A & D) and a monoclonal Vif antibody (B & E). APOBEC3G 
was visualized using a Texas red-conjugated secondary antibody; Vif was visualized with a Cy2-
conjugated secondary antibody. Panels C and F are merged images of panels A & B and D & E, 
respectively.  Arrow  heads  are  defined  as  follows:  white  =  APOBEC3G:Vif-double-positive  cells; 
yellow = Vif-negative cells; red = cells exhibiting nuclear and cytoplasmic staining for Vif. Taken 
from reference 108 (No permission required to reprint).   39 
While  it  is  clear  that  the  charge-changing  D128K  APOBEC3G  polymorphism 
selectively facilitates APOBEC3G to bind HIV-1 vif or SIVagm vif, respectively
50-53, 
the corresponding binding site(s) on vif are unclear. Using competitive phage-ELISA 
assays  to  detect  specific  interactions  between  phage-displayed  APOBEC3G  and 
overlapping clade B vif  15-mers spanning the entire vif protein, significant inhibition 
of APOBEC3G-vif complex formation was observed with peptides spanning amino 
acids  13-39,  73-99,  133-147  and  169-192  at  salt  concentrations  that  favour  low 
energy  interactions
50.  Using  high  salt  concentrations  that  select  for  strong 
APOBEC3G-vif peptide interactions, only vif peptides spanning amino acids 85-99 
and  169  to  192  significantly  inhibited  APOBEC3G-vif  complex  formations, 
implicating both the C- and N-terminal regions (Figure 1.22)
50. Consistent with these 
results, work by Simon and colleagues (2005) using a panel of vif mutants containing 
naturally  occurring mutations, found expression of  vif mutants harbouring  K22E, 
S32P,  Y40H,  E45G,  F115S,  G138R  or  L150P  mutants  failed  to  maintain  HIV-1 
infectivity  in  293T  cells  coexpressing  APOBEC3G.  Furthermore,  specific  amino 
acids within the C-terminus were found to selectively neutralise APOBEC3G and 
APOBEC3F. The K22E vif mutant retained partial activity against APOBEC3F, but 
was  inactive  against  APOBEC3G  and  conversely,  Y40H  and  E45G  vif  mutants 
neutralised  APOBEC3F  as  efficiently  as  wild  type  vif  but  failed  to  neutralise 
APOBEC3G.   40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.22 Vif peptides comprised of vif amino acids 85-99 and 169 to 192 significantly inhibit 
interaction between phage-displayed APOBEC3G and vif. Competitive ELISA of phage-displayed 
APOBEC3G against vif protein using HIV-1 consensus B vif (15-mer) peptides covering the complete 
vif sequence. Recombinant vif protein was added to a 96-well plate. Phage-displayed APOBEC3G 
was preincubated with 100 µM of independent peptides in low or high ionic buffer. After incubation, 
excess phages were washed off, and HRP-conjugated anti-M13 monoclonal antibody was used for 
detection. The results were measured by optical density at 405 nm. Taken from reference 50 (No 
permission required to reprint).   41 
1.1.4  CLINICAL SIGNIFICANCE 
 
1.1.4.1  APOBEC3G GENETIC VARIATION 
Two studies to-date have examined the clinical significance of APOBEC3G genetic 
variation;  each  examining  the  influence  of  APOBEC3G  genetic  variation  on 
progression to AIDS. The first study, conducted by An and colleagues
109 identified 
seven single nucleotide polymorphisms (SNPs) utilising nonisotopic RNA cleavage 
assays  and  DNA  sequencing  targeting  the  putative  5’  regulatory  region,  exonic 
regions,  intron/exon  junctions,  intron  1  and  the  3’  untranslated  region  of  the 
APOBEC3G  gene  from  92  European  Americans  and  92  African  American 
individuals. The genotype of each SNP was then determined for 2,430 individuals 
enrolled in the United States-based HIV/AIDS prospective cohorts, 643 participants 
in the Swiss HIV Cohort Study (SHCS) and 129 healthy Chinese individuals and 
haplotypes deduced by the expectation maximisation algorithm. Comparing allele, 
genotype  and  haplotype  frequencies  in  seropositive  individuals  to  seronegative 
individuals revealed no association between APOBEC3G genetic variation and HIV-
1  transmission.  Regarding  AIDS  progression,  the  186R  APOBEC3G  variant, 
common amongst African Americans but rare amongst European Americans (37% 
allele  frequency  versus  3%,  respectively)  was  significantly  associated  with  both 
rapid progression to AIDS and death and more rapid decline of CD4
+ T-cell slope 
than  individuals  homozygous  for  the  H185  APOBEC3G  variant  (Figure  1.23A). 
However, in vitro studies did not reveal a significant difference in antiviral activity 
between the H186R APOBEC3G variants (Figure 1.23B), although the influence of 
the 186 polymorphism on G→A mutation, which may promote the emergence of 
escape mutants, was not determined.   42 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.23 The APOBEC3G 186R variant associated with accelerated progression to AIDS 
exhibits similar antiviral activity to the 186H variant. (A) Kaplan-Meier survival curves of HIV-1 
progression to AIDS-1987 after seroconversion for the three genotypes of APOBEC3G-H186R in 
African Americans. RH and P values are from an adjusted Cox model analysis, and log rank P value 
compares the Kaplan-Meier curves. (B) 293T cells were transfected with R9 HIV-1 or with the vif-
defective R9∆vif proviral clone in the presence of empty vector, wt hAPOBEC3G (H186R), or 186R 
APOBEC3G-expressing  vector.  Supernatant  was  filtered,  and  viral  titer  was  scored  by  infecting 
HeLa-CD4-LacZ  reporter  cells  not  expressing  APOBEC3G.  Virion  infectivity  is  normalized  for 
particle  amount,  as  measured  by  RT  activity  assay.  Taken  from  reference  109  (reprinted  by 
permission from American Society for Microbiology) [J. Virol. 2004;78:11070-76]. 
 
The second study, conducted by Do and colleagues
110 identified 42 polymorphisms, 
of which 29 had allele frequencies greater than 1% and 14 were novel from 327 
clade  B  infected  French  individuals  from  the  Genetics  of  Resistance  to 
Immunodeficiency  Virus (GVIR)  cohort and 446 healthy controls. Similar to the 
previous study by An et al
109, this study failed to identify any significant associations 
between  APOBEC3G  polymorphisms  or  deduced  haplotypes  or  haploblocks  on 
progression to AIDS. These studies reveal APOBEC3G to be a highly conserved 
protein  amongst  Caucasian  individuals,  with  only  two  non-synonymous 
polymorphisms  identified  at  very  low  frequencies.  Thus,  among  Caucasian 
individuals,  it  is  likely  that  viral  genetic  variation  contributes  greater  to 
hypermutation and its clinical consequences than host genetic variation. 
B A B A  43 
1.1.4.2  VIF GENETIC VARIATION  
Vif  genetic  variation  has  been  associated  with  long-term  non-progression  status 
although  whether  these  associations  manifest  through  hypermutation  is  unclear. 
Yamada and Iwamoto
111 observed nonsense mutations in the vif  open reading frame 
in 11/30 (37%) and 1/229 (0.4%) clones from seven long-term non-progressors and 
seven progressors, respectively, while Wang et al
112 noted tryptophan to stop codon 
mutations were a consistent feature in longitudinal samples isolated from a long-term 
non-progressor  over  eight  years.  Tryptophan  to  stop  codon  mutations  are 
characteristic  mutations  mediated  by  APOBEC3G  and  therefore,  the  associations 
between  nonsense  mutations  and  long-term  non-progression  described  above  are 
likely  to  represent  associations  between  hypermutation  and  long-term  non-
progression. Indeed, comparison of three full-length clade B HIV proviral clones 
from a long-term non-progressor to the hxb2 clade B reference sequence revealed 
extensive  G→A  hypermutation  and  numerous  in-frame  stop  codons  all  due  to 
tryptophan to stop codon mutations
113. However, whether the defective vif sequences 
and  hypermutation  associated  with  long-term  non-progression  is  the  cause  or  an 
effect is unclear. 
Hassaine and colleagues
114 identified significant correlations between vif amino acid 
132 and progression status. S132 was present significantly more frequently in long-
term non-progressors with low viral loads than long-term non-progressors with high 
viral loads. In vitro studies revealed that the replicative capacity of the S132 variant 
was reduced 5.1 ± 0.5 fold compared to the R132 variant only in non-permissive 
cells, with similar replicative capacity observed in permissive cells. Thus, the S132   44 
vif variant associated with long-term non-progression status is likely to mediate this 
effect through hypermutation.    45 
1.1.5  HYPOTHESIS & AIMS 
 
1.1.5.1  HYPOTHESIS  
We hypothesised that G→A hypermutation conforming to the APOBEC3G and/or 
APOBEC3F sequence context would be evident in a minority of HIV-1 proviral 
DNA  and  would  be  associated  with  reduced  pre-treatment  viremia.  In  addition, 
G→A  hypermutation  would  be  associated  with  host  (APOBEC3G,  and/or 
APOBEC3F depending on which appears to be the dominant contributor to G→A 
hypermutation) and viral (vif) genetic variation. 
1.1.5.2  AIMS 
1.  To estimate G→A hypermutation in HIV-1 proviral DNA at the population 
level  to  address  whether  APOBEC3G  or  APOBEC3F  is  the  dominant 
contributor to HIV-1 hypermutation. 
2.  To sequence the entire gene of the causative APOBEC3 enzyme to determine 
its influence on G→A hypermutation. 
3.  To  determine  whether  vif  genetic  variation  is  associated  with  G→A 
hypermutation. 
4.  To determine whether G→A hypermutation influences pre-treatment viremia.   46 
1.2  MATERIALS & METHODS 
 
 
1.2.1  PATIENT SELECTION 
One  hundred  and  thirty  six  adult  antiretroviral-naïve  HIV-infected  patients  were 
selected from the Western Australian HIV cohort
115 representing a predominantly 
Caucasian  (84%)  male  (88%)  study  population  who  had  acquired  HIV  infection 
through  sexual  contact  (83%).  To  be  included  in  the  present  study,  >1000 
nucleotides of proviral HIV sequence assigned as clade B (see below) were required 
per  sequence.  All  clade  B  sequences  were  utilised  in  the  construction  of  the 
population consensus HIV-1 sequence in this study.  For the investigation of G→A 
substitutions, nine sequences having fewer than 100 nucleotide substitutions from 
consensus were excluded from the analysis, leaving n=127 cases. 
1.2.2  HIV-1 CLADE ASSIGNMENT 
HIV  sequences  were  analysed  by  phylogenetic  analysis  using  Molecular 
Evolutionary  Genetic  Analysis,  version  3  (MEGA  3.0, 
http://www.megasoftware.net)  as  follows.  The  nucleic  acid  sequences  for  the 
individual  HIV-1  protein  products  (e.g.,  p17,  p24,  reverse  transcriptase)  were 
extracted from the database. These were combined with 6 to 15 sequences from each 
of clades A, B, C, D, and F as well as the sequence for HXB2 and the M-group 
ancestral  sequence;  these  reference  sequences  were  downloaded  from  the  Los 
Alamos  HIV  sequence  database.  Phylogenetic  trees  were  constructed  using  the 
parameters 1) neighbour-joining tree inference, 2) pairwise deletion, and 3) Kumara 
2-parameter substitution model. The resulting trees were then rooted on the M-group   47 
ancestral  sequence  and  inspected.  Most  of  the  sequences  clearly  sorted  with 
reference sequences of a particular clade and these were assigned as belonging to 
that clade. Sequences that did not clearly belong to a specific clade were assigned as 
unknown. A final assignment of clade was made based on the assignments for all of 
the  proteins.  If  all  of  the  protein  products  for  a  particular  patient  were 
unambiguously assigned as the same clade, that sample was assigned as that clade. If 
all protein products were the same clade except for one protein product assigned as 
ambiguous, the consensus clade was again assigned to that sample. Samples where 
the  proteins  belonged  to  several  clades  were  noted  as  such  (e.g.  AB,  BC)  and 
excluded from subsequent analysis. 
1.2.3  AMPLIFICATION AND SEQUENCING OF HIV-1 PROVIRAL DNA, 
MEASUREMENT OF PRE-TREATMENT HIV RNA LEVELS, HLA 
AND CCR5 GENOTYPING 
These were performed as previously described in Moore et al
116. Patient DNA was 
extracted from blood samples using the QIAGEN DNA extraction kit according to 
the manufacturer’s instructions. The PCR conditions and primers used for the full-
length amplification of the proviral HIV genome have been previously described in 
Oelrichs et al
117. Briefly, the first-round PCR was performed with the Expand Long 
Templates PCR Kit (Boehringer Mannheim) to produce a 9kb amplified product. 
This first round product was then used as a template for 13 individual nested PCR 
reactions using Taq polymerase (Boehringer Mannheim) to amplify the entire HIV 
genome from gag p17 to the 3’ LTR. First and second round PCR reactions were 
performed  on  ABI  9700  and  9600  thermocyclers.  Successfully  amplified  PCR 
products  were  sequenced  in  the  reverse  and  forward  directions  using   48 
BigDyeTerminator ready reaction prism kits (v3). The samples were electrophoresed 
on  the  ABI  3100  Genetic  Analyser,  and  sequencing  data  analysed  using  ABI 
software  package,  Seqscape  Version  1.1.  Mixtures  (sites  where  more  than  one 
nucleotide was observed) were named according to the IUPAC standard. Sites that 
were unable to be assigned were designated as ‘N’ and excluded from the analyses. 
Nucleotide  sequence  length  within  the  study  population  averaged  6820  ±  1187 
nucleotides (range 1329 – 8768 nucleotides).  
1.2.4  ANALYSIS OF G→ → → →A SUBSTITUTIONS  
To estimate G→A substitutions, individual HIV-1 proviral DNA sequences  were 
aligned  against  the  population  consensus  clade  B  sequence  (n=136).  Only  G→A 
substitutions  where  the  nucleotide  at  position  +1  in  the  sample  matched  the 
corresponding nucleotide in the consensus sequence were examined (where GA, GC, 
GG, and GT dinucleotides in the consensus sequence were observed as AA, AC, AG, 
and AT in the sample sequence, respectively. Mixture nucleotide results obtained 
from  chromatograph  analysis  (indicating  the  presence  of  mixed  nucleotide 
populations)  were  assigned  as  missing  values.  To  estimate  ‘non-specific’  G→A 
hypermutation for each sequence (ie. without reference to the expected dinucleotide 
sequence context for APOBEC3F or APOBEC3G), we incorporated two previously 
used  measures  of  hypermutation11,  G→A  preference  (#G→A  substitutions/#all 
mutations)  and  G→A  burden  (#G→A  substitutions/#  consensus  G)  into  a  single 
formula: 
   49 
Non-specific G→A hypermutation score =  (#G→A substitutions/# consensus G) 
            (#mutations/#nucleotides sequenced) 
 
This represents the proportion of all mutations that are G→A substitutions adjusted 
for the proportion of nucleotides sequenced that are G in the consensus sequence. 
 
1.2.5  ANALYSIS OF APOBEC3G AND APOBEC3F TARGET MOTIFS 
To investigate the contribution of APOBEC3G and APOBEC3F to hypermutation, 
we examined the dinucleotide sequence contexts of G→A substitutions using the 
following formulae: 
3G-specific G→A substitution score =  (#GG→AG substitutions/#consensus GG) 
                                        (#G→A/#G)   
 
3F-specific G→A substitution score =  (#GA→AA substitutions/#consensus GA) 
                                       (#G→A/#G)   
These represent the proportion of all G→A substitutions that occurred in the GG 
(APOBEC3G) and GA (APOBEC3F) contexts adjusted for the number of available 
GG (APOBEC3G) and GA (APOBEC3F) dinucleotides.   50 
1.2.6  ANALYSIS OF APOBEC3G- AND APOBEC3F-MEDIATED 
HYPERMUTATION 
We  combined  the  hypermutation  formula  with  either  the  3G  or  3F  formula  to 
identify sequences that had both an inordinate number of G→A substitutions relative 
to other substitutions and a high preference for G→A substitutions specifically in the 
sequence context targeted by either APOBEC3G or APOBEC3F as follows: 
Consolidated 3G score =           (#GG→AG/#consensus GG) 
       (#mutations/#nucleotides sequenced)   
 
Consolidated 3F score =         (#GA→AA/#consensus GG) 
      (#mutations/#nucleotides sequenced)   
Thus, these represent the proportion of all G→A substitutions that occurred in the 
GG (consolidated 3G score) and GA (consolidated 3F score) dinucleotide contexts, 
adjusted for the overall mutational rate.   
Histogram  and  Q-Q  plots  of  the  consolidated  3G  values  (log10  transformed) 
suggested  a  bimodal  distribution  with  a  normally  distributed  main  group  and  a 
smaller group with higher values. The bimodal distribution was fitted by a mixture 
of  two  normal  distributions  using  maximum  likelihood,  giving  estimated 
distributions with means, SD of -0.277, 0.151 and 0.417, 0.151, respectively, and an 
estimated 9.4% of observations in the latter group. The presence of a mixture was 
highly significant (p<0.00005, likelihood ratio test). The likelihood of belonging to 
the upper group was higher for the largest 12 observations, with one likelihood ratio   51 
of  8  and  the  rest  greater  than  140.  Hierarchical  cluster  analysis  using  between-
groups- and centroid-linkage both give two clear groups with n=115 and n=12 as 
does  k-means  clustering.  The  non-hypermutated  (NH)  group  is  approximately 
normal. The corresponding analysis of the non-APOBEC3G-mediated hypermutated 
cases suggests three cases with inordinate consolidated 3F values. 
1.2.7  APOBEC3G ALLELE FREQUENCIES 
From 8 participants with the highest G→A hypermutation scores and a pooled DNA 
control  sample  (n=187  Caucasian  individuals)
118,  the  entire  APOBEC3G  gene, 
including 2kb 5’ of the transcription start site and 1.0 kb 3’ of the transcription stop 
site, was amplified as 2 products of approximately 6.5kb (3’ half) and 8kb (5’ half), 
size. For amplification of each product, 1 µL of DNA was amplified in a volume of 
50 µL containing 10X Hi-Fi PCR buffer, 2mM MgSO4 (1.5mM MgSO4 for 3’ half), 
0.8mM dNTP mix, 100nM of each forward and reverse primer, 1U of PlatinumTaq 
Hi-Fi
® and 2% DMSO (1.5% for 5’ half) under the following conditions: 94°C for 
30 s, followed by 35 cycles of 94°C for 30 s, 63°C for 30 s (60°C for 5’ half) and 
68°C for 9 m. The PCR products were then purified using Exosap
® according to the 
manufacturer’s protocol and sequenced using overlapping primers (Supplementary 
Figure 1 and Supplementary Table 1) and the Big Dye Terminator kit, version 3.3 
(PE, Applied Biosystems, USA). The allele frequencies of the pooled DNA sample 
were determined by chromatograph relative peak height and compared to the allele 
frequencies  of  the  8  patients  harbouring  the  HIV-1  proviral  sequence  with  the 
greatest G→A hypermutation scores. Allele frequencies estimated from sequencing 
of pooled DNA have previously been shown to correlate well with allele frequencies   52 
measured  by  other  methods  and  provide  an  accurate,  cost-effective  method  for 
determining allele frequencies
118,119. To determine the lower limit at which alleles 
could  be  detected  by  sequencing  pooled  DNA,  PCR  products  homozygous  for 
alternative alleles of a thymidine kinase 2 SNP were mixed at various proportions 
and sequenced. The results, presented in Supplementary Figure 1.31s, suggest that 
the lower limit of allele detection by sequencing is approximately 10-15%. 
1.2.8  STATISTICAL ANALYSIS 
Statistical analyses were performed using SPSS software (version 12.0.1, SPSS Inc. 
USA).  All  values  are  expressed  as  mean  ±  standard  deviation  unless  otherwise 
stated.  Where  data  were  normally  distributed,  ANOVA  was  used  for  group 
comparisons,  with  correction  for  multiple  comparisons  utilising  the  Bonferroni 
method  where  appropriate.  For  non-normal  data,  Mann-Whitney  tests  were 
performed. The presence of in-frame stop codons in vif amino acid sequences was 
determined by putative translation of the proviral DNA sequences. With reference to 
analyses  of  the  determinants  of  plasma  HIV  RNA  levels  prior  to  antiretroviral 
therapy,  HLA-B27  (n=7)  and  HLA-B58  (n=4)  were  also  considered  as  covariates 
along with HLA-B57 (n=12) and the CCR5∆32 genotype (n=25).   53 
1.3  RESULTS 
 
 
1.3.1  ANALYSIS OF G→ → → →A SUBSTITUTIONS  
We first sought to ascertain the population distribution of HIV-1 G→A substitutions, 
in order to identify hypermutated HIV-1 sequences within the context of natural in 
vivo sequence variation. The study was restricted to sequences identified as clade B 
by phylogenetic analysis, involving a study population of predominantly male (87%) 
Caucasian  (84%)  patients  with  chronic  HIV-1  infection.  All  participants  were 
antiretroviral-naïve at the time of clinical assessment and collection of proviral HIV-
1 DNA for sequencing, as reflected in the distribution of HIV RNA/mL viral load 
(mean  ±  SD,  4.903  ±  0.760  log10  copies),  CD4
+    T  cell  counts  (380.6  ±  298.3 
cells/mL)  and  percentage  CD4
+  T  cells  (19.3  ±  10.9%).  To  investigate  G→A 
substitutions at the population level, we aligned each individual’s HIV-1 proviral 
sequence to the population consensus sequence, and for each sequence considered 
two measures of hypermutation as previously described
120; (1) the preference for 
G→A substitutions relative to all other substitutions (defined by the proportion of all 
mutations that were G→A substitutions); and (2) the burden of G→A substitutions 
relative to the number of available consensus guanine nucleotides (defined by the 
proportion of consensus guanines that exhibited G→A substitutions). As expected, 
we  found  that  G→A  substitutions  were  the  most  common  substitution  observed 
(median ± IQR; 21.0 ± 4.0% of all substitutions), and there was a highly significant 
correlation  between  G→A  preference  and  G→A  burden  in  the  study  population 
(Spearman’s r=0.631, P<0.001), as shown in Figure 1.24.   54 
 
 
 
 
 
Figure 1.24 G→ → → →A burden and G→ → → →A preference are highly correlated. Blue open circles – NH 
sequences; red shaded circles – HM-3G sequences; black open triangles – HM-3F sequences; *, † - 
see Materials and Methods sections “Analysis of APOBEC3G and APOBEC3F dinucleotide target 
motifs” and “Analysis of G→A substitutions”, respectively. 
We then analysed appropriately transformed data to ascertain if the distribution of 
G→A substitutions conformed to a model in which a proportion of sequences could 
be described as ‘hypermutated’ relative to natural sequence variation (see Methods). 
Using various cluster analyses as well as analyses of population mixtures, these data 
were  best  described  by  a  bimodal  distribution  rather  than  a  normal  distribution 
(P<0.001),  consistent  with  the  hypothesis  that  a  proportion  of  proviral  DNA 
sequences exhibited HIV-1 hypermutation. 
1.3.2  ANALYSIS OF APOBEC3G AND APOBEC3F DINUCLEOTIDE 
TARGET MOTIFS  
As mentioned previously, APOBEC3G and APOBEC3F are known to target specific 
single-stranded  polynucleotide  DNA  motifs.  Therefore,  in  order  to  further 
characterize and investigate APOBEC3-associated HIV-1 hypermutation, we further 
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examined  the  preference  for  G→A  substitutions  in  the  APOBEC3G  (GG)  and 
APOBEC3F  (GA)  dinucleotide  contexts.  This  was  first  accomplished  by 
investigating  the  dinucleotide  sequence  context  for  G→A  substitutions  (see 
Methods).  Again,  the  population  distribution  of  G→A  substitutions  indicated  the 
presence of APOBEC3G-mediated G→A substitutions in a proportion of sequences, 
in that there was distinct bimodality in the distribution of GG→AG substitutions in 
the study population (Figure 1.25A, P<0.001). A small number of sequences were 
identified  that  exhibited  an  extreme  preference  for  APOBEC3F-mediated  G→A 
substitutions (ie. GA→AA), although this small group (n=3) could not be identified 
as a distinct data cluster (Figure 1.25B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.25 G→ → → →A substitutions in HIV-1 proviral DNA with inordinate G→ → → →A preference and 
G→ → → →A  burden  occur  predominantly  in  the  dinucleotide  sequence  contexts  targeted  by 
APOBEC3G  (GG)  and,  to  a  lesser  extent,  APOBEC3F  (GA).  (A)  G→A  preference  (#  G→A 
substitutions/all  mutations)  was  highly  significantly  correlated  to  G→A  burden  (#G→ 
substitutions/#consensus G) (r=0.853, P<0.001). (B and C) The general G→A hypermutation scores 
were significantly correlated with the 3G-specific G→A substitution scores (r=0.318, P<0.001) but 
not with the 3F-specific G→A substitution scores (r=0.065, P=0.465). Red shaded circles – HM-3G 
sequences  determined  by  mixed  population  analysis  of  the  consolidated  3G  score;  black  open 
triangles – HM-3F sequences determined by mixed population analysis of the consolidated 3F score; 
Blue open circles – NH sequences determined by mixed population analyses of the consolidated 3G 
and consolidated 3F scores; † - general G→A hypermutation score (#G→A substitutions/#consensus 
G)/(#mutations/#nucleotides  sequenced);  *  -  3G-specific  G→A  substitution  score  (#GG→AG 
substitutions/#consensus  GG)/(#G→A/#G);  ‡  -  3F-specific  G→A  substitution  score  (#GA→AA 
substitutions/#consensus GA)/(#G→A/#G). 
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1.3.3  CLASSIFICATION OF APOBEC3G- & APOBEC3F-
HYPERMUTATED HIV-1 SEQUENCES  
In  order  to  formally  identify  sequences  with  evidence  of  APOBEC3G-mediated 
hypermutation  (HM-3G),  we  then  analysed  the  population  distribution  of  HIV-1 
G→A  substitutions  incorporating  both  (1)  G→A  preference  relative  to  other 
mutations, and (2) preference for G→A substitutions within the GG context (Figure 
1.26, see Materials & Methods “Classification of APOBEC3G- and APOBEC3F-
hypermutated HIV-1 sequences”). Mixture models and cluster analyses consistently 
identified 12 sequences (9.4%) that fulfilled these criteria (P<0.001). As shown in 
Table 1.1, these sequences exhibited a 1.9-fold preference for G→A substitutions on 
average, and a 3.1-fold increase in G→A burden compared with the remaining ‘non-
hypermutated’ (NH) sequences (all P<0.001). In addition, 42.7 ± 8.7% of all G→A 
substitutions  were  in  the  GG  context,  compared  with  17.7  ±  5.0%  in  the  NH 
sequences  (P<0.001).  The  average  proportion  of  consensus  guanine  bases  that 
demonstrated  G→A  substitutions  in  these  hypermutated  sequences  (14.2%)  was 
consistent with previous descriptions of hypermutated HIV-1 proviral DNA obtained 
from env gene sequences in vivo (16%)
20 and utilising ∆vif virions in vitro
65.  
Three additional sequences showed a strong preference for APOBEC3F-mediated 
hypermutation  (HM-3F)  using  these  criteria  (Table  1),  with  59.9  ±  11.3%  of  all 
G→A substitutions occurring in the GA context, compared with only 26.1 ± 7.0% 
and 32.1 ± 6.0% in the HM-3G and NH sequences, respectively (both P<0.001).    57 
While G→A substitutions were the most common substitution observed in the 112 
NH sequences, there was no significant association between the non-specific G→A 
hypermutation  score  and  the  3G-specific  G→A  substitution  score  (Pearson’s 
r=0.093,  P=0.331)  or  3F-specific  G→A  substitution  score  (r=0.140,  P=0.142). 
Hence,  it  is  unlikely  that  APOBEC3G  or  APOBEC3F-mediated  DNA  editing 
contribute significantly to the rate of G→A substitutions (identified by bulk PCR 
sequencing) within these non-hypermutated proviral DNA sequences. 
 
 
 
 
 
Figure 1.26 The consolidated 3G scores reflect a bimodal distribution . The bimodal distribution 
of the consolidated 3G scores (see Materials and Methods section “Analysis of APOBEC3G- and 
APOBEC3F-medaited hypermutation”) was fitted by a mixture of two normal distributions utilising 
maximum likelihood, giving estimated distributions with means, SD of -0.636, 0.348 (blue shaded 
bars;  subsequently  defined  as  non-hypermutated  sequences,  NH)  and  0.964,  0.344  (red  partially-
shaded  bars;  subsequently  defined  as  APOBEC3G-mediated  hypermutated  sequences,  HM-3G), 
respectively. The presence of a population mixture was highly significant (P<0.0005, likelihood ratio 
test). 
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1.3.4  HIV-1 GENOMIC DISTRIBUTION OF G→ → → →A HYPERMUTATION 
From the data presented in Figure 1.27, measures of general G→A hypermutation 
(Figure  1.27A),  APOBEC3G-specific  G→A  substitutions  (Figure  1.27B)  and 
APOBEC3G-mediated  hypermutation  (Figure  1.27C)  were  distributed  relatively 
evenly along the genome. Consistent with results from Yu and colleagues
121, general 
G→A hypermutation and APOBEC3G-mediated hypermutation scores in HM-3G 
sequences  were  significantly  higher  in  pol  than  gag  (P<0.001  and  P=0.005, 
respectively),  however  in  contrast,  significantly  lower  in  env  than  in  pol  (both 
P<0.001). Furthermore, consistent with results from Wurtzer and colleagues
122, the 
distance  from  the  central  polypurine  tract  was  significantly  negatively  correlated 
with  the  general  G→A  hypermutation  (r=-0.283,  P=0.007),  APOBEC3G-specific 
substitution  (r=-0.250,  P=0.020)  and  APOBEC3G-mediated  hypermutation  (r=-
0.297, P=0.006) scores. 
1.3.5  ASSOCIATION OF VIF AMINO ACID POLYMORPHISMS AND 
G→ → → →A HYPERMUTATION  
We  subsequently  sought  to  investigate  associations  between  vif  amino  acid 
polymorphisms  and  hypermutation.  For  such  analyses,  we  performed  a  putative 
translation  of  available  vif  sequences  (n=124)  and  examined  vif  polymorphism 
within the NH sequences (vif amino acids 1-193) compared with the corresponding 
amino acid in the HM-3G sequences. HM-3F sequences were omitted from these 
analyses  so  that  specific  associations  relevant  to  the  APOBEC3G-vif  interaction 
could  be  examined,  as  it  has  recently  been  reported  that  specific  vif  amino  acid   60 
nucleotide position
C
A
B
nucleotide position
C
nucleotide position
C
A A
B B
polymorphisms  differentially  influence  APOBEC3G  versus  APOBEC3F 
interaction
123.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.27  General  G→ → → →A  hypermutation  ((#G→ → → →A  substitutions/#consensus 
G)/(#mutations/#nucleotides sequenced)), APOBEC3G-specific G→ → → →A substitutions ((#GG→ → → →AG 
substitutions/#consensus  GG)/(#G→ → → →A/#G))  and  APOBEC3G-mediated  hypermutation 
((#GG→ → → →GA substitutions/#consensus GG)/(#G→ → → →A/#G)) scores were relatively constant along 
the HIV-1 genome. Red shaded circles – HM3G sequences; blue open circles – NH sequences; 
nucleotide position relative to HXB2 (GenBank Accession Number K03455); Y-axis values are log10 
transformed; curves are locally weighted (Loess) smoothers). 
 
Vif peptide sequences derived from the HM-3G group were significantly different 
from NH vif sequences in terms of a higher overall rate of non-consensus amino   61 
acids  (Figure  1.28,  Mantel-Haenszel,  P<0.0005).  The  strongest  associations  were 
tryptophan  to  in-frame  stop  substitutions  at  positions  70,  89,  174  and  21  and 
substitution of isoleucine for the methionine start codon (all Pc<0.04, Bonferroni). 
These  substitutions,  which  would  be  anticipated  to  encode  for  truncated  and 
functionally  defective  vif  proteins,  are  all  in  the  trinucleotide  sequence  context 
targeted by APOBEC3G (TGG) and therefore are likely to have resulted from, rather 
than  caused  HIV-1  hypermutation.  HM-3G  was  also  associated  with  an  R90K 
polymorphism (Pc=0.07, Bonferroni); again however, this could be attributed to the 
action of APOBEC3G. No other vif polymorphisms were found to be significantly 
associated with APOBEC3G-associated hypermutation (all Pc>0.4). 
Regarding the potential role of truncated vif sequences in permitting APOBEC3G-
mediated HIV-1 hypermutation, it is notable that while HM-3G was significantly 
associated  with  in-frame  stop  codons  specifically  in  vif  (P<0.001),  in-frame  stop 
codons  in  non-vif  or  non-vif,  non-env  proteins  were  not  associated  with  HM-3G 
sequences  (P=0.20  and  P=0.63,  respectively).  Additionally,  HIV-1  hypermutation 
was not evident in the two sequences in which the only vif in-frame stop codon was 
at vif amino acid positions 153 (leucine) or 174 (tryptophan). In these sequences, 
G→A  substitutions  accounted  for  only  20.7%  and  24.9%  of  all  substitutions, 
affecting only 4.0% and 5.0% of consensus guanine residues, respectively. It has 
previously  been  demonstrated  that  a  naturally  occurring  vif  protein  truncated  at 
tryptophan174  is  indistinguishable  from  wild  type  vif  in  maintaining  viral 
infectivity
73.  
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Here, the occurrence of a naturally occurring vif protein truncated at leucine153 also 
suggests that the C-terminal 39 amino acids are dispensable for this protein’s roles in 
promoting  viral  infectivity  as  well  as  counteracting  APOBEC3G.  Interestingly, 
despite the codon for tryptophan being a target for APOBEC3G, tryptophan residues 
5, 11 and 79 were entirely conserved in the hypermutated vif sequences and are 
therefore unlikely to play a role in inhibiting APOBEC3G or APOBEC3F activity, in 
contrast to data from Tian and colleagues
124. 
Figure 1.28 demonstrates the high degree of vif polymorphism that appears to be 
tolerated  without  apparently  increasing  viral  susceptibility  to  the  effects  of 
APOBEC3G  and/or  APOBEC3F.  Within  the  non-hypermutated  group, 
polymorphism was observed at the serine144 and leucine148 residues of the SOCS-box 
N-terminal BC-box motif (144SLQYLA149) required for vif phosphorylation
103 and 
Elongin BC and Cul5 binding
47, respectively, and the proline162 (1.0%) residue of the 
SOCS-box  C-terminal  motif  161PPLP164  required  for  vif  multimerisation  and 
subsequently vif function
92. In contrast, the existence of polymorphism at these sites 
in  our  population  suggests  that  they  may  not  be  essential  for  maintaining  vif 
function.  However,  the  recently  described  Hx5Cx17-18Cx3-5H  zinc-binding  motif
125, 
critical for assembly and activity of the vif-Cul5-E3 ligase
126, was entirely conserved. 
We also identified vif polymorphisms that were unique to the HM-3G sequences 
within this study population, given previous evidence that sequence variation at a 
number  of  critical  residues  can  affect  vif-APOBEC3G  interactions
50,127.  Twenty-
three  vif  amino  acid  variants  were  found  uniquely  in  HM-3G  sequences  (Figure 
1.29), of which 82% were within regions previously shown to be required for vif-   64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.29 Schematic representation of HM and truncated vif proteins identified in vivo from 
putative translation of proviral DNA sequences. HM-3G – APOBEC3G-mediated hypermutated 
sequence;  HM-3F  –  APOBEC3F-mediated  hypermutated  sequence  NH  –  truncated  vif  proteins 
translated from non-hypermutated proviral sequences; shaded bar indicates translated vif sequence; 
unshaded bar indicates untranslated vif sequence; partially shaded bar indicates region not sequenced; 
red line indicates unique polymorphism from consensus that could not potentially be attributed to the 
corresponding  APOBEC3  enzyme;  blue  line  indicates  unique  polymorphism  from  consensus  that 
could potentially be attributed to the corresponding APOBEC3 enzyme; sequences are ordered by 
HM-3G,  HM-3F  and  NH  in  descending  consolidated  3G  score;  amino  acid(s)  below  the  peptide 
indicate consensus, amino acids above the peptide indicate amino acid(s) unique to the individual 
peptide sequence. 
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APOBEC3G  interaction
50,127.  Of  these,  thirteen  could  not  have  resulted  from  an 
APOBEC3G-mediated G→A substitution of the NH consensus amino acid, all of 
which were located within the vif N-terminus. It is also interesting to note that a 
charged consensus amino acid was present in 14/23 of these positions, and that the 
variant vif sequence was frequently associated with either a reversal of the charge 
state (6/14,43%) or substitution of a neutral amino acid (3/14, 21%). An additional 
three vif amino acids were unique to the two HM-3F vif sequences available and 
could  also  not  have  resulted  from  a  G→A  substitution  of  any  of  the  alternative 
amino acids present in the NH sequences. Again, two of the HM-3F unique amino 
acids were located within the vif N-terminus (L98, S103). 
1.3.6  APOBEC3G GENETIC VARIATION AND G→ → → →A 
HYPERMUTATION 
To assess the contribution of APOBEC3G genetic variation to hypermutation, we 
sequenced  the  entire  10.5  kb  APOBEC3G  gene,  including  2  kb  5’  of  the 
transcription  start  site  and  0.5  kb  3’  of  the  3’UTR.  We  initially  compared  the 
frequency of APOBEC3G alleles from 8 patients with the greatest G→A burden to 
that estimated from a pooled DNA sample (187 Caucasian individuals
118) as control, 
based  on  relative  chromatogram  peak  height.  As  demonstrated  in  Table  1.2,  the 
APOBEC3G  amino  acid  sequence  was  highly  conserved  in  this  predominantly 
Caucasian  study  population.  Based  on  the  estimated  allele  frequencies  of  the  22 
single nucleotide polymorphisms (SNPs) identified (17 previously described and 5 
novel SNPs) and the sample size, we had sufficient power (Supplementary Figure 
1.32S)  to  detect  significant  differences  in  allele  frequencies  between  the  patients   66 
with  hypermutated  sequences  for  SNP  positions  625  (rs9607609)  and  6,892 
(rs5757467) relative to the transcription start site (Table 1.2). We then genotyped the 
625 and 6,892 SNPs for patients that had DNA available (n=119). The frequency of 
the 6,892 C allele tended to be higher in patients with evidence of APOBEC3G-
mediated hypermutation (50.0% versus 29.9%, P=0.062), with homozygosity for the 
6,892 C allele present in 25% of patients with evidence of APOBEC3G-mediated 
hypermutation compared with 7.5% of non-hypermutated sequences (P=0.082). 
Table 1.2 APOBEC3G allele frequencies among 8 patients with marked G→ → → →A hypermutation. 
Comparisons with a pooled DNA control sample and a published study (Do et al,
110). 
 
  Control   Do et al, 
2005 
HM-3G 
NCBI 
dbSNP ID  Position  Allele 
1 
Allele 
2 
Allele 2  Allele  1  Allele 
2 
A1.A1  A1.A2  A2.A.2 
7291971  -1,193  0.60  0.40  0.40  0.44  0.56  2  3  3 
6519166  -1,190  0.70  0.30  0.31  0.56  0.44  2  5  1 
 5750743  -321  0.50  0.50  0.28  0.44  0.56  1  5  2 
12160242  480  >0.90  <0.10  0.09  0.94  0.06  7  1  0 
9607609  625  0.80  0.20  ND  0.38  0.62  2  2  4 
5757465  3,756†  0.60  0.40  0.51  0.75  0.25  4  4  0 
12158985  5,985  >0.90  <0.10  0.07  0.88  0.12  6  2  0 
2294366  5,986  0.70  0.30  0.34  0.56  0.44  2  5  1 
2294367  6,207  0.60  0.40  0.42  0.44  0.56  2  3  3 
nl  6,848  >0.90  <0.10  ND  0.88  0.12  6  2  0 
3091374  6,878  0.50  0.50  ND  0.44  0.56  2  3  3 
5757467  6,892  0.70  0.30  ND  0.31  0.69  0  5  3 
5757468  6,893  0.70  0.30  ND  0.56  0.44  2  5  1 
nl  6,894  >0.90  <0.10  ND  0.88  0.12  6  2  0 
nl  8,984‡  >0.90  <0.10  ND  0.88  0.12  6  2  0 
5757471  9,218  >0.90  <0.10  ND  0.94  0.06  7  1  0 
28474760  9,250  >0.90  <0.10  0.07  0.88  0.12  6  2  0 
28474761  9,432  >0.90  <0.10  0.12  0.88  0.12  6  2  0 
nl  10,393  0.50  0.50  ND  0.92  0.08  5  1  0 
nl  10,399  0.70  0.30  ND  1.00  0.0  8  0  0 
5757472  10,600  0.50  0.50  ND  0.44  0.56  1  5  2 
3891126  10,811  >0.90  <0.10  ND  0.88  0.12  6  2  0 
Allele frequencies of the pooled DNA sample were estimated by chromatogram relative peak height. 
Significant differences in the allele frequencies of the 625 and 6,892 SNPs were evident between the 
hypermutated  patients  and  the  pooled  DNA  sample.  NCBI  dbSNP  ID  –  National  Centre  for 
Biotechnology  Information  SNP  database  reference  number;  †  -  synonymous  SNP;  ‡  -  non-
synonymous  SNP;  A1.A1  –  number  of  patients  homozygous  for  allele  1;  A1.A2  –  number  of 
heterozygous patients; A2.A2 – number of patients homozygous for allele 2; <0.10 – allele frequency 
below the limit of detection; nl – novel SNP; ND – not determined; positions are relative to the 
transcription start site with reference to NCBI accession number NT_011520.     67 
However,  this  marginally  significant  univariate  association  was  abrogated  after 
adjusting for multiple comparisons (Pc>0.5). The frequency of the 625 C allele was 
similar amongst patients with evidence of APOBEC3G-mediated hypermutation and 
patients harbouring NH sequences (allele frequency, 75.0% versus 77.2%, P=0.80; 
CC genotype frequency, 58.3% versus 57.3%, P=1.0).  
1.3.7  G→ → → →A HYPERMUTATION AND HIV-1 VIREMIA  
The  biological  and  clinical  relevance  of  HIV-1  hypermutation  in  proviral  DNA 
sequences  is  ultimately  a  function  of  its  impact  on  productive  HIV  infection, 
measured  by  the  level  of  viremia  in  plasma  samples.  We  therefore  sought  to 
investigate the effect of HIV-1 hypermutation on pre-treatment viremia in this study 
population.  Univariate  analysis  indicates  that  patients  harbouring  hypermutated 
sequence  as  defined  had  significantly  lower  viral  load  than  those  with  non-
hypermutated sequence (4.32 ± 0.60 versus 4.98 ± 0.75 log10copies HIV RNA/mL, 
P=0.001). Utilising linear regression models, this association between hypermutation 
and lower pre-treatment viremia remained highly significant (P=0.013) even after 
adjusting for CD4
+ percent (P<0.001) and presence of at least one of the known 
protective host alleles, CCR5∆32
128, HLA-B57, HLA-B58 or HLA-B27
129 (P=0.096) 
and  approximates  67%  and  40%  reductions  in  viral  loads  attributable  to 
hypermutation and host protective alleles, respectively. Hence, the clinical influence 
of HIV-1 hypermutation appears to be demonstrable within this group of patients 
who  manifest  a  marked  preference  for  G→A  substitutions  in  an  APOBEC3G  or 
APOBEC3F sequence context.   68 
1.4  DISCUSSION  
The  data  presented  in  this  population-based  study  of  clade  B  HIV-1  sequences 
suggest that HIV-1 G→A hypermutation is a prevalent phenomenon associated with 
significantly reduced plasma HIV RNA levels in vivo, indicating that APOBEC3G 
and 3F-mediated hypermutation can take its place alongside other protective host 
genetic  factors  as  a  clinically  and  biologically  relevant  antiretroviral  restriction 
factor.  Indeed,  the  reduced  HIV-1  viremia  associated  with  hypermutation  was 
substantially greater than that exerted by known host factors such as the CCR5∆32 
chemokine receptor variant and remained highly significant after adjusting for these 
variables as well as for the influence of CD4
+ count. Such reductions in viral load are 
substantially greater than those previously associated with protective HLA alleles
130 
and are comparable to the effects of zidovudine monotherapy in early studies of 
antiretroviral treatment
131. 
Here,  hypermutated  proviral  DNA  was  estimated  in  12%  of  study  participants, 
utilising a bulk PCR sequencing approach that approximates the dominant species 
within  a  heterogeneous  viral  population.  In  many  respects  these  findings 
complement the work of Kieffer and colleagues
132 who examined the phenomenon 
of in vivo hypermutation in detail utilising 319 pol clones derived from 9 patient 
samples. This study revealed at least one hypermutated proviral DNA sequence from 
each individual examined, although hypermutated sequences accounted for less than 
10%  of  the  proviral  population  within  an  individual.  Similar  results  have  been 
obtained by Janini et al
19 who detected the presence of G→A hypermutation in 45% 
of HIV protease sequences from a Tanzanian study population. These observations   69 
are  consistent  with  in  vitro  data  demonstrating  low-level  APOBEC3G  and  3F-
mediated cytidine deaminase activity directed against HIV-1 sequences even in the 
presence of functional vif
75,108. It has also been suggested that the rapid turnover of 
vif through proteasomal degradation contributes to constitutively low cellular protein 
expression
133,  thereby  providing  an  incomplete  barrier  to  APOBEC3G  and/or  3F 
activity. In this study, we now provide evidence that hypermutated proviral HIV-1 
DNA sequences can be demonstrated by bulk PCR methods in a significant minority 
of  clade  B  HIV-1-infected  individuals.  Taken  together,  these  data  suggest  that 
APOBEC3-mediated  cytidine  deamination  is  highly  prevalent  but  effectively 
constrained  by  functional  interactions  with  vif,  so  that  G→A  hypermutation  is 
generally confined to a minor proportion of the overall viral population. 
It should be noted that the sequence context targeted by APOBEC3G appears to 
specifically select for loss-of-function mutations, including within the vif genomic 
sequence. For example, targeted substitutions involving tryptophan residues (TGG) 
produce in-frame stop codons (TAG) while the vif start codon and adjacent aspartic 
acid residue also create an APOBEC3G target motif (ATGG) that results in loss of 
the methionine initiation signal following G→A substitution. To some extent this 
susceptibility  appears  to  have  been  overcome  by  the  utilisation  of  multiple 
alternative start codons at methionine residues 8, 16 and 29, although it is notable 
that  the  capacity  to  counteract  APOBEC3G  activity  appears  to  be  lost  as  a 
consequence  of  these  N-terminal  truncations
123,133.  In  this  study,  substitutions 
associated with truncated vif sequences could be entirely explained by APOBEC3G-
mediated  cytidine  deamination  (Figure  1.29),  although  it  is  notable  that 
hypermutation was associated specifically with vif in-frame stop codons but not with   70 
in-frame stop codons in non-vif viral peptides. Hence, while it is difficult to attribute 
causality  in  the  relationship  between  hypermutation  and  defective  vif,  the  most 
parsimonious  explanation  appears  to  be  provided  by  a  mechanism  in  which 
APOBEC3-mediated G→A substitutions, occurring in a relatively non-permissive 
cellular environment but targeting TGG trinucleotide motifs stochastically along the 
genome, can become unconstrained if this process selects for defective vif sequences. 
Although the translated vif sequences in this cohort were highly polymorphic (Figure 
1.28),  there  were  23  vif  amino  acid  variants  unique  to  HIV-1  hypermutated 
sequences, of which 13 associated with HM-3G sequences and three unique to HM-
3F  sequences  could  not  have  resulted  from  APOBEC3G-mediated  cytidine 
deamination (Figure 1.29). These data are consistent with those that suggest the vif 
N-terminal contains distinct motifs that are likely to interface with APOBEC3G and 
APOBEC3F
123,124,127,  and  may  therefore  represent  true  vif  allelic  variants  that 
facilitate hypermutation. Although the associated amino acid differed, four of the 
twenty-three vif amino acids unique to HM-3G sequences (K45, E75, E138, K185) 
occurred at positions previously associated with naturally occurring non-functional 
vif variants
123. 
With reference to the non-hypermutated vif sequences, we observed polymorphism 
at residues within key motifs shown to be required for vif phosphorylation
103, vif-E3 
ligase complex formation
47, vif multimerisation
92 and β-sheet formation
134. In this 
study  however,  these  variants  were  not  associated  with  APOBEC3-mediated 
hypermutation,  suggesting  that  polymorphisms  within  these  motifs  are  tolerated 
without  significantly  compromising  vif  function.  While  it  is  unclear  if  these   71 
polymorphisms  alter  the  efficiency  of  polyubiquitination  and  proteasomal 
degradation  of  the  vif-APOBEC3G-E3  ligase  complex  in  vivo,  the  lack  of 
hypermutation in these sequences could potentially be attributed to an undiminished 
capacity  for  vif-APOBEC3G  complex  formation,  which  is  sufficient  to  restrict 
APOBEC3G-mediated  hypermutation  in  vitro 
108.  Despite  the  high  degree  of  vif 
polymorphism, several stretches of conserved residues, most notably the first 18 N-
terminal amino acids, were observed that may represent novel drug targets. 
The  dinucleotide  sequence  context  of  the  G→A  substitutions  suggests  that 
APOBEC3G was the dominant contributor to hypermutation in this study  group. 
These findings are consistent with the previously mentioned in vivo study by Kieffer 
et  al
132,  involving  clade  B  HIV-1  sequences.  In  contrast,  two  studies  involving 
Tanzanian  study  populations  infected  with  predominantly  non-clade  B  virus
19,20 
indicate less bias towards the APOBEC3G context. These differences warrant further 
exploration,  particularly  as  a  non-synonymous  APOBEC3G  186R  polymorphism 
associated  with  accelerated  progression  to  AIDS  (and  therefore  implying  loss  of 
APOBEC3G function) has been found to be frequent in African Americans (37%) 
but rare in European Americans (5%)
109. Hence, a relatively greater contribution of 
APOBEC3F to HIV-1 cytidine deaminase editing may be anticipated in at least some 
populations of African origin. In this study, there was no convincing evidence that 
APOBEC3G  genetic  variation  contributed  to  the  development  of  HIV-1 
hypermutation, and it is notable that we were unable to identify significant amino 
acid variation within APOBEC3G sequences in these Caucasian populations (Table 
1.2). A marginal univariate association between an intronic APOBEC3G 6,892 C 
allele  and  hypermutation  was  demonstrated,  although  the  role  of  this  intronic   72 
polymorphism  on  APOBEC3G  function  is  unclear.  It  is  however  possible  that 
functional polymorphism are located in the as-yet-undefined promoter or regulatory 
regions of this genetic locus, and in this regard it is notable that APOBEC3G mRNA 
levels in peripheral blood mononuclear cells have recently been found to exhibit an 
inverse correlation with HIV-1 pre-treatment viremia
135. 
In  conclusion,  this  study  provides  strong  support  for  the  proposition  that 
APOBEC3G-mediated cytosine deamination provides a potent source of innate HIV-
1  restriction  at  the  population  level.  Moreover,  the  prevalence  and  antiretroviral 
impact of APOBEC3G and APOBEC3F-mediated HIV-1 hypermutation within the 
study population can be compared favourably with known host protective factors. 
Thus, less than four years after Malim and colleagues first isolated the APOBEC3G 
gene and tentatively proposed a cytosine deaminase function for its product
11, we 
submit that these data fulfil the promise contained within these early in vitro studies, 
that APOBEC3G comprises a form of innate antiviral resistance that is clinically and 
biologically  relevant  and  which  may  lend  a  fresh  perspective  to  the  area  of 
HIV/AIDS therapies
18.   73 
1.5  SUPPLEMENTARY DATA 
 
  
Table 1.3S Oligonucleotide sequences used for the amplification and sequencing of the entire 
human APOBEC3G gene, including 2.0 kb 5’ of the transcription start site and 1 kb 3’ of the 
transcription stop site.  
 
Oligo Name  Sequence (5’- 3’)  5’ Binding Position 
154F  AGACCTGGCAAATTTTGGTG  18,861,852 
6636R  GGCCTCTCACTCACAGGAAG  18,868,334 
5117F  GTGATGCTTCAACAGCAGGA  18,866,874 
13356R  GTGTCTAGGCCAGGGAAACA  18,875,054 
902F  TTTTTGGCTGTTCCAGACTT  18,862,600 
1581F  ACATCTGAGGCCCACACC  18,863,279 
2107F  AAAACCAGAAGCTTGGAGCA  18,863,805 
2893F  CCAGCATGGATAAACCCTGT  18,864,591 
3556F  CGGAATTTCGCTCTTGTCG  18,865,254 
4172F  TCTTGTTGCTCAGGCTGGA  18,865,870 
4899F  TCAGGTGCCCAGGTCTCTAA  18,866,597 
5647F  TGGCAAGATCTCCTGGACTC  18,867,345 
6442F  CTCTCACCTCCTGCTCATCC  18,868,140 
7109F  GCCCACACTGAAGGTCTCAT  18,868,807 
7852F  CCAGAATCTTCCCAGTTCCA  18,869,550 
8595F  TGAACCTTGGGTCAGAGGAC  18,870,293 
9039F  GCCAAGTGGGATCAAAGAAA  18,870,737 
9449F  GGCCTACCTGACCTCACAAG  18,871,147 
10191F  AGGGGAATTGACGGGTAGAC  18,871,889 
10931F  AGCCTGAACCACATGGAGAA  18,872,629 
11717F  AGGGAAAGGAGGGACTGAAA  18,873,415 
12489F  CAAACCTACTAATCCAGCGACA  18,874,187 
930R  GCAGCCAAGAAGTCTGGAAC  18,862,628 
1617R  GAGGGAGGGACAGCAGGT  18,863,315 
2373R  GACAACACAGCAGGGCAAG  18,864,071 
3193R  GGACCGGGCTCTCTTCTTAC  18,864,891 
3630R  GAATTTCGGCGGAGACTGTA  18,865,328 
4276R  TCGCAGCTACTTGCGCGTCT  18,865,974 
4960R  ACATGGCCAAGGGACTACTG  18,866,658 
5813R  CACTTGCTGAACCAGTGGAA  18,867,511 
7162R  GGAGACAGGTCCTTTCATCAG  18,868,860 
7908R  GGATGCCACCTTTGATAGGA  18,869,606 
8713R  TGGTCACCTGGTTGCATAGA  18,870,411 
9556R  TCAGGACAGAATCCCTGGTC  18,871,254 
10263R  GGAGGACAGATGCCACTGAG  18,871,961 
11095R  AAAGAAAGCAAGCCATGAGG  18,872,793 
11738R  GGTTTCAGTCCCTCCTTTCC  18,873,436 
12519R  GATTCAAATTGTCGCTGGATT  18,874,217 
 
5’ binding position relative to NCBI accession number NT_011520. 
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Figure  1.31S  Chromatograph  results  of  sequencing  pooled  PCR  products  homozygous  for 
alternative  alleles  at  varying  proportions  to  estimate  the  lower  limit  of  allele  detection  by 
sequencing. Ratios represent the ratio at which PCR products homozygous for the T allele were 
mixed with PCR products homozygous for the G allele prior to sequencing.  
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Figure 1.32S Power calculations used to determine sample size required to detect significant 
differences in APOBEC3G allele frequencies between HM-3G and NH sequences based on the 
allele frequencies of the HM-3G sequences and those estimated from a pooled DNA control 
sample. 
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CHAPTER TWO 
 
2  CHARACTERISATION OF THE HUMAN 
DEOXYTHYMIDYLATE KINASE AND THYMIDINE KINASE 2 
GENES AND THEIR INFLUENCE ON AZT AND D4T 
TOXICITIES    80 
2.1  GENERAL INTRODUCTION AND REVIEW OF THE LITERATURE 
 
 
2.1.1  AZT AND D4T THERAPY 
Zidovudine  (AZT;  ZDV;  3’-azido-3’-deoxythymidine;  Retrovir™)  and  stavudine 
(d4T;  2’,3’-didehydro-3’-dideoxythymidine;  Zerit)  are  currently  recommended 
components of highly active antiretroviral therapy (HAART) for the treatment of 
HIV-1 infection in adults, adolescents and children by the US Department of Health 
and Human Services (http://aidsinfo.nih.gov). Initially intended to treat cancer, AZT 
was first synthesised in 1964 under a US National Institutes of Health grant, but 
failed to show efficacy and had an unacceptably high side effect profile. Then in 
1985,  through  collaborations  between  scientists  at  the  National  Cancer  Institute 
(NCI) and Burroughs Wellcome Co., AZT proved effective in vitro against HIV and 
was clinically demonstrated to increase CD4
+ counts in AIDS patients leading to 
Federal Drug Administration (FDA) approval for use against HIV, AIDS, and AIDS 
Related Complex on March 20, 1987, and then as a preventive treatment in 1990; 
AZT  was  the  first  compound  approved  by  the  FDA  for  the  treatment  of  HIV-1 
infection
136.  
Stavudine,  the  fourth  drug  approved  by  the  FDA  for  the  treatment  of  HIV-1 
infection, was initially approved for the treatment of patients with advanced HIV 
disease intolerant to, or experiencing progression of disease on, previously approved 
drugs.  Other  NRTIs  currently  approved  for  treatment  of  HIV-1  infection  include 
zalcitabine  (ddC;  2’,3’-dideoxycytidine;  HIVID),  didanosine  (ddI;  2’,3’-
dideoxyinosine;  VIDEX),  lamivudine  (3TC;  3’-thiacytidine;  cis-1-[2’-
hydroxymethyl-5’-(1,3-oxathiolanyl)]cytosine;  EPIVIR),  emtricitabine  [(-)FTC],   81 
abacavir  (ABC;  4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-1-cyclopent-2-
enyl]methanol; Ziagen) and tenofovir (TDF; Viread) (TDF is a nucleotide analogue 
rather than a nucleoside analogue)
137.  
Both AZT and d4T are highly effective inhibitors of viral replication
138-144 and as 
such  are  integral  components  of  contemporary  HIV-1  treatment  regimens
141. 
However, their utilisation is limited by their toxicity. This review will address AZT 
and  d4T  pharmacology,  the  mechanisms  of  their  toxicities  and  the  role  of 
pharmacogenetics in HIV-1 therapy. 
2.1.1.1   MODE OF ACTION OF NRTIS  
NRTIs have a wider spectrum of antiviral activity than the other classes of HIV-1 
therapies;  protease  inhibitors  (PIs)  and  non-nucleoside  reverse  transcriptase 
inhibitors (NNRTIs)
145. As illustrated in Figure 2.1, NRTIs are synthetic analogues 
of naturally occurring nucleosides. The 5’-triphosphate metabolite of NRTIs differ 
from those of naturally occurring nucleosides in that they lack the hydroxyl group at 
the 3’-position of the ribose ring that acts as an acceptor for the covalent attachment 
of subsequent nucleosides 5’-monophosphate
145-147.  
NRTIs inhibit HIV-1 replication by two mechanisms. Firstly, as their name implies, 
NRTIs inhibit HIV-1 reverse transcriptase (RT), the enzyme required to catalyse the 
synthesis of proviral double-stranded DNA from the RNA template, by binding to 
the RT active site. Secondly, NRTIs may become incorporated into the nascent DNA   82 
chain in place of naturally occurring endogenous nucleotides resulting in termination 
of DNA elongation
145.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.1  Structure  of  nucleoside  reverse  transcriptase  inhibitors  and  their  corresponding 
deoxynucleoside. ADV and TDF are nucleotide analogues of adenosine and are shown with their 
corresponding nucleotide. Taken from reference 148 (reprinted by permission from Bentham Science 
Publishers Ltd) [Curr. Med. Chem. – Anti-Infective Agents, 2003;2:241-62].  
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2.1.2  CLINICAL TOXICITIES OF THYMIDINE-ANALOGUE THERAPY 
Clinical toxicities associated with NRTI therapy are tissue-specific manifestations of 
mitochondrial  toxicity  and  resemble  those  seen  in  inherited  mitochondrial 
diseases
148,149 and mitochondrial abnormalities are typically observed histologically 
in NRTI-associated myopathy, lipoatrophy and neuropathy. Toxicities mediated by 
mtDNA  depletion  and  subsequent  deficiencies  in  oxidative  phosphorylation  are 
commonly observed with both AZT and d4T, but more commonly with d4T therapy, 
due in part, to the greater potency of d4T to inhibit mitochondrial DNA polymerase γ 
compared to AZT
150,151, and in part, to tissue differences in expression of cellular 
kinases  required  for  their  anabolism
152.  For  example,  lactic  acidosis, 
hyperlactataemia
153-159, lipoatrophy
148,160-168, pancreatitis
160 and neuropathy
161-163 are 
more commonly observed in d4T recipients than AZT recipients. However, AZT 
induces  mitochondrial  toxicity  independent  of  mtDNA  depletion  and  is  therefore 
associated with certain toxicities more commonly than d4T therapy. These include 
myopathy
164-166  and  haematological  toxicities  such  as  anaemia
167-169  and 
neutropenia
170. The mechanisms of toxicity shall be discussed in sections 2.1.3 and 
2.1.4.  
2.1.2.1  HAEMATOLOGICAL TOXICITIES  
Haematological  toxicities  are  the  most  common  toxicities  observed  with  AZT 
therapy but rarely associated with d4T therapy
167-171. In early clinical trials of AZT in 
patients with advanced AIDS disease using doses of 1500mg/day, Grade 3 marrow 
suppression  was  evident  in  45%  of  AZT  recipients;  anaemia  (Hb  <7.5g/dL)  and   84 
neutropenia  was  observed  in  24%  and  16%  of  AZT  recipients,  respectively, 
compared  to  only  4%  and  2%  of  HIV-1+  antiretroviral  therapy  naïve  patients. 
Furthermore, 31% of AZT recipients compared to only 11% of placebo recipients 
required red-cell transfusions (P<0.05). Such prevalence of toxicity led to reductions 
in  AZT  doses  to  500mg/day  which  was  demonstrated  to  be  as  efficacious  as 
1500mg/day regimens in delaying progression to AIDS, increasing CD4
+ counts and 
reducing  p24  antigen,  but  significantly  reduced  the  frequency  of  haematological 
toxicities  from  11.8%  to  2.9%
172,173.  Even  in  the  HAART  era,  haematological 
toxicities remain common. From studies of contemporary HAART regimens, a meta-
analysis of six prospective, randomised, comparative studies conducted by Moyle et 
al
167, all grades of anemia and neutropenia were more frequently observed with AZT 
therapy (5%-18% and 26%-43%, respectively) than d4T therapy (4%-9% and 15-
31%, respectively). 
Despite  the  substantial  reductions  in  the  frequency  of  AZT-associated 
haematological toxicities owing to dose-reductions, such toxicities remain clinically 
relevant  due  to  their  influence  on  disease  progression
174-176.  In  the  large, 
observational, prospective EuroSIDA study including 6,725 HIV-1+ patients, 40.8% 
and 15.9% of patients with severe and moderate anaemia at baseline respectively, 
died within 12 months of recruitment compared to only 3.1% of patients with mild 
anaemia. In a multivariate time-updated Cox proportional hazards model, as little as 
1g/dL decrease in the latest haemoglobin level increased the hazard of death by 57% 
and had a greater effect than a 50% drop in CD4
+ count (50% drop) or a log decrease 
in viral load (37% drop)
174.   85 
Macrocytosis develops in most AZT and d4T recipients within weeks, albeit less 
severe in d4T recipients than AZT recipients
177-182. Macrocytosis is not however, a 
marker of haematological toxicity; it can occur in the absence of haematological 
toxicity
183 and in fact, elevated mean corpuscular volume (MCV) can actually define 
the  subgroup  of  patients  resistant  to  AZT-associated  erythroid  hypoplasia  and 
consequent anemia
184, and is a useful marker of adherence to thymidine-analogue 
therapy
185. 
2.1.2.2  MYOPATHY 
NRTI-associated  myopathies  are  almost  exclusively  observed  with  AZT  therapy, 
occurring in at least 17% of patients in the HAART era and in up to 33% in the pre-
HAART era
186-188. Symptoms of myopathy, including fatigue, muscle weakness, and 
elevation of muscle enzymes (creatine kinase or aldolase in some cases) often begin 
after  the  first  6  months  of  therapy  and  are  often  reversible,  clinically  and 
histologically,  within  as  little  as  3  months  following  discontinuation  of 
AZT
164,165,187,189-191. Clinically, AZT myopathy mimics HIV-associated polymyositis 
to  such  an  extent  that  debate  exists  as  to  whether  they  represent  one  disease  or 
two
190,192. However, it has been reported by several groups that AZT myopathy can 
be distinguished from HIV-associated polymyositis by the presence of “AZT fibres”, 
a termed coined by Dalakas and colleagues
193 to designate atrophic ragged red fibres 
with  marked  myofibrillar  alterations,  including  thick  myofilament  loss  and 
cytoplasmic body formation
194-196, although they have also been observed in HIV-
1+, AZT-naïve individuals
191. Mitochondrial dysfunction is common to both AZT-
associated  myopathy  and  HIV-associated  polymyositis
191,197,  however  impaired   86 
cytochrome c oxidase (complex IV of the mitochondrial respiratory chain comprised 
of nDNA and mtDNA encoded subunits) activity is a unique and consistent feature 
of AZT-associated myopathic fibres, even in the absence of histological changes
194 
(Figure 2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.2  Focal  cytochrome  oxidase  deficiency  is  a  unique  and  consistent  feature  of  AZT-
associated myopathy. (A) AZT-associated myopathy is characterised by focal cytochrome oxidase 
deficiency. Cryostat section, x450 magnification before 8% reduction. (B) HIV-associated myopathy 
characterised by normal cytochrome oxidase deficiency. Cryostat section, x280 magnification before 
8% reduction. Taken from reference 194 (reprinted by permission from Bentham Science Publishers 
Ltd) [Acta Neuropathol (Berl), 1993;85:431-6]. 
 
 
2.1.2.3  LACTIC ACIDOSIS AND HYPERLACTATAEMIA 
Lactic acidosis (LA) and hyperlactataemia (HL) are probably the most recognisable 
features  of  mitochondrial  dysfunction  in  clinical  disease  and  represent  varying 
degrees of derangement in systemic homeostasis
198-200. At one end of the spectrum, 
LA indicates an extreme ‘decompensated’ metabolic state in which homeostasis is 
completely lost, while HL represents the other end of the spectrum, a ‘compensated’ 
homeostatic system in which elevated lactate production is balanced by effective 
mechanisms of lactate clearance
156,198. 
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Lactate is produced in the cytoplasm during the glycolytic pathway as a product of 
trans-formation  of  pyruvate  and  is  primarily  metabolised  oxidatively  in 
mitochondria, with no intracellular accumulation of lactate. However, in the absence 
of oxygen or a functional respiratory chain, lactate can accumulate in the cytoplasm 
and result in increased lactate production
200. 
HL  may  be  symptomatic  or  asymptomatic.  Asymptomatic  HL  (generally  <2.5 
mmol/L)  is  a  benign  syndrome  and  affects  between  9  and  42%  of  antiretroviral 
recipients and approximately 2% of antiretroviral therapy-naïve outpatients
156,201-206. 
In the WA HIV Cohort Study, chronic mild asymptomatic HL (lactate concentrations 
1.5-3mmol/L), maintained over many months, was the most common pattern of HL 
observed, indicating that overall, lactate concentrations rise from the pre-treatment 
baseline in most NRTI-recipients but are largely maintained at only mildly elevated 
levels in the long term
156 (Figure 2.3). Similar observations have been reported from 
the Swiss HIV-1 Cohort Study by Imhof et al
201 and such mild elevations are not 
considered to warrant therapy revision
156,205. 
Symptomatic HL is characterised by mild to moderate increases in plasma lactate 
concentration  (<2.5  mmol/L),  non-specific  symptoms  including  nausea,  vomiting 
and  abdominal  pain,  in  the  absence  of  metabolic  acidosis  or  hepatic  steatosis. 
Reported prevalence of clinically relevant HL is approximately 1-3%
201,207 and is 
predominantly  associated  with  d4T  and  ddI  therapy
200,201,204,208.  From  the  French 
HIV-1  Cohort  Study,  substitution  of  d4T  and/or  ddI  in  hyperlactataemic  patients 
decreased HL prevalence from 25% to 3%
204 and Garcia-Benayas et al
209 reported 
significant reductions in plasma lactate concentrations in patients that substituted   88 
abacavir for d4T compared to those that continued d4T therapy. Large observational 
studies  have  also  identified  associations  with  the  non-nucleoside  reverse 
transcriptase inhibitor (NNRTI) efavirenz and boosted- and double-protease inhibitor 
regimens
201,210,211. Host-related risk factors for development of HL include older age, 
increased waist-hip ratio, high CD4
+ cell count and liver dysfunction
201. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Rise in population average venous lactate concentrations after start of highly active 
antiretroviral therapy (HAART) in patients treated with stavudine (dashed line) and zidovudine 
(solid line). Taken from reference 156 (reprinted by permission from Lippincott Williams & Wilkins) 
[AIDS, 2001;15:717-23]. 
 
LA, characterised by persistently elevated plasma lactate levels (usually >5mmol/L), 
metabolic  acidosis  (pH  <7.35  or  bicarbonate  <20mmol/L)  and  almost  always 
accompanied by hepatic steatosis, is an uncommon but life-threatening complication 
of antiretroviral therapy
156. LA is unpredictable in that it can occur rapidly in patients 
who  have  been  on  stable  NRTI  therapy  for  months  or  even  years  and  is  poorly 
predicted by HL
156. Reported incidence rates range from 1.3 to 10 cases per 1000 
person years of antiretroviral therapy depending on the definition
156,212 with fatality 
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rates ranging from 33% to 64%
202,213-215. LA is predominantly associated with d4T 
and ddI exposure
156,200,201,203,204,216-218, but also with chronic
157,159,219,220, neonatal
158 
and perinatal
221 exposure to AZT, although in contrast to d4T, the majority (90%) of 
AZT-associated LA cases were reported in the monotherapy era
202. Host risk factors 
of  LA  include  female  gender,  concurrent  liver  disease  (HCV  co-infection),  age, 
severe immunodeficiency and obesity
201,202,211. 
2.1.2.4  NEUROPATHY 
Distal sensory neuropathies which include HIV-1-associated sensory neuropathies 
(HSN) and antiretroviral-associated neuropathy (AAN) remain common during the 
HAART era, affects between 30% and 70% of HIV-1+ HAART recipients
222-225 and 
results  in  significant  reductions  in  health-related  quality  of  life
226.  Clinically, 
electrophysically  and  histologically,  HSN  and  AAN  are  difficult  to  distinguish 
(reviewed  by  Keswani  et  al
227).  HSN  and  AAN  are  characterised  clinically  by 
peripheral  pain  and  dysaesthaesia,  with  rare  motor  involvement; 
electrophysiologically by diminished or absent sensory action potential amplitudes 
with normal or slightly slowed motor conduction velocities
228; and histologically by 
a ‘dying-back’ axonopathy and axonal degeneration of myelinated and unmyleinated 
fibres
229. However, consistent with a mitochondrial toxicity, it has been reported that 
raised serum lactate levels can discriminate AAN from HSN with 90% sensitivity 
and specificity
230. 
Risk  factors  for  HSN  and  AAN  include  AIDS,  age  (older  subjects),  alcohol 
abuse/dependence and use of d4T and ddI
231-233. From the large Johns Hopkins AIDS   90 
Service cohort study (n=1116), ddI and d4T were associated with crude incidence 
rates of 6.8 and 1.4 cases per 100 person-years; concurrent use of these drugs further 
increased risk to 3.5-fold relative to ddI alone
162. 
2.1.2.5  LIPOATROPHY 
Lipoatrophy, the pathological loss of subcutaneous fat tissue, is a component of the 
‘lipodystrophy’  syndrome,  which  also  includes  metabolic  complications  such  as 
dyslipidaemia and insulin resistance and often accompanied by visceral/abdominal 
fat  accumulation  (reviewed  by  Nolan  &  Mallal
198,234).  Lipoatrophy  is  highly 
prevalent  among  HIV-1-infected  individuals  (38%  compared  to  5%  for  healthy 
controls)
235-237, predominantly associated with NRTI therapy; NRTI therapy alone is 
sufficient  to  cause  lipoatrophy
238-240,  and  is  an  independent  risk  factor  for  its 
occurrence  in  HAART  recipients
241-247.  Among  NRTI  recipients,  prevalence  of 
lipoatrophy is as high as 57%
248. 
Lipoatrophy is observed predominantly in d4T recipients, and to lesser extent AZT 
recipients,  with  risks  of  clinically  apparent  lipoatrophy  of  40-50%  among  d4T 
recipients  and  10-20%  among  AZT  recipients
248-250  (Figure  2.4).  Studies 
investigating  the  role  of  ddI  and  3TC  in  development  of  lipoatrophy  failed  to 
demonstrate  associations
248-250  and  similarly,  clinical  trials  of  less  mitochondrial 
toxic NRTIs such as abacavir, tenofovir and emtricitabine show no association with 
lipoatrophy
150,251,252. Furthermore, substitution of d4T and  AZT to abacavir
253-258 
and even d4T to AZT or abacavir
259-261 has been demonstrated to halt progression 
and even reverse lipoatrophy.   91 
 
 
 
 
 
 
 
 
 
Figure 2.4 Proportion of patients with peripheral fat depletion according to each body area, in 
the zidovudine and stavudine arms. Unshaded bars - zidovudine arm; shaded bars - stavudine arm. 
* - means significantly different from zidovudine arm (P<0.05). Taken from reference 250 (reprinted 
by permission from Lippincott Williams & Wilkins) [AIDS, 2002;16:2447-54]. 
 
 
 
2.1.2.6  PANCREATITIS    
Pancreatitis is characterised clinically by abdominal pain, nausea and vomiting, and 
biochemically by elevations of lipase/ and or amylase. From a large meta-analysis 
study  by  Reisler  and  colleagues
262  of  twenty  Adult  AIDS  Clinical  Trials  Group 
(AACTG) studies involving 6,287 individuals, incidence rates (per 100 person years) 
of  pancreatitis  ranged  from  0.47-0.79  based  on  clinical  diagnoses,  and  1.95-2.55 
based  on  laboratory  diagnoses.  The  clinical  incidence  rates,  while  likely 
underestimating  the  incidence  rates,  provide  specificity  regarding  diagnosis,  as 
hyperamylasemia and hyperlipasemia are commonly associated with conditions such 
as renal insufficiency, liver disease and cancer
262.  
Pancreatitis is predominantly associated with combined ddI and d4T therapy
263, with 
little  evidence  of  a  contribution  by  AZT.  The  mean  clinical  incidence  rate  of 
pancreatitis from the previously mentioned meta-analysis
262 was 4.16 per 100 person   92 
years (PY) for ddI/d4T regimens, compared to 0.38 and zero PY for ddI and d4T 
monotherapy, respectively. Regarding AZT, incidence rates ranged from zero PY for 
AZT/3TC, AZT/d4T and AZT/3TC/ddC to 0.28 PY for AZT monotherapy and 1.70 
PY for AZT/ddI/nevirapine. 
The  risk  of  pancreatitis  associated  with  ddI  is  highlighted  from  studies  of 
concomitant ddI and tenofovir (TDF) use, which increases plasma ddI concentrations 
by  60%
264.  Several  case  studies  of  acute  pancreatitis  in  individuals  receiving 
ddI/TDF therapy
265,266 and significantly higher incidence rates of pancreatitis with 
ddI/TDF  regimens  (2.3  PY)  compared  to  ddI  without  TDF  (0.5  PY)  and  TDF 
without ddI (0 PY) in a Spanish cohort have been reported
267. 
There  have  also  been  case  reports  of  pancreatitis  associated  with  ritonavir-  and 
nelfinavir-containing regimens
268-270. In the ritonavir cases, pancreatitis was likely to 
be secondary to hypertriglyceridaemia, which is commonly associated with ritonavir 
therapy  (reviewed  by  Lee  et  al
271  and  Nolan
272)  and  a  known  risk  factor  for 
pancreatitis (Bae et al
273; reviewed by Yadav & Pitchumoni
274). In the nelfinavir 
case, the pancreatitis that developed initially and in response to a rechallenge with 
nelfinavir occurred in the absence of hypertriglyceridaemia
268. 
Additional  risk  factors  reported  for  pancreatitis  include  lamivudine,  older  age, 
female sex, symptomatic HIV-1 infection, substance and alcohol abuse, and liver and 
cardiovascular diseases
160,275-277. 
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2.1.3  MECHANISMS OF THYMIDINE-ANALOGUE INDUCED 
MITOCHONDRIAL DYSFUNCTION 
The adverse clinical outcomes associated with thymidine-analogue therapy described 
in section 2.1.2, or indeed, associated with NRTI therapy in general, are believed to 
be  due  to  mitochondrial  dysfunction
246,278-282.  The  mechanisms  by  which  the 
thymidine-analogues AZT and d4T induce mitochondrial dysfunction are primarily 
mtDNA-mediated,  although  the  haematological  toxicities  associated  with  AZT, 
appear to involve mtDNA-independent mechanisms.  
2.1.3.1  MITOCHONDRIAL DNA DEPLETION  
Simpson and colleagues
283 first proposed impaired mtDNA replication, leading to 
insufficient production of the 13 mtDNA-encoded protein subunits of the respiratory 
chain  and  resulting  in  insufficient  energy  production  and  cellular  toxicity,  as  a 
mechanism of AZT toxicity and mitochondrial dysfunction. 
The mechanism by which NRTIs induce mtDNA depletion is unclear. In vitro, most 
NRTIs  directly  inhibit  the  mitochondrial-specific  DNA  polymerase  (pol-γ)  and 
mtDNA  synthesis  at  pharmacological  concentrations,  with  a  consistent  order  of 
potency ddC >> ddI > d4T > AZT > ABC = TDF
150,252,284,285. Importantly 3TC, 
abacavir and tenofovir, which are not associated with mitochondrial toxicity, do not 
significantly inhibit mtDNA synthesis at pharmacological doses. In support of this, 
reduced  mtDNA  copy  number  per  cell  has  been  observed  in  various  cell  types 
following AZT or d4T exposure in vitro, including HepG2 cells
280 and rat skeletal   94 
myocytes
286 and in vivo in rat cardio(myocytes) and adipose tissue
164,287-289, heart, 
skeletal muscle, cerebellum, and cerebrum of transplacentally exposed Erythrocebus 
patas monkeys
290, muscle of perinatally-exposed infants
291, and adipose tissue of 
lipoatrophic AZT-recipients
292-294 (Figure 2.5). 
Clinically,  mtDNA  depletion  has  been  observed  in  cases  of  NRTI-associated 
myopathy
165,295,  neuropathy
296,  lactic  acidosis,  hyperlactataemia
157,297,298  and 
lipoatrophy
299-301.  Moreover,  the  degree  of  NRTI-induced  mtDNA  depletion  is 
significantly correlated to the degree of lipoatrophy in longitudinal analyses, with 
d4T therapy being associated with both significantly greater mtDNA depletion and 
significantly  greater  relative  risk  of  lipoatrophy  compared  to  AZT  therapy
302.  In 
addition, utilising multivariate models, the univariate association of duration of d4T 
and AZT therapy with lipoatrophy was lost after adjustment for the effect of mtDNA 
concentrations, suggesting that the association between choice of NRTI (d4T>AZT) 
and lipoatrophy is mediated through mtDNA concentrations
302.    95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 The effect of AZT on mtDNA/ nDNA ratio in vitro and in vivo. (A) AZT exerts a 
concentration-dependent  effect  on  the  mtDNA/nDNA  ratio  (expressed  as  a  percent  of  untreated 
controls) of CD34+ haematopoietic progenitor cells cultured for 12 days. Taken from reference 303 
(reprinted by permission from Hodder Arnold Ltd) [Hum Exp Toxicol, 2004;23:173-85]. (B) AZT 
recipients have significantly reduced adipocyte mtDNA/nDNA ratios compared to antiretroviral-naïve 
individuals. Taken from reference 294 (reprinted by permission from Lippincott Williams & Wilkins) 
[AIDS, 2003;17:1329-38].  
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2.1.3.2  NON-MITOCHONDRIAL DNA DEPLETION MECHANISMS OF AZT 
INDUCED MITOCHONDRIAL TOXICITY 
While depletion of mtDNA following AZT exposure has been reported in neuronal 
and myocyte cell lines, only one study has detected mtDNA depletion in erythroid 
cells, either in vitro or in vivo
303. Thus, AZT-associated haematological toxicities are 
unlikely to be mediated by mtDNA depletion. Indeed, in vitro cytotoxicity is closely 
related to the concentration of AZT monophosphate (AZT-MP) rather than the AZT 
triphosphate (AZT-TP)
304. In the absence of mtDNA depletion, AZT exerts almost 
immediate effects on primary human lymphocyte proliferation
305 and a marked yet 
reversible reduction in mitochondrial membrane potential of rat myotubes
306. AZT 
induces an increased production of ROS, which in rat heart mitochondria, resulted in 
inhibition of the inorganic phosphate (Pi) translocator that affects the distribution of 
flux control among the enzymes of oxidative phosphorylation
307. In isolated rat liver 
mitochondria, AZT inhibited the ADP/ATP antiport
308 and adenylate kinase
309 which 
may  contribute  to  the  ATP  deficiency  observed  in  AZT  exposed  cells  and 
mitochondria
282.  That  AZT  did  not  inhibit  the  Pi  translocator  in  rat  liver 
mitochondria  highlights  the  tissue  specificity  in  AZT  sensitivity
307.  Thus,  AZT 
exerts an effect on oxidative phosphorylation, which may be mediated by mtDNA 
depletion and/or inhibition of key oxidative phosphorylation enzymes. 
Increased production of reactive oxygen species (ROS) is a common observation of 
cells cultured in the presence of AZT
310,311 and a higher urinary excretion of 8-oxo-
7’8-dihydro-2’deoxyguanosine, a common marker of oxidatively damaged DNA, has 
been  reported  in  AZT-treated  HIV+  patients  compared  with  HIV+,  AZT-naïve   97 
controls that could be prevented with co-administration with antioxidants, vitamin C 
and E
312. In  addition, significant increases of 8-oxo-2’-deoxyguanisine in nuclear 
DNA has been reported in mice following transplacental exposure to AZT
313. 
2.1.4  NON-MITOCHONDRIAL DYSFUNCTION MECHANISMS OF AZT 
TOXICITY 
While it is clear from the overwhelming evidence that mitochondrial dysfunction is 
central to NRTI toxicity in general, non-mitochondrial mechanisms contribute, at 
least in part, to the haematological toxicities and carcinogenesis associated with AZT 
therapy. These shall be discussed below. 
2.1.4.1  GENOTOXICITY  
Consistent with the known mechanism of AZT as a DNA chain terminator, AZT is 
known to be genotoxic in mammalian cells
314. The genotoxicity of AZT includes 
gene mutations, sister chromatid exchanges, micronucleus formation, chromosomal 
aberrations, and cell transformation
315. Incorporation of AZT into DNA of human 
bone  marrow
316,317,  T-lymphoblastoid  cells 
318  and  multiple  organs  of  mice  and 
primates,  including  liver,  uterus,  spleen  and  kidney
319,320  has  been  reported.  In 
humans,  incorporation  of  AZT  into  DNA  was  detected  in  70%  of  peripheral 
leukocyte and cord blood DNA samples from HIV-1+ pregnant women and their in 
utero exposed infants, respectively, at concentrations up to 183 and 344 molecules of 
AZT/106 nucleotides, respectively, with exposure times ranging from 10 days to 9 
months
321.  Even  with  only  4  hours  of  in  utero  exposure  to  equivalent 
pharmacological doses of AZT, DNA incorporation of AZT at rates between 29 and   98 
1944 molecules of AZT/106 nucleotides was detected in liver, lung, heart, skeletal 
muscle, brain and testis of foetal Rhesus macaca mulatta monkeys which exhibit 
similar AZT pharmacokinetics to pregnant humans
322. 
DNA incorporation of AZT has been proposed by Sommadossi and colleagues
317 as 
a  mechanism  of  NRTI-associated  haemotoxicity.  As  mentioned  previously, 
haematological toxicities are predominantly associated with AZT therapy, and while 
macrocytosis  does  occur  in  d4T  recipients,  its  severity  is  significantly  lower 
compared to AZT therapy, consistent with in vitro data that indicate d4T is 20-100-
fold less toxic than d4T in a human CFU-GM clonogenic assay
323. Sommadossi et 
al
317 proposed that this is due to the observed 10-50 fold lower steady state levels of 
d4T incorporation into human bone marrow DNA relative to AZT. This was not due 
to  differential  incorporation  rates  per  se,  as  d4T-TP  and  AZT-TP  have  similar 
affinities  for  human  nuclear  DNA  polymerases,  but  to  enzymatic  excision  of 
incorporated  d4T,  which  was  not  detected  with  AZT.  The  failure  of  AZT  to  be 
excised from DNA was attributed to the high intracellular concentrations of AZT-
MP,  which  is  known  to  inhibit  the  3’  to  5’  exonuclease  activity  of  DNA 
polymerases
324 and while it is unclear if d4T-MP also inhibits 3’ to 5’ exonuclease 
activity of DNA polymerases, intracellular concentrations of d4T-MP are low and 
therefore unlikely to have an influence on the excision process
316. Such a mechanism 
of AZT toxicity is consistent with data that suggest AZT toxicity is associated with 
AZT-MP concentrations, rather than AZT-TP concentrations.   99 
2.1.4.2  INHIBITION OF HEME SYNTHESIS  
Current evidence indicates that AZT directly inhibits erythroid differentiation via 
multifactorial  mechanisms.  Spiga  and  colleagues
325  have  provided  evidence  that 
AZT  specifically  inhibits  the  binding  level  of  the  erythroid-specific  transcription 
factor  GATA-1  at  concentrations  as  low  as  0.1  µM.  In  primary  erythroid  blast 
forming unit (BFU-E) cells cultured in the presence of pharmacologically relevant 
concentrations of AZT (1 µM) for 14 days, binding levels of GATA-1 were reduced 
in a dose-dependent manner and resulted in a 5-fold reduction in steady state levels 
of β-globin mRNA (Figure 2.6) (due to a decrease in gene transcription rather than 
mRNA  stability)  and  47%  reduction  in  haemoglobin  concentrations  compared  to 
controls.  
 
 
 
 
 
 
 
Figure 2.6 The effect of AZT on cell growth and haemoglobin  production. Human erythroid 
progenitor  cells  were  cultured  in  the  presence  or  absence  of  1  mM  AZT.  Cell  number  and 
haemoglobin production were determined after 14 days in culture. Each value is the mean ± S.D. of 
the value obtained from at least three different experiments. Taken from reference 325 (reprinted by 
permission from Elsevier Science) [Antiviral Res, 1999;44:167-77).   100 
The inhibitory effect of AZT on β-globin transcription was specific and was not due 
to a temporal inhibition of differentiation, as AZT has no detectable effect on mRNA 
expression of other genes involved in heme biosynthesis including erythroid-specific 
5-aminolevulinic  (ALAS-E)  and  porphobilinogen  (PBGD-E),  which  are  normally 
upregulated  during  the  differentiation  process  earlier  and  later  than  β-globin, 
respectively
326. However, inhibition of ALAS activity (71%) has been reported in rat 
bone marrow cells exposed to pharmacologically relevant concentrations of AZT
327.  
2.1.4.3  NUCLEOTIDE POOL IMBALANCE 
Manipulation of the intracellular nucleotide pool composition has also been shown to 
reduce the toxicity exerted by  NRTIs. The effect of administration of  NRTIs on 
intracellular  nucleotide  pools  is  uncertain.  Twenty  four  hour  treatment  of 
osteosarcoma  cells  with  0.1µM  AZT  has  been  demonstrated  to  induce  a  60% 
depletion of the dTTP pool, although the relevance of this is unknown
328. That the 
administration of 100µM of β-D-uridine (an endogenous natural nucleoside), but not 
β-L-uridine or α-D-uridine, protected against the toxic effects of AZT, 3’-fluoro-3’-
deoxuthymidine (FLT)  and the toxic AZT metabolite 3’-amino-3’deoxythymidine 
(AMT) in granulocyte-macrophage colony-forming units (CFU-GM), indicates that 
β-D-uridine  had  to  be  metabolised  to  nucleotides  to  produce  a  pharmacological 
effect
329. The observation that 50µM of uridine achieved complete reversal of AZT 
toxicity  in  vitro,  greater  than  that  achieved  with  cytidine,  suggested  that  the 
conversion of cytidine to uridine, mediated by cytidine deaminase, is required for the 
reversal of AZT toxicity by cytidine; 100µM of thymidine can also protect against 
AZT  toxicity  in  vitro.  As  the  deamination  of  cytidine  to  uridine,  followed  by   101 
methylation of uridine, is the dominant pathway by which thymidine is synthesised 
intracellularly, the above evidence suggests that AZT toxicity is a consequence of a 
dTTP deficiency. Coadministration of non-toxic concentrations of thymidine with 
AZT however, reduces the anti-HIV activity of AZT by 50%, probably due to a 
decrease  in  the  ddNTP:  dNTP  ratio.  Uridine  however,  could  be  administered  at 
concentrations several-fold higher than thymidine without interfering in the anti-HIV 
activity of AZT
330. Therefore, AZT may induce a dTTP deficiency that is associated 
with AZT toxicity. 
2.1.5  PHOSPHORYLATION OF AZT & D4T  
Each of the mechanisms of NRTI toxicity described above is dependent on NRTI 
phosphorylation  as  NRTIs  have  no  intrinsic  activity  and  require  sequential 
phosphorylation to their respective 5’-mono-, 5’-di- and 5’-triphosphate anabolites 
by cellular kinases in order to exert both antiviral activity and toxicity
136,331. Thus, 
the efficiency which the cellular kinases responsible for nucleotide phosphorylation 
phosphorylate NRTIs is likely to be central to NRTI toxicity. As depicted in Figure 
2.7, upon entering the cell by passive diffusion
332,333, AZT and d4T phosphorylation 
is  achieved  by  salvage  pathway  enzymes  thymidine  kinase  (TK)  1  and/or  2, 
deoxythymidylate kinase (dTMPK) and the base-unspecific nucleoside diphosphate 
kinase (NDK), respectively.   102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 TMPK is at the junction of the de novo and salvage pathways of dTTP synthesis. AZT 
and d4T are first phosphorylated by the salvage pathway enzyme thymidine kinase 1 and 2, and 
subsequently by dTMPK and nucleoside diphosphate kinase to yield the antiviral triphosphate forms. 
Taken from reference 335 (reprinted by permission from Bentham Science Publishers Ltd) [Mini Rev 
Med Chem, 2004;4:351-9]. 
 
 
2.1.5.1  THYMIDINE KINASE 2 
As mentioned above, the initial phosphorylation of AZT and d4T is catalysed by 
thymidine kinase 1, the cytosolic, S-phase specific thymidine kinase, and thymidine 
kinase  2,  the  constitutively  expressed,  mitochondrial  isozyme
334-337.  Thus,  in 
proliferating cells, AZT and d4T are predominantly phosphorylated by TK1, while in 
resting  or  mitotically  quiescent  cells,  AZT  and  d4T  are  predominantly 
phosphorylated by TK2.  
   103 
This  initial  phosphorylation  of  the  free-drug  is  the  rate-limiting  step  in  d4T 
anabolism. As shown in Figure 2.8, the free-drug form of d4T is the major d4T form 
in  vivo,  accounting  for  approximately  90%  of  all  d4T  metabolites,  with 
approximately equal concentrations of the -DP and -TP metabolites
338-340. This is 
attributed to the very low affinities of TK1 and TK2 for d4T, which compared to 
thymidine, phosphorylate d4T at efficiencies of only 7% and 1%, respectively
336,339-
342. Therefore, TK2 is likely to be the rate limiting enzyme for d4T anabolism in 
mitotically quiescent cells, cells which are typically affected by d4T toxicities. 
 
 
 
 
 
Figure 2.8 Comparison of phosphorylation of 2 ,uM D4T with 2 F,M AZT in CEM cells. Cells 
were incubated for 24 h with labelled drug and then processed to quantitate intracellular metabolites. 
Taken  from  reference  342  (reprinted  by  permission  from  American  Society  for  Microbiology) 
[Antimicrob Agents Chemother, 1989;33:844-9]. 
 
The  role  of  TK2  genetic  variation  to  d4T  toxicities  has  not  been  investigated. 
Numerous mutations in the human TK2 gene have been associated with myopathic 
forms of mtDNA depletion syndrome, highlighting the role of TK2 in maintenance 
of  mtDNA  copy  number  and  the  tissue  specificity  of  both  mtDNA  depletion   104 
syndromes and TK2 deficiencies. Such mutations include T77M, R161K, T64M, 
R183W, H121N and I212N. The T77M, R161K and I212N mutations have been 
shown to reduce TK2 activity 80-99% in vitro compared to wild type TK2
343-345 
resulting in reductions in mtDNA copy numbers in affected muscle to approximately 
92%  compared  to  unaffected  organs
344.  While  the  described  TK2  mutations  are 
typically lethal and thus unlikely to play a role in susceptibility to d4T toxicities, the 
potential role of novel, non-lethal TK2 polymorphisms remains to be determined.  
2.1.5.2  DEOXYTHYMIDYLATE KINASE   
In  contrast  to  d4T  metabolism,  the  phosphorylation  of  AZT-MP  to  AZT-DP 
catalysed by deoxythymidylate kinase (dTMPK) is the rate-limiting step for AZT 
activation.  AZT-MP  is  the  major  AZT  metabolite  in  vivo  and  represents 
approximately 95% of all phosphorylated forms
337,346,347. Concentrations of AZT-DP 
and AZT-TP are approximately equal, accounting for approximately 0.5-3% of total 
AZT intracellular metabolites in stimulated and resting PBMCs at clinically relevant 
AZT  concentrations
348,349.  AZT-MP  exerts  negative  feedback  on  dTMPK  by 
reducing the catalytic rate constant (k) by approximately 200-fold and by inhibiting 
the  substrate  binding  of  adenosine  triphosphate,  the  phosphate  donor  to  the 
enzyme
350. Such inhibition of dTMPK, together with the AZT-mediated competitive 
inhibition of TK1 and TK2, reduces phosphorylation of dT
351, further accentuating 
the AZT-TP:dT-TP ratio and consequent antiviral efficacy. Although constitutively 
expressed,  dTMPK  activity  is  negatively  associated  with  cell  cycle  progression. 
dTMPK  activity  in  dividing  3T3-L1  adipocytes  was  1049  pmol/(mg/min)  and   105 
decreased in resting 3T3_L1 and adipocytes 4.8- and 2.7-fold, respectively although 
this has not been confirmed in other studies
152. 
AZT-MP  concentrations  are  positively  associated  with  AZT  cytotoxicity.  
Cytotoxicity,  determined  by  the  MTT  assay,  was  closely  related  to  intracellular 
concentrations of the AZT-MP but not with the active metabolite AZT-TP in various 
cell lines (Figure 2.9). Furthermore, AZT-MP concentrations are significantly higher 
in patients with CD4
+ T cell counts < 100 x 10
6 cells/L
349,351 and may explain the 
well known occurrence of increased AZT toxicity in patients with more advanced 
disease
349. 
The inefficiency of phosphorylation of thymidine-analogues by dTMPK is due to a 
combination of the size and hydrogen bonding abilities of the 3’ substituent and its 
effect on the sugar ring conformation (for review see Lavie & Konrad, 2004
352). In 
the case of AZT, the substitution of the 3’-hydroxyl for the bulky nonreactive azido 
group results in a 60-fold reduction in the rate of phosphorylation compared to that 
of dT-MP phosphorylation
353. From studies of yeast
354 and human
355 dTMPK it has 
been demonstrated that the azido group reduces phosphorylation because it interferes 
with the conformational change in the phosphate binding loop (P-loop) required for 
binding the phosphoryl donor (ATP) to the phosphoryl acceptor (dT-MP) via the 3’-
hydroxyl group, causing the P-loop to remain in the ‘open’ conformation rather than 
the ‘closed’ conformation observed with dT-MP.   106 
 
 
 
 
 
 
 
 
Figure 2.9 The relationship between MTT cytotoxicity (bars) and AZT-MP and AZT-TP (trend 
lines) in five cell lines. Histogram shows percentage decrease in MTT absorbance following a 72-h 
incubation  with  AZT  (100  mM).  Intracellular  levels  of  AZT-MP  and  AZT-TP  following  a  24-h 
incubation with AZT (0.1 mM; 1.2 mCi). All data from n=4 experiments (mean±SD). Taken from 
reference  305  (reprinted  by  permission  from  Elsevier  Science)  [Toxicol  Appl  Pharmacol, 
2001;177:54-8]. 
d4T-MP is phosphorylated to d4T-DP by dTMPK relatively efficiently, with a rate 
one fourth of that observed with dT-MP
356. Compared to AZT-MP, d4T-MP is a 
better substrate for dTMPK because it allows dTMPK to form a ‘partially-closed’ 
conformation, which is in part attributed to the conformation of the ribose moiety. 
With  all  thymidine  analogues  tested,  the  ribose  moieties  are  in  a  3’-endo 
conformation, which allows their phosphate group to makes two interactions with 
Arg97 (to Nε and NH2) via two of its phosphate oxygens. In contrast, the ribose   107 
atoms of d4T-MP are in plane due to the double bond between atoms C2’ and C3’ 
which causes the phosphate group to shift away from Arg97, breaking the interaction 
with the NH2 atom and moves within 3.1 Å to Arg45. The Arg97 NH2 atom that 
previously  made  an  interaction  with  the  phosphate  group  forms  an  H-bond  with 
Asp15 of the P-loop which stabilises the ‘partially-closed’ conformation
356.  
Despite  the  role  of  dTMPK  in  AZT-MP  phosphorylation  and  the  association  of 
AZT-MP concentrations with AZT toxicities, no data exists regarding the role of 
dTMPK genetic variation in AZT metabolism and associated toxicities. 
2.1.5.3  NUCLEOSIDE DIPHOSPHATE KINASE  
The  conversion  of  di-phosphates  to  tri-phosphates  catalysed  by  NDK  is  not 
considered rate-limiting because NDK is expressed at high levels in cells at exhibits 
broad substrate specificity. All NDK isoforms (eight isoforms in total, the cytosolic 
isoforms A and B contribute approximately 80% of the total cellular activity and the 
mitochondrial form contributes the remaining 20%) are base-unspecific but exhibit 
steady state efficiencies in the order of dG-TP > dA-TP = dT-TP >> dC-TP. d4T and 
AZT diphosphates however, are catalysed at efficiencies 5,000-10,000 fold lower 
than the natural substrates, due to a 500-1000-fold reduction in phosphotransfer rate 
and 10-fold reduction in affinity
357. The inefficiency of AZT and d4T catalysis is due 
to the absence of the 3’-OH group, which normally forms a hydrogen bond network 
with Lys12 and Asn115 of the NDK amino acid side chains involved in catalysis 
(Figure 2.10).   108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10 The reduced phosphorylation of nucleoside analogues is due to the absence of the 
3’-OH group which reduces the catalytic efficiency rather than the binding affinity. (A) View of 
human NDK isoform B active site  with bound dTDP (pruple). Some amino acid side chains are 
shown  in  yellow.  The  3’-OH  of  the  ribose  H-bonds  with  Lys12  and  Asn115  side  chains.  (B) 
Correlation of catalytic efficiencies of NDK for several nucleotides triphosphate and analogues and 
their binding efficiencies. Substrates were found to belong to two classes according to the presence of 
a  3’-OH  group  which  corresponds  to  a  difference  in  catalytic  efficiencies  of  three  orders  of 
magnitude. Taken from reference 358 (reprinted by permission from Bentham Science Publishers 
Ltd) [Mini Rev Med Chem, 2004; 4:361-9]. 
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2.1.6  HYPOTHESES & AIMS 
 
2.1.6.1  HYPOTHESIS  
We  hypothesised  that  genetic  variation  in  thymidine  kinase  2  (TK2)  and 
deoxythymidylate  kinase  (dTMPK)  would  influence  the  efficiency  of 
phosphorylation of AZT and d4T, respectively, which would be reflected in mtDNA 
levels and haematological parameters in response to such therapy. 
2.1.6.2  AIMS 
1.  To  identify  single  nucleotide  polymorphisms  (SNPs)  and  characterise 
haplotypes of the human TK2 and dTMPK genes. 
2.  To investigate whether TK2 and dTMPK SNPs and/or haplotypes influence 
adipocyte mtDNA concentrations and haematological parameters in response 
to AZT and d4T therapy, respectively, in HIV-1+ individuals.   110 
2.2  MATERIALS & METHODS 
 
 
2.2.1  IDENTIFICATION OF SNPS AND CHARACTERISATION OF HUMAN 
TK2 & DTMPK HAPLOTYPES  
Identification of human TK2 and dTMPK single nucleotide polymorphisms (SNPs), 
and characterisation of dTMPK genetic haplotypes, was performed using a pooled 
DNA sample and DNA from 8 parent-pairs, respectively. The pooled DNA sample 
comprised  of  DNA  from  187  northern  European  individuals  and  has  been  used 
previously by others to estimate allele frequencies
118. Estimation of allele frequency 
from the pooled DNA sample was achieved by chromatogram relative peak height. 
Oligonucleotide primers were designed to allow PCR amplification and sequencing 
of  the  TK2  and  dTMPK  exonic  and  flanking  intronic  regions,  the  putative  5’ 
promoter region (up to approximately 2.5kb 5’ of transcription start site (TSS)) and 
0.5kb 3’ of the 3’ untranslated region (UTR). Optimisation of the PCR amplification 
of each dTMPK and TK2 amplicon was achieved by adjusting MgCl2 concentrations 
and  annealing  temperature.  The  PCR  products were  then  purified  using  Exosap® 
according  to  the  manufacturers  protocol  and  sequenced  using  M13  forward  and 
reverse  primers  (and  overlapping  primers  for  the  dTMPK  5’  putative  promoter 
regions)  and  the  Big  Dye  Terminator  kit,  version  3.3  (PE,  Applied  Biosystems, 
USA).  Sequences  were  analysed  using  Assign  SBT  software  v.  3.2.7  (Conexio 
Genomics, Australia).   111 
2.2.1.1  AMPLIFICATION OF DTMPK 
The human dTMPK gene, located on chromosome 2q37.3, is comprised of 5 exons 
spanning approximately 11 kb. For amplification of the dTMPK exonic and flanking 
intronic sequence, 2µL of DNA was amplified in a volume of 50µL containing 10X 
PlatinumTaq PCR buffer, 2mM MgCl2 (4mM MgCl2 for exon 1), 0.8mM dNTP mix, 
100nM  of  each  forward  and  reverse  primer  and  1U  of  PlatinumTaq  under  the 
following conditions; 94°C for 2 min, followed by 35 cycles of 94°C for 30 s, 60°C 
for  30  s  and  70°C  for  90  s  and  a  final  incubation  at  72°C  for  10  min.  For 
amplification  of  the  putative  dTMPK  5’  promoter  region,  2  µL  of  DNA  was 
amplified in a volume of 50µL containing 10X PCRx buffer, 0.8mM dNTP mix, 
1.5mM MgSO4, 100nM of each forward and reverse primer (Table 2.1), 1X PCRx 
Enhancer solution and 0.5U of PlatinumTaq under the following conditions; 95°C 
for 2 min, followed by 35 cycles of 95°C for 30 s, 60°C for 30 s and 68°C for 3 
mins.   112 
Table  2.1  Oligonucleotide  characteristics  used  for  the  amplification  and  sequencing  of  the 
human dTMPK gene. 
 
Region  Primer 
Name  Orientation  5’ Binding 
Position  Sequence (5’-3’) * 
103,755F†  Forward   25,401  aaaccgcacagttcacagc 
106,366R†  Reverse  22,790  ggccacaagacagaaactcc 
104,504R‡  Reverse  24,653  catctcgctcgttcgtctc 
104,485F‡  Forward  24,672  cgagacgaacgagcgagat 
105,213R‡  Reverse  23,944  tagataccggggacacttcg 
105,105F‡  Forward  24,052  tctttccatgcctccaactc 
5’ Prom 
105,920R‡  Reverse  23,237  agggtgcagtgagctgagat 
Exon 1  103,619F  Forward  25,537  gcctatgttcccggctacc 
  104205R  Reverse  24,951  ccaggacacggctccagt 
Exon 2  102865F  Forward  26,290  aacatcaggcccagcactac 
  102865R  Reverse  25,920  gcagaagatccaagcctgtc 
Exon 3  97350R  Forward  31,806  aatctgaggcatgtcactcg 
  97350R  Reverse  31,542  gcacagcctgttgggataat 
Exon 4  95543F  Forward  33,613  cacatctgggaggaccagac 
  95543R  Reverse  33,199  tcaccaaatgtcccctcatt 
92891F  Forward  36,264  gatggaggttcccattcaaa  Exon 5 
92891R  Reverse  35,588  tacaagcagtcctccctcgt 
 
*  -  all  oligonucleotide  sequences  (except  for  103,755F  and  106,366R)  contained  M13F  (5’-
tgtaaaacgacggccagt-3’)  and  M13R  (5’-caggaaacagctatgacc-3’)  tags  at  the  5’  end  of  the 
oligonucleotide for sequencing practicality; 5’ binding position – nucleotide position of the 5’ end of 
the oligonucleotide relative to NCBI accession number AC133528; † - oligonucleotides used for both 
PCR amplification and sequencing of the putative 5’ promoter amplicon; ‡ - oligonucleotides used for 
sequencing only of the 5’ promoter amplicon. 
 
 
2.2.1.2  AMPLIFICATION OF TK2  
The human TK2 gene, located on chromosome 16q22-q23.1, is comprised of 9 exons 
spanning approximately 39 kb. For amplification all TK2 exons and their flanking 
intronic sequence and the putative 5’ promoter, 2µL of DNA was amplified in a 
volume of 50µL containing 10X PlatinumTaq PCR buffer, 3mM MgCl2 (1.5mM 
MgSO4 for putative 5’ promoter) 0.8mM dNTP mix, 100nM of each forward and 
reverse primer (Table 2.2) and 1U of PlatinumTaq under the following conditions;   113 
94°C for 2 min, followed by 35 cycles of 94°C for 30 s, 60°C for 30 s (65° for 60 s 
for putative 5’ promoter) and 70°C for 90 s and a final incubation at 72°C for 10 
min.  
Table  2.2  Oligonucleotide  characteristics  used  for  the  amplification  and  sequencing  of  the 
human TK2 gene. 
 
Region  Primer 
Name  Orientation  5’ Binding 
Position  Sequence (5’-3’)* 
8680F  Forward  8,680  caggtgatctgccttccttg  5’ Prom 
9611R  Reverse  9,611  ctctccatcccagaaccaaa 
9429F  Forward  9,429  ctatgcgcccacctactcc 
10016R  Reverse  10,016  aggcagaacagcctccact 
9836F  Forward  9,836  actgttacacccgggttctg 
Exon 1 
10484R  Reverse  10,484  tctccctggagatcctcttgt 
17235F  Forward  17,235  cgaggagggattttggttta  Exon 2 
17576R  Reverse  17,576  tacacctgtggcttgcactt 
22228F  Forward  22,228  tctcctcactttcccctcaa  Exon 3 
22495R  Reverse  22,495  ccctggtcttctccaactca 
27809F  Forward  27,809  tcagtgccttgtgagaccag  Exon 4 
28015R  Reverse  28,015  aagtttcccttcctggcaat 
30122F  Forward  30,122  ggtcctcctgcttcactctct  Exon 5 
30480R  Reverse  30,480  tttgttacaccgcattgcta 
41328F  Forward  41,328  gatcacactgtgccctggta  Exon 6 
41694R  Reverse  41,694  cctcagggagaaagctgaact 
42021F  Forward  42,021  gagctgtgcagaccttcctc  Exon 7 
42362R  Reverse  42,362  ggccaaacaggaagtcagag 
45369F  Forward  45,369  ctgtccacttgagccaggtt  Exon 8 
45778R  Reverse  45,778  agactcagcccagaaacagg 
47139F  Forward  47,139  atctgcctgcaaccttctgt 
47674R  Reverse  47,674  cacaacaggtgctctcccta 
47512F  Forward  47,512  tctttgtcatgcgtctctgg 
48159R  Reverse  48,159  aggagactgagcacccttca 
47995F  Forward  47,995  cccaaggacagtcagcattt 
Exon 9 
48687R  Reverse  48,687  tggcctgtttctccagagtt 
 
*  -  all  oligonucleotide  sequences  contained  M13F  (5’-tgtaaaacgacggccagt-3’)  and  M13R  (5’-
caggaaacagctatgacc-3’)  tags  at  the  5’  end  of  the  oligonucleotide  for  sequencing  practicality;  5’ 
binding position – nucleotide position of the 5’ end of the oligonucleotide relative to NCBI accession 
number AC010289. 
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2.2.2  THE INFLUENCE OF DTMPK GENETIC VARIATION ON 
HAEMATOLOGICAL RESPONSE TO AZT THERAPY 
The influence of dTMPK genetic variation on  haematological parameters (MCV, 
haemoglobin and neutrophil count and percent) in response to AZT was assessed in 
one  hundred  and  sixteen  patients  receiving  AZT  as  part  of  their  initial  HAART 
regimen  and  forty  eight  d4T-experienced,  AZT  recipients.  Forty  one  patients 
receiving  d4T  as  part  of  their  initial  HAART  regimen  and  eighty  two  AZT-
experienced, d4T recipients were used as controls. All patients were male Caucasian. 
Analysis of patients’ MCV and haemoglobin profiles indicated that equilibration of 
such values in response to AZT therapy occurred within six months of initiation of 
therapy (Figures 2.11 & 2.12). Consequently, mean values for each parameter in 
response to therapy were calculated on serial values obtained at least six months 
after initiation of AZT/d4T until discontinuation of the corresponding drug. 
2.2.3  THE INFLUENCE OF DTMPK GENETIC VARIATION ON AZT-
INDUCED MTDNA DEPLETION 
The influence of dTMPK genetic variation on AZT-induced mtDNA depletion in the 
context of lipoatrophy was examined in a subset of the patients for whom we had 
previously obtained subcutaneous adipose tissue biopsies. This subset comprised of 
29 AZT recipients and 19 d4T recipients that had been receiving the corresponding 
thymidine-analogue therapy for 42.7 ± 34.0 and 36.2 ± 22.4 months, respectively 
(P=0.468). The number of copies of mtDNA per cell was calculated from isolated 
adipocytes by real-time PCR quantification of the mitochondrial-encoded 16S gene 
and the nuclear-encoded HGH gene as previously described
294.   115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.11.  Longitudinal  mean  corpuscular  volume  (MCV)  profiles  of  AZT-recipients.  (A) 
MCV profiles of individuals receiving AZT as part of initial HAART regimen. (B) MCV profiles of 
AZT recipients with had received previous d4T treatment. Individual on-treatment MCV values were 
calculated from serial values obtained at least 176 days (approximately 6 months) after initiation of 
AZT. 
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Figure  2.12.  Longitudinal  haemoglobin  concentration  profiles  of  individuals  initiating  AZT 
therapy. (A) Haemoglobin profiles of individuals receiving AZT as part of initial HAART regimen. 
(B) Haemoglobin profiles of AZT recipients with had received previous d4T treatment. Individual on-
treatment  haemoglobin  values  were  calculated  from  serial  values  obtained  at  least  176  days 
(approximately 6 months) after initiation of AZT; Hb – haemoglobin. 
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2.2.4  STATISTICAL ANALYSIS 
Statistical analyses were carried out using SPSS software (version 12.0.1, SPSS Inc. 
USA).  All  values  are  expressed  as  mean  ±  standard  deviation  unless  otherwise 
stated.  Comparisons  of  means  were  performed  using  T-test  or  ANOVA  and 
adjustment for multiple comparisons where appropriate.   118 
2.3  RESULTS 
 
 
2.3.1  IDENTIFICATION OF TK2 AND DTMPK SNPS 
As mentioned in section 1.2.7, use of a pooled DNA sample allowed identification of 
APOBEC3G  SNPs  with  allele  frequencies  greater  than  approximately  10-15%. 
Utilising  this  approach,  we  identified  nine  novel  and  three  previously  reported 
dTMPK SNPs (Figure 2.13). The three previously reported dTMPK SNPs identified 
from  the  pooled  DNA  sample  include  a  synonymous  (33,309,  rs4675906),  an 
intronic (33,508, rs4076639) and a 3’UTR (35,887, rs3209844) SNP. The nine novel 
dTMPK SNPs identified include four intronic (25,421, 25,424, 25,946 and 33,567), 
two  putative  5’  promoter  (24,537  and  24,880)  and  three  3’UTR  SNPs  (35,830; 
35,897; 36,187). 
 
 
 
 
 
 
 
Figure 2.13 Schematic representation of the human dTMPK gene and location 
of identified SNPs. Vertical line – position of observed SNPs; turquoise shading – 
exons;  grey  shading  –  untranslated  regions;  blue  shading  –  putative  5’  promoter 
regions. 
 
Regarding TK2, we did not observe any SNPs in the regions examined from the 
pooled DNA sample, suggesting that the putative 5’ promoter, exonic and flanking 
intronic regions of the TK2 gene lacks SNPs with allele frequencies greater than 
approximately 10%. In order to identify TK2 SNPs with allele frequencies less than 
approximately  10%,  we  sequenced  the  aforementioned  genetic  regions  in  the  8 
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5’ 3’
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parent-pairs used for haplotype characterisation. From this, we identified 2 intronic 
SNPs,  both  of  which  were  previously  unreported,  located  at  nucleotide  positions 
47,207  and  47,254  relative  to  NCBI  accession  number  AC010289  (Figure  2.14). 
Each SNP was only observed in one individual, and only in the heterozygous state, 
giving allele frequencies of approximately 3% and as such, TK2 genetic variation 
was not investigated any further. 
 
 
 
 
 
 
 
Figure 2.14 Schematic representation of the human TK2 gene and location of identified SNPs. 
Vertical line – position of observed SNPs; turquoise shading – exons; grey shading – untranslated 
regions; blue shading – putative 5’ promoter regions. 
 
The previously reported non-synonymous (25,263, rs11555213; 33,383 rs1803267), 
synonymous (33,345, rs1803266) and 3’UTR (35,878, rs1803265; 35,899 rs5860; 
35,961, rs1131266) dTMPK SNPs were not identified in either the pooled DNA 
sample or any of the 286 individual DNA samples. Of the twelve SNPs identified in 
the  pooled  DNA  sample,  the  mean  difference  between  the  estimated  allele 
frequencies and that determined from the 286 individual DNA samples was 5.53 ± 
3.46%  (range  1.31-11.85%).  Thus,  allele  frequency  estimated  by  relative 
chromatograph  peak  height  generated  from  sequencing  a  pooled  DNA  sample 
reflects the ‘true’ allele frequency determined by individual genotype frequency. The 
frequency of the dTMPK 25,421 G allele determined from the 286 HIV+ individuals 
was  13%,  which  reflects  the  frequency  estimated  from  the  pooled  DNA  sample 
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5’ 3’
exon 1 exon 2 exon 3 exon 4 exon 5 exon 6
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exon 7
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(10%)  and  estimates  the  lower  detection  limit  of  allele  detection  by  sequencing 
pooled DNA is below 13%. 
2.3.2  CHARACTERISATION OF DTMPK HAPLOTYPES 
Of the eight, parent-pairs, five provided sufficient genetic variation to characterise 
dTMPK  haplotypes,  the  pedigrees  of  which  are  displayed  in  Figure  2.15.  By 
genotyping the parent-pairs and their children, we identified five haplotypes, ranging 
in frequency from 4.5% to 37.1% (Table 2.3). The five haplotypes appear to have 
evolved from recombination of three distinct 3’ haplotypes, restricted by the 24,537 
and 25,946 SNPs, with three distinct 5’ haplotypes, restricted by the 33,309 and 
36,187 SNPs.   121 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.15  dTMPK  haplotype  pedigrees.  Numbers  represent  haplotype  number  in  Table  2.3; 
squares represent males; circles represent females.  
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Table  2.3  Human  deoxythymidylate  kinase  haplotypes  identified  from  studies  of  family 
members. 
 
Haplotype  AC133528  rs#  Ps  Region  Ref Seq 
1  2  3  4  5 
24,537  -  -624  5’P  C  C  C  T  T  T 
24,880  -  -281  5’P  G  G  G  A  A  G 
25,421  -  260  I1  T  T  T  T  T  G 
25,424  -  263  I1  C  C  C  G  G  G 
25,946  -  785  I1  T  T  T  A  A  T 
 
33,309  4675906  8,148  E 4 syn  T  T  C  C  T  T 
33,508  4076639  8,347  I4  T  T  T  T  C  C 
33,567  -  8,406  I4  T  T  C  C  C  C 
35,830  -  10,669  3’UTR  C  C  C  C  ∆C  ∆C 
35,887  3209844  10,726  3’UTR  C  C  C  C  T  T 
35,897  -  10,736  3’UTR  A  A  G  G  G  G 
36,187  -  11,026  3’UTR  C  C  A  A  C  C 
 
Freq (%)  -  -  -  -  37.1  4.5  34.1  11.5  11.8 
5’ Hap  -  -  -  A  A  A  B  B  C 
3’ Hap  -  -  -  A  A  B  B  C  C 
 
Position – nucleotide number on Genbank Accession AC133528. Haplotypes 2 and 4 appear to have 
evolved from recombination of haplotypes 1 and 3 and 3 and 5, respectively; Ps – nucleotide position 
relative  to  transcription  start  site;  5’  P  –  putative  5’  promoter;  I1  –  intron  1;  E4  syn  –  exon  4, 
synonymous; I4 – intron 4; 3’UTR – 3’ untranscribed region; Freq (%) – frequency of the haplotype 
determined from 286 individuals. 
 
 
 
2.3.3  HAEMATOLOGICAL RESPONSE TO AZT AND D4T  
Haematological toxicities such as anaemia and neutropenia are commonly observed 
amongst AZT recipients, with few reports of such toxicities amongst d4T recipients, 
and while macrocytosis does develop in d4T recipients, its severity is substantially 
lower  than  that  observed  in  AZT  recipients
167,179.  Consistent  with  this,  AZT 
recipients in this study (n=163) had significantly lower haemoglobin (142.9 ± 13.3 
g/dL vs 151.1 ± 13.1 g/dL, P<0.001), neutrophil percent (51.6 ± 8.7 vs 54.7 ± 8.3%, 
P=0.003) and higher MCV (109.4 ± 6.4 fl vs 104.7 ± 7.3 fl, P<0.001) than d4T 
recipients (n=123) (Table 2.4).   123 
Table 2.4 Characteristics of AZT and d4T recipients. 
 
Pre-treatment  AZT (n=163)  d4T (n=123)  P value 
Viral load  4.997± 0.690  4.792 ± 0.789  0.180 
CD4
+ cell count  293.9 ± 229.5  303.4 ± 166.1  0.800 
Haemoglobin   137.9 ± 16.5  139.2 ± 22.3  0.763 
MCV  89.0 ± 4.7  88.7 ± 5.5  0.830 
Neutrophil count  2.68 ± 1.18  2.92 ± 1.36  0.422 
Neutrophil percent  48.8 ± 15.9  56.3 ± 12.9  0.064 
On-treatment 
Haemoglobin  142.9 ± 13.3  151.1 ± 13.1  <0.001 
MCV  109.4 ± 6.4  104.7 ± 7.3  <0.001 
Neutrophil count  3.68 ± 7.4  3.67 ± 1.23  0.991 
Neutrophil percent  51.6 ± 8.7  54.7 ± 8.3  0.003 
 
Haemoglobin  ,  g/L;  viral  load,  log10  copies/mL;  CD4
+  cell  count,  10
6  cells/mL;  MCV,  mean 
corpuscular volume, femtolitres; neutrophil count, 10
6 cells/mL.   
Of the 163 AZT recipients, 71 (44%) had haemoglobin concentrations determined 
within 62 days (mean 17.1 ± 17.3 days) of initiating therapy. Using these measures 
as estimated pre-treatment values, 37.3% of AZT-recipients experienced a decrease 
in  haemoglobin  in  response  to  AZT,  with  23.5%  experiencing  a  reduction  in 
haemoglobin greater than 5 g/dL. These frequencies were higher in a subset of AZT 
recipients  (n=29)  with  actual  day  zero  pre-treatment  haemoglobin  values  (50% 
experienced a reduction in haemoglobin, with 46% experiencing a reduction greater 
than 5 g/dL). In contrast, only 12.5% of d4T-recipients with estimated pre-treatment 
haemoglobin values (estimated within a similar duration of initiating therapy, n=24, 
mean 19.1 ± 22.5 days) experienced a reduction in haemoglobin, with 41.7% of d4T 
recipients experiencing an increase in haemoglobin greater than 5 g/dL.   124 
2.3.4  INFLUENCE OF DTMPK GENETIC VARIATION ON 
HAEMATOLOGICAL RESPONSE TO ZIDOVUDINE  
 
2.3.4.1  HAEMOGLOBIN 
Given  the  high  degree  of  dTMPK  polymorphism,  we  sought  to  determine  the 
influence of dTMPK genetic variation on the response of haematological parameters 
examined above to AZT therapy. We observed significant associations between both 
the  synonymous  33,309  SNP  and  the  3’  UTR  36,187  SNP  and  haemoglobin 
concentrations in response to AZT therapy. The 33,309 C and 36,187 A alleles are 
haplospecific for the 3’ haplotype B, which comprises the common haplotype 3 and 
the rare haplotype 2. As depicted in Figure 2.16A, AZT-recipients homozygous for 
the  3’  haplotype  B,  had  significantly  higher  on-treatment  haemoglobin 
concentrations  than  non-homozygotes  (n=22,  149.0  ±  8.4  versus  n=132,  142.1  ± 
13.8,  P=0.024).  This  comparison  was  essentially  a  comparison  of  individuals 
homozygous for haplotype 3 versus non-homozygotes, as 20/22 of the 3’ haplotype 
B homozygotes are also homozygous for haplotype 3, and indeed, such a comparison 
remained significant (n=20, 149.1 ± 8.8 versus n=134, 142.2 ± 13.7, P=0.031). 
AZT-recipients homozygous for the 3’ haplotype B were significantly more likely 
than  non-homozygotes  to  have  mean  on-treatment  haemoglobin  concentrations 
greater than 150 g/L (7/14 versus 11/54, P=0.04) while individuals homozygous for 
haplotype 3 tended to be associated with on-treatment haemoglobin concentrations 
greater than 150 g/L (6/12 versus 12/56, Fishers Exact, P=0.068). Furthermore, as 
depicted  in  Figure  2.16B,  0/22  and  0/20  AZT-recipients  homozygous  for  3’ 
haplotype  B  or  haplotype  3,  respectively,  compared  to  22/132  (17%)  or  22/134   125 
(16%)  of  non-homozygotes,  respectively,  had  mean  on-treatment  haemoglobin 
concentrations below 130g/L, (Fishers Exact, P=0.045 & 0.079, respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.16  AZT  recipients  homozygous  for  3’  haplotype  B  have  significantly  higher  on-
treatment  haemoglobin  concentrations  (A)  and  were  significantly  less  likely  to  have  on-
treatment haemoglobin concentrations less than 130 g/L (B).  
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The  association  of  the  3’  haplotype  B  or  haplotype  3  with  higher  on-treatment 
haemoglobin concentrations was unique to AZT therapy. As shown in Figure 2.17, 
d4T-recipients homozygous for either the 3’ haplotype B or haplotype 3 (all d4T-
recipients homozygous for the 3’ haplotype B were also homozygous for haplotype 
3) had similar on-treatment haemoglobin concentrations as non-homozygous d4T-
recipients (n=24, 147.3 ± 17.0 versus n=96, 152.2 ± 11.8, P=0.099). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17 No association existed between the 3’ haplotype B and on-treatment haemoglobin 
concentrations in d4T-recipients.  
From  a  subset  of  AZT-recipients  with  estimated  pre-treatment  haemoglobin 
concentrations (n=68), it was revealed that individuals homozygous for 3’ haplotype 
B (n=14, 145.5 ± 14.5 versus n=54, 136.2 ± 16.7, P=0.061) or haplotype 3 (n=12, 
144.6  ±  15.5  versus  n=56,  136.8  ±  16.6,  P=0.138)  tended  to  have  higher  pre-
treatment haemoglobin concentrations than non-homozygotes. 7/14 and 6/12 AZT-
recipients (50%) homozygous for the 3’ haplotype B or haplotype 3, respectively,   127 
had pre-treatment haemoglobin concentrations greater than 150g/L compared to only 
11/54  (20%)  or  12/56  (21%)  of  non-homozygous  AZT-recipients,  respectively 
(Fishers  Exact,  P=0.068  &  P=0.04,  respectively).  Thus,  the  higher  mean  on-
treatment haemoglobin concentrations observed in AZT-recipients homozygous for 
the 3’ haplotype B or haplotype 3 may be due to an effect of the haplotype on pre-
treatment  haemoglobin  concentrations  rather  than  haemoglobin  concentrations  in 
response to AZT therapy.  
When the analysis of pre-treatment haemoglobin concentrations was extended to all 
individuals regardless of the treatment arm they belonged to after starting treatment 
(n=91),  the  association  between  lower  pre-treatment  haemoglobin  concentrations 
with the 3’ haplotype B (P=0.443) or haplotype 3 homozygosity was lost (P=0.661), 
supporting a role for dTMPK haplotypic variation in haemoglobin concentrations in 
response  to  AZT-therapy.  However,  the  ∆  haemoglobin  values  were  similar  in 
individuals homozygous for the 3’ haplotype  B (Figure 2.18A, n=13, 4.1 ± 12.4 
versus n=53, 5.9 ± 16.1, P=0.705) or haplotype 3 (n=11, 5.3 ± 13.2 g/dL versus 
n=54, 5.6 ± 15.8 g/dL, P=0.949) compared to non-homozygotes, with 5/8 (62%) and 
19/51 (37%) of 3’ haplotype B homozygotes and non-homozygotes, respectively and 
8/11 (73%) and 32/53 (60%) of haplotype 3 homozygotes and non-homozygotes, 
respectively, experiencing an increase in haemoglobin concentrations in response to 
AZT  (Figure  2.18B,  Fishers  Exact,  P=1.0  and  P=0.514,  respectively),  clearly 
showing no influence of the dTMPK 3’ haplotype B or haplotype 3 had no influence 
on haemoglobin concentrations in response to AZT-therapy. 
   128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18 Mean  ∆ ∆ ∆ ∆ haemoglobin concentrations (A) and the proportion of individuals that 
experienced an increase in haemoglobin concentrations in response to AZT-therapy (B) were 
similar  in  individuals  regardless  of  homozygosity  for  the  3’haplotype  B  or  haplotype  3, 
respectively.   
 
 
homozygous
(n=11) 
non-homozygous
(n=53) 
B
A
homozygous
(n=11) 
homozygous
(n=11) 
non-homozygous
(n=53) 
non-homozygous
(n=53) 
B
A  129 
2.3.4.2  MEAN CORPUSCULAR VOLUME 
Pre-treatment mean corpuscular volume (MCV) was significantly, albeit modestly, 
lower in AZT-recipients positive for the 24,537 and 25,424 C alleles than individuals 
homozygous for the 24,537 and 25,424 T alleles (n=34, 87.8 ± 4.4 versus n=22, 90.9 
±  5.0,  P=0.019),  and  unlike  the  pre-treatment  haemoglobin  association,  this 
association  remained  significant  when  extended  to  all  individuals  regardless  of 
treatment arm (n=48, 88.1 ± 4.7 versus n=31, 90.5 ± 4.9, P=0.035). The 24,537 and 
25,424  C  alleles  are  haplospecific  for  the  5’  haplotype  A,  which  comprises  the 
common  haplotype  1  and  rare  haplotype  2.  Lower  pre-treatment  MCV  was  also 
associated with the 24,880 G and 25,946 T alleles, which like the 24,537 and 25,424 
C alleles are haplotypic of the 5’ haplotype A, but also haplotypic of the 5’ haplotype 
C, in all individuals (n=57, 88.4 ± 4.7 versus n=22, 90.9 ± 4.9, P=0.039) and when 
restricted  to  AZT-recipients  only  (n=42,  88.2  ±  4.6  versus  n=14,  91.4  ±  4.8, 
P=0.034). Furthermore, regarding the two most common haplotypes, pre-treatment 
MCV was significantly lower in individuals homozygous for haplotype 1 than in 
individuals homozygous for haplotype 3 (n=12, 86.9 ± 3.8 versus n=16, 90.1 ± 4.3, 
P=0.050). 
However, the 5’ haplotype A had no effect on MCV in response to AZT therapy. 
While individuals that carried the 5’ haplotype B or haplotype 1 had significantly 
lower pre-treatment MCV than those that lacked the 5’ haplotype B or haplotype 1, 
on-treatment MCV (n=101, 143.8 ± 13.0 versus n=53, 141.7 ± 14.1, P=0.360) and ∆ 
MCV (n=34, 20.9 ± 5.2 versus n=19, 18.3 ± 5.9, P=0.102) were similar amongst 
individuals  carrying  the  5’  haplotype  B  or  not.  Similarly,  on-treatment  MCV   130 
(P=0.105) and ∆ MCV (P=0.509) were similar amongst individuals homozygous for 
the two common haplotypes, 1 and 3. Thus, the 5’ haplotype B or haplotype 1 did 
not influence MCV in response to AZT-therapy, but may represent a response to 
HIV-1 infection per se. 
2.3.5  INFLUENCE OF DTMPK SNPS AND HAPLOTYPES ON AZT-
INDUCED MTDNA DEPLETION  
The influence of dTMPK genetic variation on AZT-induced mtDNA depletion was 
investigated in a preliminary study in a subset of patients, comprised of twenty nine 
AZT recipients and nineteen d4T recipients. Two dTMPK SNP positions were found 
to be significantly associated with adipocyte mtDNA values. As shown in Figure 
2.19,  homozygosity  for  either  the  33,567  T  or  35,897  A  alleles,  which  are 
haplospecific  for  haplotype  1,  was  significantly  associated  with  higher  mtDNA 
values than patients carrying the 33,567 C or 35,897 G alleles (n=4, 3.198 ± 0.253 
log10  copies/cell  versus  n=26,  2.904  ±  0.226  log10  copies/cell,  P=0.023)  despite 
similar duration of AZT therapy (44.7 ± 53.9 versus 42.7 ± 30.5 months, P=0.912). 
The  effect  of  haplotype  1  on  mtDNA  values  in  response  to  thymidine-analogue 
therapy was specific to AZT, consistent with the role of dTMPK as the rate-limiting 
enzyme  for  AZT,  but  not  d4T,  metabolism.  D4T  recipients  homozygous  for 
haplotype 1 had similar mtDNA levels to d4T recipients carrying other haplotypes 
(n=3, 2.285 ± 0.062 versus n=16, 2.326 ± 0.262, P=0.796) despite them tending to 
have  shorter  duration  of  d4T  exposure  (20.8  ±  17.6  versus  39.1  ±  22.4  months, 
P=0.203).   131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.19 AZT recipients homozygous for the dTMPK haplotype 1 have significantly higher 
adipocyte mtDNA values than non-homozygous AZT recipients (A), despite similar duration of 
AZT exposure (B).    
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Figure 2.20 illustrates that the level of mtDNA observed in patients homozygous for 
haplotype 1 reflects the values obtained from antiretroviral-naïve HIV-1+ patients 
(n=  34,  3.194  ±  0.312,  P=0.982),  HIV-1+  patients  that  were  not  receiving 
antiretroviral therapy at the time of biopsy (n=5, 3.120 ± 0.141, P=0.572) or HIV-1+ 
patients  receiving  HAART  regimens  not  containing  thymidine-analogues  (n=25, 
3.195 ± 0.239, P=0.979), suggesting that haplotype 1 was not associated with AZT-
induced mtDNA depletion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.20 mtDNA values in AZT recipients homozygous for the dTMPK haplotype 1 reflect 
that  observed  in  recipients  of  non-thymidine-analogue  therapy,  HIV-1+  individuals  not 
receiving antiretroviral therapy or HIV-1 seronegative controls. d4T – d4T-recipients; AZT (non-
hm) – AZT-recipients that are non-homozygous for haplotype 1; AZT (hm) – AZT-recipients that are 
homozygous for haplotype 1; non AZT/d4T – recipients of antiretroviral regimens that do not contain 
AZT or d4T; NT – HIV
+ individuals not receiving antiretroviral therapy at the time of adipose tissue 
biopsy; ART-naïve – HIV
+ individuals that have never received antiretroviral therapy; HIV-1 neg – 
HIV-1 seronegative individuals; mtDNA (log10 copies/mL) – mtDNA/nDNA (log10 copies/mL).  
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2.4  DISCUSSION 
In this study, we observed substantial genetic variation in the human dTMPK gene 
amongst Caucasian individuals. Although we did not identify any non-synonymous 
polymorphisms, suggesting that the dTMPK protein is highly conserved and has not 
been subject significant selective pressure, we did identify two putative 5’ promoter 
and  four  3’UTR  SNPs  which  may  influence  its  transcription  or  translation, 
respectively.  Furthermore,  from  the  nucleotide  sequence  of  the  five  dTMPK 
haplotypes  identified,  it  appears  that  they  evolved  from  recombination  of  three 
distinct 3’ haplotypes, extending from upstream of the 24,537 SNP to the 25,946 
SNPs, with 3 distinct 5’ haplotypes, restricted by the 33,309 SNP and extending 3’ 
of the 36,187 SNP. In contrast, the human TK2 gene was highly conserved, with 
only two intronic polymorphisms identified at frequencies of 3%. 
The  two  most  common  dTMPK  haplotypes  were  associated  with  higher  pre-
treatment  haemoglobin  concentrations  and  maintained  adipocyte  mtDNA 
concentrations in response to AZT therapy, respectively. The influence of dTMPK 
genetic variation on haemoglobin concentrations in this HIV-1 cohort was modest. 
The 33,309 C allele and the 36,187 A allele, both of which are haplospecific of the 
3’ haplotype B, shared by the common haplotype 3 and the rare haplotype 2, was 
significantly associated with higher haemoglobin concentrations in response to AZT 
therapy  (P=0.024),  with  homozygous  AZT-recipients  significantly  more  likely  to 
experience  mean  on-treatment  haemoglobin  concentrations  greater  than  150  g/L 
(P=0.04)  and  non-homozygotes  more  likely  to  experience  mean  on-treatment 
haemoglobin concentrations less than 130 g/L (P=0.045). However, the higher pre-
treatment haemoglobin concentration in 3’ haplotype B homozygotes was likely due   134 
to  higher  pre-treatment  haemoglobin  concentrations  (P=0.061),  as  homozygotes 
tended to be more likely than non-homozygotes to also have mean pre-treatment 
haemoglobin concentrations greater than 150 g/L (P=0.068), and this was reflected 
in  the  similar  ∆  haemoglobin  concentrations  amongst  homozygotes  and  non-
homozygotes (P=0.705). 
The influence of the 3’ haplotype B on pre-treatment haemoglobin concentrations 
suggests  that  the  3’  haplotype  B  may  influence  haemoglobin  concentrations  in 
response  to  HIV-1  infection  per  se  or  physiological  haemoglobin  concentrations, 
rather  than  a  response  to  treatment.  Haemoglobin  concentrations  are  known  to 
correlate with disease progression
358-361 and baseline haemoglobin concentrations are 
significant  predictors  of  AIDS  and  death
176.  As  little  as  10  g/L  decrease  in 
haemoglobin concentrations has been associated with increased hazard of death by 
57%  in  AIDS  patients
174.  In  this  cohort,  although  significant  correlations  existed 
between pre-treatment viral load and pre-treatment haemoglobin concentrations (r=-
0.251,  P=0.032,  data  not  shown)  and  between  pre-treatment  viral  load  and  pre-
treatment MCV (r=-0.329, P=0.004, data not shown), which was also significantly, 
albeit modestly, higher in individuals homozygous for haplotype 3 (P=0.05), pre-
treatment  viral  loads  were  similar  amongst  individuals  homozygous  for  the  3’ 
haplotype B and non-homozygotes (P=0.355, data not shown). Therefore, although 
the  clinical  relevance  of  dTMPK  haplotyping  was  limited  in  the  relatively 
haematologically-stable WA HIV-1 cohort, in third world populations where up to 
80%  of  individuals  with  HIV-1  present  with  anemia
360,362  and  where  routine 
monitoring of haemoglobin concentrations prior to commencement of highly active 
antiretroviral therapy  is  recommended to  ensure that mortality and morbidity are   135 
minimized and quality of life optimized
362, dTMPK haplotyping may contribute, at 
least  in  part,  to  identifying  individuals  that  are  least  likely  to  experience 
haematological  complications  of  AZT  therapy.  In  this  respect,  it  would  be 
informative to determine the role of dTMPK genetic variation on such complications 
in large African clinical trials, such as the DART (Development of AntiRetroviral 
Therapy in Africa) study which aims to investigate whether intermittent rather than 
continuous AZT-containing regimens alleviate toxicity while maintaining virological 
control  from  3,300  participants  over  5  years  (http://www.ctu.mrc.a 
c.uk/dart/summary.asp). 
The results of the pilot study (n=48) regarding the role of dTMPK in AZT-induced 
mtDNA depletion are encouraging, but due to the small number of samples analysed, 
interpretations  of  the  data  are  limited.  Homozygosity  for  haplotype  1,  the  most 
common  dTMPK  haplotype  observed  in  this  Caucasian  cohort,  was  significantly 
associated  with  higher  adipocyte  mtDNA  concentrations  than  non-homozygotes 
(P=0.023).  The  mtDNA  concentrations  observed  in  individuals  homozygous  for 
haplotype  1  reflected  those  observed  in  antiretroviral-therapy  naïve  and  HIV-1 
seronegative individuals and thus appear to protect against AZT-induced mtDNA 
depletion. Whether the haplotype protects against toxicities associated with AZT-
induced  mtDNA  depletion  remain  to  be  determined.  The  lack  of  an  effect  of 
haplotype  1  in  d4T-induced  mtDNA  depletion  (P=0.796)  was  expected  and 
consistent with data that indicate that dTMPK is able to phosphorylate d4T-MP at 
greater efficiency than AZT-MP and consequently, and in contrast to AZT, is not 
rate-limiting for d4T anabolism
356.   136 
The  mechanism  by  which  the  dTMPK  haplotypes  influence  mtDNA  and 
haemoglobin concentrations is unclear. It would be of great interest to determine in 
future  studies  whether  the  SNPs  located  in  the  putative  5’  promoter  and  3’UTR 
regions alter the expression and translation of  dTMPK mRNA and whether they 
mediate effects on cellular concentrations of thymidine-(analogue) anabolites. The 
absence of mtDNA depletion associated with haplotype 1 may result from greater 
phosphorylation of AZT-MP, resulting in decreased cellular AZT-MP concentrations 
and increased AZT-TP concentrations. Sommadossi and colleagues
317 demonstrated 
that although equivalent amounts of AZT-TP and d4T-TP are incorporated into bone 
marrow DNA, AZT-TP fails to be excised due to the high cellular concentrations of 
the  MP,  which  is  known  to  inhibit  the  3’-5’  exonuclease  activity  of  DNA 
polymerases  and  proposed  this  as  a  mechanism  for  the  selective  bone  marrow 
toxicity of AZT. Thus, haplotype 1 may be associated with greater excision of AZT-
TP from incorporated DNA than other haplotypes and thus less mtDNA depletion. 
However, the observed preservation of mtDNA levels associated with haplotype 1 in 
this study occurred in adipocytes, where d4T, which does not accumulated in the MP 
form, consistently causes greater mtDNA depletion than AZT. Thus, haplotype 1 
may mediate less mtDNA depletion simply through less AZT-MP phosphorylation 
and thus lower AZT-TP concentrations and therefore less AZT-TP incorporation.  
This is consistent with the suboptimal intracellular nucleotide pool mechanism of 
HIV-mediated haemotoxicity proposed by Bofill and colleagues
363. If haplotype 1 
mediates  less  mtDNA  depletion  than  the  other  haplotypes  through  less  AZT-MP 
phosphorylation,  haplotype  3  may  mediate  higher  pre-treatment  haemoglobin 
concentrations through greater thymidine phosphorylation. In rapidly dividing cells   137 
such  as  CD34
+  haematopoietic  progenitor  cells,  which  differentiate  into  both 
myeloid and erythroid lineages and have been shown to support infection of both M-
tropic  and  T-tropic  HIV-1
364-366,  an  inability  to  maintain  optimal  nucleotide  pool 
composition  in  the  presence  of  HIV-1-  infection  would  make  it  impossible  for 
progenitor  cells  to  complete  the  cell  cycle  and  terminally  differentiate
363.  Thus 
haplotype 3 may maintain optimal dT-TP concentrations in the presence of untreated 
HIV-1  infection.  However,  conflicting  data  exists  regarding  the  susceptibility  of 
CD34
+ cells to HIV-1 infection in vitro
367-370 and in vivo
371,372. 
In  conclusion,  although  the  mechanism  by  which  dTMPK  genetic  variation 
influences pre-treatment haemoglobin concentrations and adipocyte mtDNA values 
remains to be determined, these data suggest that dTMPK haplotyping may have 
promising  applications  in  identifying  individuals  relatively  protected  from 
developing  lipoatrophy  in  response  to  AZT  therapy  and  may  play  a  role  in 
identifying  individuals  susceptible  to  anaemia  in  susceptible  populations. 
Pharmacogenetics  has  proved  to  be  clinically  relevant  in  predicting 
neuropsychological  toxicity  associated  with  efavirenz
373  and  hypersensitivity  to 
abacavir
374,375, and this study suggests that pharmacogenetics may prove useful in 
predicting AZT toxicities.   138 
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